Bridging the Translation Gap: A Strategic Guide to Integrating Epidemiological and Animal Evidence in Systematic Reviews

Abstract

This article provides a comprehensive guide for researchers, scientists, and drug development professionals on the strategic integration of epidemiological (human) and animal evidence within systematic reviews. The synthesis addresses four core objectives: establishing the foundational rationale and current landscape for evidence integration; detailing methodological frameworks and practical application steps; identifying common challenges and optimization strategies to enhance review rigor; and presenting frameworks for validating integrated evidence and comparing outcomes across species. By synthesizing findings from both human population data and preclinical animal models, this approach enhances the translational validity of systematic reviews, reduces research waste, and provides a more robust evidence base to inform clinical trials and public health decisions.

The Why and What: Defining the Imperative for Integrating Human and Animal Evidence in Research Synthesis

The high attrition rate in drug development underscores a critical translational gap between preclinical discovery and clinical success [1]. While epidemiological studies identify associations and risk factors in human populations, and preclinical animal models elucidate biological mechanisms and therapeutic potential, each approach has intrinsic limitations. Epidemiological data can signal correlation but not causation, whereas preclinical findings often suffer from poor external validity, failing to predict human responses [2] [1]. Systematic reviews (SRs) that integrate these two evidence streams offer a powerful methodological "bridge" to overcome these limitations. A preclinical SR provides a formal, unbiased synthesis of animal data, assessing the robustness, reproducibility, and translational readiness of a proposed intervention [3] [4]. When its findings are directly contextualized with epidemiological evidence on disease burden and human pathophysiology, it creates a stronger, more holistic rationale for clinical translation or for the refinement of preclinical research. This integrated approach mitigates research waste, supports ethical animal use, and provides empirical evidence to inform clinical trial design and funding decisions [3] [4].

Quantitative Landscape of Preclinical and Epidemiological Systematic Reviews

The field of evidence synthesis is expanding rapidly in both preclinical and clinical domains. The tables below summarize key quantitative data illustrating this growth, the characteristics of preclinical SRs, and persistent methodological challenges.

Table 1: Growth and Volume of Systematic Review Evidence

Evidence Stream	Key Metric	Data	Source & Context
Preclinical SRs	Approximate total published (1992-2023)	~3000 SRs	One-third included a meta-analysis [4].
Preclinical SRs	Annual Growth Trend	Increasing exponentially	54% focused on pharmacological interventions (2015-2018 data) [4] [5].
Clinical SRs (for comparison)	Publications in Pediatric Medicine (2022)	>130,000 publications	Highlights the vast scale of clinical literature vs. preclinical [4].
Clinical Prediction Model SRs	Total Published (2001-2023)	1004 SRs	66.6% published after 2020, indicating rapid recent growth [6].

Table 2: Epidemiological Characteristics of Preclinical Systematic Reviews (2015-2018 Sample)

Characteristic	Category	Prevalence / Finding
Geographic Distribution	Published across 43 countries	Global activity with concentration in North America and Europe [5].
Disease Domain Coverage	Spanning 23 different domains	Demonstrates wide application across biomedical research [5].
Animal Species Reviewed	Use of 26 different species	Rodents (mice, rats) are most common; includes dogs, primates, etc. [5].
Methodological Reporting	Risk of Bias Assessment Reported	<50% of reviews [5].
Methodological Reporting	Construct Validity Assessment Reported	0% of reviews [5].

Table 3: Methodological Gaps in Systematic Review Reporting

Review Type	Reporting Gap	Percentage/Evidence	Implication
Clinical Prediction Model SRs [6]	Lacked a standardized review question (e.g., PICO)	88.3%	Compromises reproducibility and focus.
Clinical Prediction Model SRs [6]	Did not follow a standardized checklist for data extraction	79.8%	Increases risk of error and bias in data collection.
Clinical Prediction Model SRs [6]	Did not assess certainty of evidence (e.g., GRADE)	94.8%	Limits interpretation of findings' reliability.
All SRs [4]	Had a preregistered/published protocol (2020-2021)	38%	Improves transparency; reduces duplication and bias.

Foundational Protocols for Integrated Evidence Synthesis

Protocol 1: Conducting a Preclinical Systematic Review and Meta-Analysis

This protocol outlines the core steps for synthesizing preclinical animal evidence, forming one pillar of the translational bridge [3] [4].

• I. Protocol Development & Registration (Mandatory): Define a focused research question (e.g., "What is the efficacy of compound X in animal models of disease Y?"). Develop a detailed statistical analysis plan. Register the protocol on platforms like PROSPERO, SYRF, or Open Science Framework to prevent bias and duplication [3] [4].
• II. Systematic Search Strategy: Collaborate with a biomedical librarian. Search multiple electronic databases (e.g., PubMed, Embase, Web of Science) using animal search filters [3]. Do not rely solely on Google Scholar. Search strategies must be reproducible.
• III. Study Selection & Screening: Two independent reviewers screen titles/abstracts and then full-text articles against pre-defined inclusion/exclusion criteria. A PRISMA flow diagram records the process [3].
• IV. Data Extraction & Annotation: Two reviewers independently extract data using standardized forms. Extract details on study design, animal model, intervention, outcomes, and risk of bias. Use tools like WebPlotDigitizer to extract data from graphs [3].
• V. Risk of Bias & Quality Assessment: Use a domain-based tool like the SYRCLE Risk of Bias tool for animal studies [3] [1]. Assess internal validity (randomization, blinding, etc.) and report on external validity factors (model relevance, sex of animals) [1] [5].
• VI. Data Synthesis & Meta-Analysis: Perform a narrative synthesis of study characteristics. If sufficient homogeneous data exist, conduct a meta-analysis to calculate a summary effect size. Use random-effects models. Explore heterogeneity via subgroup analysis or meta-regression (e.g., by species, model type, risk of bias) [3].
• VII. Assessment of Publication Bias: Use funnel plots and statistical tests (e.g., Egger's) to assess small-study effects, which may indicate publication bias [3].
• VIII. Reporting & Dissemination: Report according to the PRISMA-Preclinical guidelines. Submit data and code to a repository (e.g., Figshare). Publish in an open-access format to maximize reach [3] [4].

Protocol 2: Integrating Epidemiological Data with Preclinical SR Findings

This protocol describes how to contextualize preclinical SR results within the human disease context.

• I. Define the Epidemiological Scope: Based on the preclinical research question, define key epidemiological parameters to search for: disease incidence/prevalence, key demographic risk factors (age, sex, ethnicity), major environmental or genetic determinants, and natural history/progression data [1].
• II. Targeted Epidemiological Evidence Search: Conduct a focused, narrative review of high-quality epidemiological sources. Search for large cohort studies, disease registries, and authoritative reports from organizations like the WHO or CDC. The goal is not an exhaustive SR but to gather relevant contextual data [4].
• III. Align Preclinical Models with Human Disease: Systematically compare the models used in the preclinical SR to human disease. Utilize a framework like the Framework to Identify Models of Disease (FIMD), which scores models across eight domains: Epidemiology, Symptomatology/Natural History, Genetics, Biochemistry, Aetiology, Histology, Pharmacology, and Endpoints [1]. This identifies which human disease features are recapitulated.
• IV. Comparative Analysis & Gap Identification: Create a side-by-side analysis:
  • Consistency: Do the mechanistic pathways and intervention effects in animals align with known human pathophysiology and risk factor data?
  • Population Relevance: Do the animal models reflect key at-risk human demographics (e.g., age, sex, co-morbidities)?
  • Outcome Translation: Are the preclinical outcome measures clinically relevant biomarkers or surrogates for patient-centered outcomes?
• V. Generate Integrated Conclusions & Recommendations: Synthesize findings into a translational assessment:
  • Strong Case for Translation: Preclinical evidence is robust, low bias, and effects are consistent across models that faithfully mirror key human epidemiological and pathophysiological features.
  • Case for Refined Preclinical Research: Preclinical evidence is promising but models lack critical human disease features (e.g., a model lacks genetic heterogeneity present in the human population). Recommend next-step studies using more representative models.
  • Case Against Current Translation: Preclinical evidence is weak, inconsistent, or derived from models with poor face/construct validity for the human condition [1].

Visualizing the Translational Workflow and Methodology

Figure 1: The Translational Bridge Workflow. This diagram illustrates the bidirectional integration of epidemiological and preclinical evidence streams through a formal systematic review process to produce translational decisions.

Figure 2: Preclinical Systematic Review Workflow. A linear representation of the seven mandatory stages for conducting a rigorous preclinical SR, with an optional feedback loop [3] [4].

Figure 3: Framework to Identify Models of Disease (FIMD). This radial diagram shows the eight domains used to systematically score and compare how well an animal model recapitulates key features of a human disease, critical for assessing external validity [1].

The Scientist's Toolkit: Research Reagent Solutions

Table 4: Essential Resources for Integrated Translational Reviews

Tool / Resource Name	Type	Primary Function in Integration	Key Reference/Source
SYRCLE Risk of Bias Tool	Methodological Tool	Assesses internal validity (e.g., selection, performance bias) of individual animal studies within an SR.	[3] [1]
Framework to Identify Models of Disease (FIMD)	Analytical Framework	Systematically scores and compares animal models across 8 domains (Epidemiology, Aetiology, etc.) for translational relevance.	[1]
ARRIVE & PREPARE Guidelines	Reporting Guidelines	Ensures complete and transparent reporting of animal experiments, improving the quality of primary data for SRs.	[1]
Systematic Review Facility (SyRF)	Online Platform	Provides a free, integrated platform for managing the preclinical SR process (screening, data extraction, analysis).	[3]
Compound 48/80-Induced Ocular Allergy Model	Preclinical Disease Model	A non-immunogenic mast cell degranulation model used to study allergic conjunctivitis and test antihistamines (e.g., alcaftadine).	[7]
Antigen-Challenge Ocular Allergy Model	Preclinical Disease Model	Uses sensitization and topical challenge (e.g., with ovalbumin) to induce a T-cell mediated response, modeling chronic ocular allergy.	[7]
Pharmacokinetic/Pharmacodynamic (PK/PD) Modeling	Analytical Method	Integrates data on a drug's absorption, distribution, metabolism, excretion (ADME) with its biological effects to predict human dosing.	[8]
PROSPERO Registry	Protocol Registry	International prospective register for SR protocols in health-related fields; mandatory for Cochrane reviews and best practice for all SRs.	[4] [6]

Application Notes: From Theory to Practice

• Note 1: Informing Clinical Trial Design with Preclinical SRs. A robust preclinical SR and meta-analysis can provide quantitative estimates of treatment effect size, optimal therapeutic time window, and effective dose ranges across species. These data directly inform the design of Phase I/II clinical trials, including first-in-human dosing, escalation schemes, and candidate biomarker selection [3] [8]. Conversely, an SR revealing inconsistent effects or high risk of bias in animal studies can justify halting translation, preventing unnecessary human trials [3].
• Note 2: Selecting the Optimal Animal Model. The integration of epidemiological data is crucial for model selection. For a pediatric disease, an SR should critically appraise whether the age of animals used corresponds to the relevant human developmental stage [4]. The FIMD framework can guide this choice: for a disease with strong genetic determinants, prioritize models with high scores in the "Genetics" domain; for a disease driven by environmental factors, "Aetiology" and "Epidemiology" become more critical [1].
• Note 3: Addressing the "Valley of Death" in Drug Development. The high failure rate between preclinical success and clinical efficacy is often attributed to poor predictive validity of animal models [1]. Integrated SRs address this by forcing an explicit, structured comparison between animal and human data before costly clinical trials begin. This process de-risks development by identifying fundamental disconnects early—such as a drug working only in acute injury models when the human disease is chronic—and directing resources toward more promising candidates or better models [1] [8].

Application Notes: Thesis Context and Research Imperative

This document synthesizes the current state of systematic reviews (SRs) of animal studies, framing the evidence within the broader thesis objective of integrating epidemiological and animal evidence to strengthen translational research. Animal SRs are critical for distilling preclinical evidence, identifying robust findings from often heterogeneous animal studies, and directly informing the design and justification of human clinical trials and public health interventions [9]. Their role is not merely to summarize animal data but to act as a bridge in the translational pathway, highlighting which animal findings have sufficient promise, mechanistic insight, and safety profiles to warrant human investigation [10] [9]. However, the utility of this bridge depends entirely on the rigor, coverage, and accessibility of the animal SRs themselves. These application notes detail the empirical landscape, identify persistent gaps, and provide standardized protocols to enhance the quality and integration potential of future animal SRs, thereby directly serving the thesis goal of creating a more cohesive and predictive evidence ecosystem.

Section 1: The Evolving Landscape of Animal Systematic Reviews

Quantitative Growth and Publication Metrics

The field of animal SRs has experienced substantial growth, particularly over the past decade. Empirical analyses reveal key metrics regarding their production and publication lifecycle.

Table 1: Growth and Publication Metrics for Animal Systematic Reviews

Metric	Findings	Data Source & Context
Cumulative Volume	Over 3,113 SRs indexed in a dedicated database (as of June 2019) [11]; 1,358 SRs in neuroscience alone (1997-2023) [10].	Demonstrates significant scholarly activity and a foundation for evidence synthesis [11].
Annual Growth Trajectory	In neuroscience, yearly publications grew from 5 (2007) to 305 (2022), indicating rapid adoption [10].	Reflects increasing recognition of the value of evidence synthesis in preclinical research [10] [9].
Protocol-to-Publication Rate	51% (694/1,365) of protocols registered in PROSPERO result in a published SR [12].	Suggests substantial publication bias or attrition due to resource constraints, potentially distorting the evidence base [12].
Median Time to Completion	11.5 months (range: 0.13–44.9 months) from start to submission [12].	Provides realistic timelines for researchers and funders; actual time often exceeds authors' anticipation [12].
Median Time to Publication	16.2 months (range: 1.0–49.7 months) from start to final publication [12].	Highlights the full timeline from inception to disseminated knowledge.

Geographic Distribution and Collaborative Trends

The production of animal SRs is a global endeavor, but with notable concentrations of activity.

Table 2: Geographic Distribution of Animal Systematic Review Production

Rank	Country	Primary Research Context	Implications for Integration
1	United States	Most prolific producer of neuroscience SRs [10].	Leads in volume; sets methodological trends.
2	China	Among the top producers [10].	Major and growing contributor to the evidence base.
3	United Kingdom	Top producer; leads in adoption of non-animal methods (NAMs) in several disease areas [10] [13].	Strong focus on methodology, quality (e.g., CAMARADES, SYRCLE), and the 3Rs principle [13].
4	Brazil	Among the top producers [10].	Indicates active evidence-synthesis communities in multiple regions.
5	Iran	Among the top producers [10].	Highlights global distribution of research expertise.
Collaboration Impact	International collaboration (≥2 countries) is common but does not significantly alter publication likelihood or timeline [12].	Supports globalized science but suggests complex logistics may offset efficiency gains.

Topical Coverage and Translational Gaps

While SRs cover many disease areas, significant mismatches exist between research focus and global health burden.

Table 3: Topical Coverage and Identified Gaps in Neuroscience SRs

Disease Area	Level of SR Coverage	Notes and Translational Implications
Neurodegenerative (e.g., Alzheimer's, Stroke)	High	Well-covered, aligning with high disease burden and extensive animal modeling [10].
Psychiatric Disorders (e.g., Depression)	Moderate	Covered, but often with less mechanistic depth from animal models [10].
Schizophrenia	Low	A major gap despite significant clinical burden [10].
Brain Tumours	Low	A major gap despite significant clinical burden [10].
Other Psychiatric Disorders	Low	Generally underrepresented [10].
General Observation	The ratio of SRs to disease prevalence is uneven [10].	Research investment does not fully align with epidemiological need, creating an integrative gap where clinical demand outpaces synthesized preclinical evidence.

Section 2: Experimental Protocols for Rigorous Evidence Synthesis

Protocol: Registration, Search, and Automated Quality Assessment

This integrated protocol combines best practices for conducting an animal SR, from inception to quality evaluation [12] [10].

Phase 1: Protocol Development and Registration

• Define Question: Formulate a clear, focused PICO (Population, Intervention, Comparator, Outcome) question relevant to translational research.
• Draft Protocol: Detail all planned methods: search strategy, inclusion/exclusion criteria, data extraction items, risk of bias (RoB) assessment tool, and synthesis plan.
• Mandatory Registration: Register the finalized protocol on a public registry before starting the review. PROSPERO is the international preferred registry (PROSPERO4animals section) [12]. Registration reduces bias, increases transparency, and allows for the tracking of protocol-to-publication attrition [12].

Phase 2: Systematic Literature Search and Screening

• Database Search: Execute the registered search string in at least two major biomedical databases (e.g., PubMed/MEDLINE, Embase) [10]. Use validated animal study filters like the SYRCLE animal filter to improve precision [10].
• Supplementary Search: Search specialized resources (e.g., Web of Science, Google Scholar for grey literature) and scan reference lists [12].
• Deduplication & Screening: Use reference management and screening software (e.g., Rayyan). Conduct title/abstract and full-text screening independently by two reviewers, with conflicts resolved by consensus or a third reviewer [10].

Phase 3: Automated Quality Assessment (AQA) of Included SRs For umbrella reviews or methodological studies assessing the quality of many SRs, manual assessment is impractical. This protocol details an automated, high-reliability method [10].

• Tool Setup: Develop a script in R (or similar) using regular expressions (regex). Create regex libraries for 11 key quality items (e.g., presence of a protocol, dual screening, RoB assessment, search string provided) [10].
• Text Processing: The script imports full-text PDFs of SRs, segments text by section (e.g., Methods, Results), and removes references.
• Pattern Matching: The script searches each text segment for matches to the predefined regex patterns for each quality item.
• Validation & Scoring: Manually check a random subset (e.g., 10%) to calculate inter-rater agreement (F1-score). The tool achieved >80% F1-score for most items [10]. Assign a point for each fulfilled item to generate a normalized quality score (0-1).

Phase 4: Data Synthesis and Reporting

• Data Extraction: Use a standardized, pilot-tested form. Extract study characteristics, results, and RoB assessments. Perform in duplicate.
• Synthesis: Conduct narrative synthesis. If studies are sufficiently homogeneous, perform a meta-analysis to calculate summary effect estimates.
• Reporting: Adhere to PRISMA guidelines. Clearly report the fate of the protocol (registration ID, amendments) and discuss findings in the context of translational potential and human evidence [10].

Protocol: Assessing Protocol Publication Status and Timelines

This protocol is designed for methodological research tracking the publication output and efficiency of registered SR protocols [12].

Objective: To determine the proportion of registered animal SR protocols that result in publication and to calculate real-world completion timelines.

Methods:

• Data Source: Manually download all records from the "Reviews of animal studies for human health" section of the PROSPERO registry [12].
• Eligibility Filter: Exclude protocols with a start date within the median time-to-publication period (e.g., 466 days) prior to data extraction to avoid misclassifying ongoing reviews as unpublished [12].
• Data Extraction (Manual & Automated):
  • Extract: PROSPERO ID, title, author names, anticipated start/end dates, submission/registration dates, country/collaboration data [12].
  • Use a web-scraping tool (e.g., Python with BeautifulSoup) to automate extraction of metadata from PROSPERO pages [12].
• Publication Status Verification:
  • Primary Check: Search PROSPERO's "Details of final report/publication" field [12].
  • Secondary Search: If primary check is negative, search Google Scholar, PubMed, and Embase using the protocol title and author names [12].
  • Categorization: Classify each protocol as "Published" (linked SR found) or "Unpublished" (no SR found after exhaustive search).
• Timeline Calculation:
  • Completion Time: Date of journal submission (from publication) minus actual start date (from protocol) [12].
  • Publication Time: Date of journal publication minus actual start date [12].
  • Anticipated Time: Anticipated completion date minus anticipated start date [12].
• Analysis: Calculate descriptive statistics (median, IQR) for proportions and timelines. Compare actual vs. anticipated times using non-parametric tests (e.g., Wilcoxon signed-rank test) [12].

Section 3: Visualizing Workflows and Relationships

Animal SR Workflow and Evidence Gaps

Integration of Animal SR and Human Evidence

Section 4: The Scientist's Toolkit for Animal Systematic Reviews

Table 4: Essential Research Reagent Solutions and Resources

Tool / Resource	Primary Function	Relevance to Integration Thesis
PROSPERO (PROSPERO4animals)	International prospective register for SR protocols [12].	Mandatory for transparency. Mitigates publication bias, allows tracking of the animal evidence pipeline, a prerequisite for integration.
SYRCLE Animal Filter	Search filter to efficiently identify animal studies in PubMed [10].	Increases efficiency and recall of primary animal studies, improving the foundation of the SR.
CAMARADES / SYRCLE Guidelines	Methodological guidance & checklists for conducting animal SRs and meta-analyses.	Critical for quality. Directly improves SR rigor, enhancing the reliability of evidence to be integrated with human data.
Database of Animal SRs	Curated database of >3,100 published animal SRs [11].	Prevents duplication, enables mapping of existing evidence, and facilitates meta-epidemiological studies for integration research.
Automated Quality Assessment (AQA) Script	R tool using regex to extract quality indicators from SR full texts [10].	Enables large-scale evaluation of the animal evidence base's reliability, identifying strengths/weaknesses for integration.
PRISMA Reporting Checklist	Standard for transparent reporting of systematic reviews [10].	Ensures animal SRs are reported with sufficient detail for critical appraisal and comparison with human evidence.
One Health Integration Frameworks	Models for combining human, animal, and environmental surveillance data [14].	Provides a direct conceptual and methodological model for integrating animal and human epidemiological evidence at the systems level.

Definitions and Comparative Roles in Drug Development

Real-World Data (RWD) refers to data relating to patient health status and/or the delivery of health care routinely collected from a variety of sources outside of traditional clinical trials [15]. Real-World Evidence (RWE) is the clinical evidence regarding the usage and potential benefits or risks of a medical product derived from the analysis of RWD [15] [16]. Preclinical Evidence encompasses all research on a drug or treatment conducted before human testing, including basic research, drug discovery, lead optimization, and safety studies in animal and cellular models [17].

These three evidence streams serve distinct but complementary purposes throughout the therapeutic development lifecycle and its subsequent evaluation within systematic reviews. The following table summarizes their core characteristics and roles.

Table 1: Comparative Analysis of Preclinical, Clinical Trial, and Real-World Evidence

Aspect	Preclinical Evidence	Randomized Controlled Trial (RCT) Evidence	Real-World Evidence (RWE)
Primary Purpose	Establish biological plausibility, mechanism of action, initial safety, and dosing [17].	Establish efficacy and safety under controlled, ideal conditions (internal validity) [18] [16].	Demonstrate effectiveness, safety, and utilization in routine clinical practice (external validity/generalizability) [18] [16].
Typical Setting	Laboratory (in vitro, in vivo animal models) [17].	Experimental, protocol-driven clinical setting [18].	Observational, routine healthcare delivery setting [18] [19].
Subject Population	Cellular systems, selected animal species (e.g., mice, rats, non-rodents) [20].	Highly selective patient population based on strict inclusion/exclusion criteria [18] [16].	Heterogeneous patient population with comorbidities, reflecting actual clinical practice [16] [21].
Key Strength	Reveals disease mechanisms; essential for first-in-human dose estimation and initial go/no-go decisions [17].	Gold standard for establishing causal efficacy with high internal validity due to randomization and blinding [18].	Assesses long-term outcomes, rare adverse events, and effectiveness in diverse, representative populations [18] [16].
Primary Limitation	Limited direct translatability to human physiology and disease [17].	Results may not generalize to broader, more complex real-world populations [18] [16].	Susceptible to confounding and bias due to lack of randomization; data quality and standardization challenges [16] [19].
Regulatory Use	Supports Investigational New Drug (IND) application to initiate human trials [17].	Supports New Drug Application (NDA) for initial market approval [15].	Supports post-approval safety monitoring, label expansions, and updates to treatment guidelines [15] [16].

Integrated Evidence Synthesis Workflow for Systematic Reviews

Systematic reviews aiming to provide a comprehensive therapeutic assessment must integrate preclinical, RCT, and RWE. The following workflow outlines a protocol for their synthesis.

Figure 1: Integrated workflow for synthesizing preclinical, RCT, and real-world evidence in systematic reviews.

Detailed Methodological Protocols

Protocol for Generating and Analyzing Real-World Evidence

A. RWD Source Selection & Acquisition:

• Primary Sources: Identify and access fit-for-purpose databases. Common sources include [15] [18] [16]:
  • Electronic Health Records (EHRs): Contain clinical notes, lab results, and treatment histories.
  • Claims & Billing Databases: Provide data on diagnoses, procedures, and prescriptions for insured populations.
  • Disease/Product Registries: Prospective, structured data collection on specific patient populations.
  • Patient-Generated Data: From wearables, mobile apps, or patient-reported outcome surveys.
• Data Linkage: Use privacy-preserving methods to link data across sources (e.g., EHR to registry) to create a more comprehensive patient journey [22].

B. Study Design & Analytical Methodology:

• Design Choice: Select based on the research question.
  • Retrospective Cohort Study: Efficient for assessing long-term outcomes; identifies exposed/non-exposed groups from past data [18].
  • Prospective Cohort Study: Collects data forward in time; reduces recall bias but is time-intensive [18].
  • Case-Control Study: Efficient for studying rare outcomes; compares cases (with outcome) to controls (without) [16].
  • Pragmatic Clinical Trial: A randomized trial integrated into routine care, blending RCT and RWE features [16] [19].
• Bias Mitigation: Employ advanced statistical techniques to address confounding and selection bias inherent in observational data [16]. Standard methods include multivariable regression, propensity score matching, and instrumental variable analysis.

C. Data Standardization Protocol (Critical for Integration):

• Transform RWD to a Common Data Model (CDM): Map heterogeneous source data (e.g., different EHR codes) to a standardized structure like the OMOP CDM to enable pooling and analysis across datasets [22].
• Map to Research Standards: For regulatory submissions, further map CDM data to clinical trial standards like CDISC SDTM to facilitate combined analysis with RCT data [22].

Protocol for Generating Preclinical Evidence

A. Experimental Progression:

• Basic Research & Target Identification: Investigate disease pathophysiology to identify molecular targets [17].
• Drug Discovery (in vitro): Screen compound libraries in cellular disease models to identify "hits" that modulate the target [17].
• Lead Optimization (in vivo): Test promising "lead" compounds in animal disease models (e.g., transgenic mice). Assess efficacy, pharmacokinetics (PK), and preliminary toxicity. Chemically modify leads to improve properties [17].
• IND-Enabling Studies: Conduct Good Laboratory Practice (GLP) compliant toxicology, PK, and safety pharmacology studies in two species (one rodent, one non-rodent) to support regulatory filing for human trials [17] [20].

B. Key In Vivo Experiment Protocol: Efficacy in Animal Model

• Objective: To evaluate the therapeutic effect of a lead compound in a validated animal model of Disease X.
• Materials: Animal model (e.g., specific transgenic mouse), test compound, vehicle control, positive control drug (if available), dosing apparatus, equipment for outcome measurement (e.g., behavioral assay, imaging, biomarker analysis).
• Methods:
  • Randomization & Blinding: Randomly assign age/weight-matched animals to Vehicle, Test Compound (multiple doses), and Positive Control groups. Ensure blinding of personnel during dosing and outcome assessment.
  • Dosing Regimen: Administer compound via clinically relevant route (e.g., oral gavage, injection) daily for defined study duration.
  • Outcome Assessment: Measure primary (e.g., tumor volume, cognitive score) and secondary (e.g., biomarker levels, histological changes) endpoints at predefined time points.
  • Toxicology Monitoring: Record body weight, clinical signs, and conduct terminal blood/ tissue analysis for signs of toxicity.
  • Statistical Analysis: Use ANOVA with post-hoc tests to compare group means. Report effect size and statistical power.

The Scientist's Toolkit: Essential Reagent Solutions for Integrated Evidence Generation

Table 2: Key Research Reagents and Materials for Integrated Evidence Studies

Item Category	Specific Examples	Primary Function in Integrated Evidence Synthesis
Preclinical Biological Models	Genetically engineered mouse models (GEMMs), patient-derived xenografts (PDXs), induced pluripotent stem cell (iPSC)-derived cells.	Provide mechanistic insight and proof-of-concept for therapeutic targets. Findings help explain molecular subgroups observed in human RWE or heterogeneous RCT responses [17] [20].
In Vivo Imaging Agents	Bioluminescent reporters (e.g., luciferin), fluorescent dyes, contrast agents for MRI/CT.	Enable non-invasive, longitudinal tracking of disease progression and treatment response in animal models, paralleling imaging biomarkers used in human RCTs and RWD [17].
Biomarker Assay Kits	ELISA kits, multiplex immunoassays (e.g., Luminex), PCR panels for gene expression.	Quantify molecular biomarkers in animal tissues and human biospecimens (from trials or biobanks linked to RWD). Essential for translational bridging between preclinical mechanism and clinical outcome [17].
Data Standardization Tools	OMOP Common Data Model (CDM) vocabularies, CDISC SDTM/ADaM mapping guides, FHIR to CDISC implementation guides [22].	Convert disparate RWD and structured trial data into standardized formats, enabling pooled analysis and direct comparison across evidence streams.
Advanced Analytics Software	Propensity score matching packages (R, Python), machine learning libraries (scikit-learn), pharmacovigilance signal detection tools.	Mitigate confounding in RWE analyses, identify novel subgroups or predictors from integrated datasets, and detect safety signals across preclinical and post-market data [16].
Bioinformatics Databases	Public genomics repositories (e.g., GEO, TCGA), drug-target databases (e.g., DrugBank), protein interaction networks (e.g., STRING).	Contextualize preclinical findings within human disease biology and drug mechanisms, informing the design of RWE studies that investigate genetic or molecular treatment effect modifiers.

The 'One Health' Paradigm as a Framework for Integration

The One Health paradigm is an integrative approach that recognizes the fundamental interconnectedness of human, animal, and environmental health [23]. This framework is predicated on the understanding that health challenges such as zoonotic diseases, antimicrobial resistance (AMR), and food safety cannot be effectively addressed within isolated disciplinary silos [23]. For researchers conducting systematic reviews, particularly those aimed at informing drug development and public health policy, One Health provides an essential structure for synthesizing evidence across species and ecosystems. The approach advocates for collaborative, transdisciplinary, and multisectoral interventions to tackle complex health issues whose root causes often span traditional boundaries [23]. Applying this paradigm to systematic review methodology necessitates the deliberate and structured integration of epidemiological, veterinary, and ecological data, moving beyond anthropocentric evidence synthesis to a more holistic model of health evidence [24].

Quantitative Data on One Health Priority Areas

The rationale for a One Health approach in systematic reviews is underscored by quantitative data highlighting shared burdens across human and animal domains. The following tables summarize key areas where integrated evidence synthesis is critical.

Table 1: Global Burden of Select Zoonotic Diseases and One Health Implications

Disease	Estimated Annual Human Cases/Deaths	Primary Animal Reservoir/Vector	Key Environmental Driver	Systematic Review Integration Need
Influenza (Zoonotic)	Variable; pandemics cause millions of deaths [23]	Wild birds, poultry, swine [23]	Agricultural intensification, land use change [23]	Joint analysis of human surveillance, poultry farm outbreaks, and wild bird migration data.
Rabies	~59,000 human deaths annually [23]	Domestic dogs ( >99% of human cases) [23]	Urbanization, low dog vaccination coverage [23]	Synthesis of human post-exposure prophylaxis efficacy, canine vaccination campaign success, and cost-effectiveness studies.
Lyme Disease	~30,000 reported cases in USA annually	Wild rodents, transmitted by ticks [23]	Climate change, habitat fragmentation [23]	Integrated review of human incidence, wildlife host seroprevalence, and climatic/tick distribution models.

Table 2: Antimicrobial Resistance (AMR) Data Under a One Health Lens

Parameter	Human Health Sector Data	Animal Health & Agriculture Sector Data	Environmental Sector Data	Integrated Review Focus
Resistance Prevalence	Percentage of clinical E. coli isolates resistant to 3rd-gen cephalosporins [23].	Percentage of E. coli from livestock resistant to same antibiotics [23].	Concentration of antibiotic resistance genes (ARGs) in river systems near farms [23].	Correlating resistance trends across sectors to identify transmission hotspots and drivers.
Driver: Antibiotic Use	Defined daily doses (DDD) per 1,000 hospital patient-days [23].	Milligrams of antibiotics per population correction unit (mg/PCU) in livestock [23].	Not directly applicable.	Comparing the impact of stewardship interventions (e.g., reduced use in animals) on human resistance patterns.
Economic Impact	Projected global GDP loss due to AMR by 2050 [23].	Cost of increased animal morbidity and reduced productivity [23].	Cost of water treatment to remove ARGs and pathogens [23].	Holistic economic models for intervention planning that account for cross-sector costs and benefits.

Application Notes & Protocols for Systematic Review Integration

Protocol: Developing a One Health Systematic Review Question

A clearly formulated review question is the cornerstone of an integrated One Health systematic review. The PECO(S) framework (Population, Exposure, Comparator, Outcome, Study Design/Sector) is recommended over the standard PICO to explicitly incorporate multiple sectors.

Detailed Methodology:

• Define Multi-Sector Populations:
  • Human: Specify demographic and clinical characteristics (e.g., "children under 5", "hospitalized patients").
  • Animal: Specify species, health status, and context (e.g., "domestic poultry in intensive farms", "wild Rattus species in urban settings").
  • Environment: Specify relevant compartments (e.g., "freshwater sources", "soil in agricultural land").

• Define Exposure/Intervention Across Sectors: The exposure (e.g., a pathogen, an antibiotic) or intervention (e.g., a vaccination campaign, an agricultural practice) must be defined in terms relevant to each sector. For example, an exposure might be "presence of Campylobacter jejuni," which is measured differently in human stool samples, poultry cecal swabs, and surface water samples.

• Define Comparable Outcomes: Identify health outcomes that are analogous or linked across sectors. For a review on influenza transmission, relevant outcomes could be "seroconversion" in humans, "viral shedding" in animals, and "viral detection in air samples" in the environment.

• Specify Study Designs and Sector of Origin: Explicitly plan to include study designs from various fields (e.g., human cohort studies, veterinary field trials, environmental surveillance reports). The search strategy must be tailored to retrieve literature from all relevant databases (e.g., PubMed, CAB Abstracts, GreenFILE).

Protocol: Integrated Search Strategy & Study Screening

This protocol ensures comprehensive evidence gathering from all relevant disciplines while maintaining methodological rigor.

Detailed Methodology:

• Database Selection: Search a combination of biomedical, agricultural, veterinary, and environmental science databases. Core databases should include PubMed/MEDLINE, Embase, CAB Abstracts, Web of Science Core Collection, and Scopus. Consider specialized databases like AGRICOLA or GreenFILE for environmental aspects [24].

• Development of Search Strings:

  • Create a core set of concepts related to the disease or health issue.
  • For each concept, compile a comprehensive list of synonyms and controlled vocabulary terms (MeSH, Emtree, CAB Thesaurus) relevant to human, veterinary, and environmental literature. For example, for "influenza," include terms like "human influenza," "avian influenza," "swine flu," and "orthomyxoviridae infections" in animals.
  • Combine concepts with Boolean operators (AND, OR). Avoid overly restrictive filters by study type in the initial search.

• Screening with a One Health PRISMA Flow Diagram: Adapt the standard PRISMA flow diagram to track the identification and screening of records from different disciplinary sources [25] [26]. The diagram below visualizes this integrated screening workflow.

One Health Systematic Review Screening Workflow

• Dual Screening with Cross-Disciplinary Teams: Implement dual, independent screening of titles/abstracts and full texts. The screening team should include reviewers with expertise in human health, veterinary science, and/or environmental science to correctly interpret discipline-specific literature [24]. Disagreements should be resolved by consensus or a third arbitrator.

Protocol: Integrated Data Extraction and Quality Appraisal

This protocol guides the extraction of data from studies across sectors into a unified framework and the assessment of their quality.

Detailed Methodology:

• Design a Unified Data Extraction Form:
  • Create a form with core modules applicable to all studies: Citation, Study Design, Objectives, Funding Source.
  • Include sector-specific modules:
    • Human Module: Population details, case definitions, diagnostic methods, confounders.
    • Animal Module: Species, husbandry/wild, sampling method, diagnostic assay.
    • Environment Module: Sample type (water, soil, air), location, collection method, lab processing.
  • Include an "Integration" module to capture data on cross-species transmission routes, shared risk factors, or direct comparisons of outcomes between sectors within a single study.

• Extraction Process: Reviewers with matched expertise should extract data from studies in their field. A lead reviewer should oversee the integration module to ensure consistency in capturing links.

• Quality Appraisal Using Hybrid Tools: No single tool fits all study types. Use a hybrid approach:

  • Human Clinical/ Epidemiological Studies: Use ROBINS-I for observational studies or Cochrane Risk of Bias 2.0 for trials.
  • Animal (in vivo) Studies: Use the SYRCLE's risk of bias tool.
  • Environmental Sampling Studies: Adapt tools based on design, focusing on sampling representativeness, confounding control, and assay validity.
  • Note and document the different appraisal criteria across sectors during synthesis.

Protocol: Synthesis of Integrated Evidence

The synthesis phase must explicitly model the interactions between evidence from different sectors, as conceptualized in the following diagram.

One Health Evidence Integration Synthesis Framework

Detailed Methodology for Narrative Synthesis:

• Develop a Preliminary Synthesis: Summarize the findings from each sector (Human, Animal, Environment) separately using text, tables, and maps (e.g., geographic distribution of findings).
• Explore Relationships Within and Between Sectors:
  • Use juxtaposition matrices to display data from different sectors side-by-side (e.g., a table showing human case incidence, animal reservoir prevalence, and a key environmental variable like rainfall over the same time period and region).
  • Generate causal loop diagrams or conceptual models based on extracted data to hypothesize how drivers and outcomes in one sector influence another. For example, model how antibiotic use in aquaculture (animal/environment) leads to resistant bacteria in waterways (environment), impacting human health through recreational exposure.
• Assess the Robustness of the Integrated Synthesis: Critically evaluate the strength and coherence of the links drawn between sectors. Consider the quantity, quality, and consistency of evidence supporting each proposed interaction. Clearly state where evidence for integration is strong versus speculative.

Detailed Methodology for Quantitative Synthesis (if feasible):

• Assess Statistical Heterogeneity Across Sectors: Recognize that direct meta-analysis of, for example, human clinical trial outcomes and animal infection prevalence rates is not statistically valid due to fundamentally different outcome measures.
• Employ Complementary Meta-Analyses: Conduct separate, parallel meta-analyses for each sector where outcomes are comparable (e.g., efficacy of the same vaccine antigen in human trials and animal challenge studies). Present these results together and discuss the concordance or discordance.
• Use Integrated Modeling: If sufficient quantitative data are extracted, a more advanced approach is to use the systematic review findings to parameterize an integrated mathematical model (e.g., a transmission model that explicitly includes human, animal, and environmental compartments). The review provides the evidence base for model structure and inputs.

The Scientist's Toolkit: Research Reagent Solutions

Implementing a One Health systematic review requires specific tools and resources to handle multi-sector evidence. The following table details key components of this toolkit.

Table 3: Essential Research Toolkit for One Health Systematic Reviews

Tool/Resource Category	Specific Item or Platform	Function in One Health Review	Key Consideration
Reference Management & Screening	Covidence, Rayyan, EndNote	Manages citations from diverse databases, facilitates dual screening, and tracks reasons for exclusion across disciplines [26].	Ensure the platform can handle large, heterogeneous imports and allows custom screening forms.
Data Extraction & Management	REDCap, Systematic Review Data Repository (SRDR+), custom spreadsheets (Excel, Google Sheets).	Hosts structured, multi-module extraction forms; enables secure data storage and collaboration among geographically dispersed, cross-disciplinary teams.	Form must be rigorously piloted to ensure sector-specific fields are clear to all reviewers.
Quality Appraisal Hybrid Toolkit	ROBINS-I, Cochrane RoB 2.0, SYRCLE's RoB tool, bespoke tools for environmental studies [24].	Enables standardized, sector-appropriate critical appraisal of included studies, highlighting different biases relevant to human trials vs. field ecology studies.	Review team must be trained on multiple tools. Document which tool was used for each study type.
Data Synthesis & Visualization	NVivo, Atlas.ti (for thematic synthesis); R, Python with metafor/ statsmodels libraries; GIS software (QGIS, ArcGIS).	Supports coding of qualitative themes across sectors; performs statistical meta-analysis where possible; creates maps to visualize spatial relationships between human, animal, and environmental data points.	Thematic analysis software helps find connections across disparate qualitative findings. GIS is crucial for spatial One Health analysis.
Regulatory & Guidance Reference	FDA IND Guidance Documents [27], WOAH Terrestrial Animal Health Code, WHO International Health Regulations (2005).	Informs the translation of review findings for regulatory submissions (e.g., for a zoonotic drug) [27] and ensures recommendations align with international health standards across sectors.	Critical for reviews intended to directly inform drug development or international policy [24].

The How-To: Methodological Frameworks and Practical Steps for Evidence Integration

The systematic review of scientific evidence represents a cornerstone of evidence-based medicine and public health decision-making. Within this domain, a critical challenge and opportunity lie in the integration of disparate evidence streams, particularly epidemiological (human) studies and preclinical (animal) research. This integration is not merely a technical exercise but a fundamental methodological advancement for understanding disease etiology, assessing chemical risks, and translating basic research into clinical applications [9]. Historically, these evidence streams have existed in parallel, with epidemiological studies providing direct human relevance but often limited by observational design constraints, and animal studies offering controlled experimental settings and mechanistic insights but facing questions regarding translational validity [9] [28].

The drive toward integration is fueled by several factors. Firstly, frameworks such as One Health explicitly recognize the interconnectedness of human, animal, and environmental health, necessitating surveillance and research that transcend traditional disciplinary boundaries [14]. Secondly, regulatory and risk assessment bodies increasingly seek to leverage all available evidence to reduce uncertainty; for instance, using human epidemiological data can eliminate uncertainties associated with interspecies extrapolation when deriving toxicological reference values [28]. Thirdly, integrating evidence can enhance the biological plausibility of observed associations in human studies and ground animal findings in real-world human exposure scenarios, thereby strengthening causal inference [29] [28].

This article details the mechanisms, protocols, and applications for integrating epidemiological and animal evidence within systematic reviews. It is structured within the context of a broader thesis arguing that such convergent integration is essential for robust, translational, and ethically efficient scientific synthesis.

Defining the Integration Mechanism Spectrum

Integration in the context of health evidence synthesis is a multi-faceted concept. A seminal systematic review categorized approaches to integrating human and animal health surveillance systems into four primary mechanisms, which provide a valuable framework for evidence synthesis in systematic reviews [14]. These mechanisms exist on a continuum from simple data exchange to full methodological and conceptual fusion.

Table 1: Spectrum of Integration Mechanisms for Evidence Synthesis [14]

Mechanism	Core Principle	Key Activities in Systematic Reviews	Level of Integration
Interconnectivity	Basic exchange of information or data between independent systems.	- Manual cross-referencing of reference lists between human and animal reviews.- Separate searches in PubMed for human and animal studies with post-hoc comparison.	Low
Interoperability	Systems or components work together using shared standards, enabling communication and data exchange.	- Using common, controlled vocabularies (e.g., MeSH terms) across searches.- Applying harmonized data extraction fields (PECO/PICO) to both study types.- Depositing shared datasets in interoperable repositories (e.g., GenBank for genetic data).	Medium
Semantic Consistency	Implementation of common data models, definitions, and formats to ensure consistent interpretation.	- Defining and applying standardized outcome measures across species (e.g., behavioral assays for aggression) [29].- Using common risk-of-bias frameworks adapted for both observational and experimental studies.- Implementing FAIR (Findable, Accessible, Interoperable, Reusable) principles for all data [30].	High
Convergent Integration	Merging of technology, processes, and knowledge to create a unified system with emergent properties.	- A priori protocol defining a single, integrated review question addressing both human and animal evidence [29].- Unified synthesis methodology (e.g., narrative synthesis across streams, integrated quantitative models).- Joint assessment of strength of evidence and causality using frameworks like GRADE or OHAT that explicitly consider both streams [4] [28].	Very High

The progression from interconnectivity to convergent integration represents a shift from post-hoc linkage to unified design. While a 2020 review found interoperability and semantic consistency to be the most commonly attempted mechanisms in health surveillance [14], the most robust systematic reviews strive for convergent integration to answer complex questions such as the causal association between lead exposure and antisocial behavior [29].

Performance and Reporting Landscape of Integrated Reviews

The implementation of integrated systematic reviews is growing but faces significant challenges in reporting quality and data availability. Understanding this landscape is crucial for developing effective protocols.

Table 2: Performance Metrics and Reporting Characteristics of Integrated Evidence Synthesis

Aspect	Findings from Current Evidence	Implication for Integration
System Performance	Integrated health surveillance systems showed: sensitivity 63.9-100% (median 79.6%), data quality improvement 73-95.4% (median 87%), and timeliness improvement 10-91% (median 67.3%) [14].	Demonstrates the tangible benefits of integration for key system attributes like sensitivity and timeliness, which are analogous to the completeness and efficiency of evidence synthesis.
Reporting Quality	A cross-sectional study of preclinical systematic reviews (2015-2018) found inconsistent reporting. Key methods like risk of bias assessment were reported in less than half of reviews, and construct validity (model relevance) was rarely assessed [31].	Poor reporting hampers reproducibility and effective integration. Highlights the need for strict adherence to reporting guidelines like PRISMA.
Data Availability (FAIRness)	A review of veterinary epidemiological studies found most non-molecular datasets were not publicly available. Where data was shared, interoperability was the weakest FAIR principle [30].	Lack of accessible, interoperable data is a major barrier to semantic consistency and convergent integration. Mandates data-sharing policies and use of standardized formats.
Review Volume & Scope	Over 3,000 systematic reviews of animal studies have been published, covering preclinical research, toxicology, and veterinary medicine [11]. A 2021 sample identified 442 preclinical reviews across 43 countries and 23 disease domains [31].	Provides a substantial evidence base for integration but also indicates a risk of duplication and waste without coordinated, integrated approaches.

Foundational Protocols for Integrated Systematic Reviews

The following protocols provide a methodological blueprint for conducting systematic reviews that aim for convergent integration of human epidemiological and animal evidence.

Protocol 1: Developing the A Priori Integrated Review Protocol

A pre-registered, detailed protocol is the bedrock of a high-quality integrated review [4].

• Define the Integrated Review Question: Formulate a question that explicitly requires both evidence streams. Use a structured framework like PECO (Population, Exposure, Comparator, Outcome), ensuring definitions are applicable across species.
  • Example from lead review: P (Human populations & laboratory animals), E (Lead exposure), C (Lower/no lead exposure), O (Antisocial behavior, aggression, social norm violation) [29].
• Establish Harmonized Search Strategies:
  • Develop comprehensive search strings for bibliographic databases (e.g., PubMed, Web of Science, Embase).
  • Use both subject headings (MeSH, Emtree) and free-text terms tailored for human and animal literature. Avoid species-specific filters in the primary search to maximize sensitivity [29].
  • Search for both primary studies and existing systematic reviews in each domain to map the evidence landscape [11].
• Set Inclusion/Exclusion Criteria: Define criteria for study design, language, and date limits. Critically, establish principles for evidence bridgeability, detailing how outcomes in animal models (e.g., specific social behavior tests) map to human outcomes (e.g., psychiatric diagnoses or recorded offenses) [29] [4].
• Register the Protocol: Submit the protocol to a public registry such as PROSPERO or an open science platform (e.g., Open Science Framework) before commencing the review [4].

Protocol 2: Unified Screening, Data Extraction, and Risk of Bias Assessment

This phase operationalizes semantic consistency.

• Screening: Use systematic review software (e.g., Rayyan, Covidence). Conduct title/abstract and full-text screening in duplicate, with reviewers screening records from both evidence streams to ensure consistent application of criteria.
• Data Extraction: Develop a single, piloted extraction form with dedicated sections for human-specific (e.g., confounders adjusted for) and animal-specific (e.g., species, strain, model induction method) data, plus common fields (e.g., exposure/metric, outcome definition, effect size) [31].
• Integrated Risk of Bias (RoB) Assessment: Apply RoB tools appropriate to each study design but within a unified framework.
  • For animal studies, use SYRCLE's RoB tool or the CAMARADES checklist [31].
  • For observational human studies, use tools like ROBINS-E or the NTP/OHAT framework [28].
  • The integrated assessment should explicitly evaluate confounding (key in human studies) and fidelity of the animal model (construct validity) as sources of bias affecting the overall evidence body [28] [31].

Protocol 3: Synthesis, Integration, and Grading of Evidence

This is the stage of convergent integration, where evidence streams are fused to draw a unified conclusion.

• Stratified Synthesis: Initially, synthesize human and animal evidence separately. For human studies, if heterogeneity in outcome assessment is too high, a narrative synthesis may be necessary [29]. For animal studies, a meta-analysis may be feasible to calculate a summary effect size [9].
• Cross-Stream Evidence Integration: Use a structured framework to integrate the synthesized bodies of evidence. Adapted approaches from the U.S. EPA or NTP OHAT are recommended [29] [28].
  • Assess coherence/consistency: Do effect directions align across species and study designs?
  • Assess biological plausibility and mechanistic evidence: Do animal studies provide a supporting mechanism for observed human associations?
  • Assess exposure-response: Is there evidence of a gradient in both streams?
  • Triangulation: Deliberately seek consistencies across evidence streams with different, non-overlapping sources of bias to strengthen causal inference [28].
• Grading the Integrated Body of Evidence: Apply an evidence grading system like GRADE or the OHAT approach to rate the overall confidence in the conclusion (e.g., "high," "moderate," "low"), considering the contributions and limitations of both evidence streams [4] [28].

Integrated Systematic Review Workflow for Convergent Evidence Synthesis

The Scientist's Toolkit: Essential Reagents for Integration

Successfully implementing the protocols above requires a suite of methodological tools and resources.

Table 3: Research Reagent Solutions for Integrated Evidence Synthesis

Tool/Resource Category	Specific Item & Source	Primary Function in Integration
Protocol & Reporting Guidelines	PRISMA (Preferred Reporting Items for Systematic Reviews and Meta-Analyses) [4] [31]	Ensures transparent and complete reporting of the integrated review process.
Protocol & Reporting Guidelines	PROSPERO International Register of Systematic Reviews [4]	Platform for a priori protocol registration to prevent bias and duplication.
Risk of Bias Assessment Tools	SYRCLE's Risk of Bias Tool for Animal Studies [31]	Standardized assessment of internal validity in preclinical studies.
Risk of Bias Assessment Tools	ROBINS-E (Risk Of Bias In Non-randomized Studies - of Exposures) [28]	Assesses risk of bias in human observational studies, enabling parallel appraisal.
Evidence Grading Frameworks	GRADE (Grading of Recommendations, Assessment, Development, and Evaluations) / OHAT (Office of Health Assessment and Translation) [4] [28]	Provides a structured system to rate the overall confidence in synthesized evidence from multiple streams.
Data Management & Sharing	FAIR Guiding Principles [30]	Framework (Findable, Accessible, Interoperable, Reusable) for managing data to enable semantic consistency and reuse.
Data Management & Sharing	Disciplinary Repositories (e.g., GenBank, ENA) & General Repositories (e.g., Figshare, Dryad) [30]	Platforms for sharing interoperable data underlying the review.
Evidence Databases	Database of Systematic Reviews of Animal Studies [11]	Resource to identify existing preclinical reviews, preventing redundancy and facilitating integration.

Advanced Applications: From Integration to Causality and Translation

Convergent integration enables powerful applications that extend beyond simple synthesis.

Quantitative Bias Assessment and Triangulation: Moving beyond qualitative RoB assessment, integrated reviews can employ quantitative bias analysis (e.g., to adjust for unmeasured confounding) and triangulation. Triangulation strengthens causal inference by seeking consistent findings from human studies (with different confounding structures) and animal experiments (free of human-style confounding but with different construct validity issues) [28].

Informing Chemical Risk Assessment: Integrated reviews are pivotal for modern risk assessment. A workshop highlighted that epidemiologic data can be used not just for hazard identification but for quantitative dose-response assessment, especially when supported by coherent animal evidence providing biological plausibility and mechanistic data [28]. This reduces reliance on default uncertainty factors for interspecies extrapolation.

Guiding Translational Research: Preclinical systematic reviews can catalyze translational efficiency. By synthesizing animal evidence, they identify the most promising interventions and robust models, informing the design of clinical trials. Conversely, they can reveal irreproducible animal findings, preventing futile or unethical human trials. Institutions like Radboud University have reported a 35% reduction in animal use following the implementation of systematic review methodology, underscoring the ethical and efficiency gains of rigorous, integrated evidence assessment [4].

Advanced Analysis and Applications of Integrated Evidence

The synthesis of preclinical animal evidence and clinical epidemiological data is a cornerstone of translational research, aiming to inform drug development and therapeutic strategies. This process hinges on methodological rigor to ensure transparency, minimize bias, and yield reproducible conclusions. This article details the application of four core standards—protocol registration, PRISMA, SYRCLE, and CAMARADES—that together provide a structured framework for conducting systematic reviews (SRs) that integrate evidence across the translational spectrum. Adherence to these standards addresses critical issues in evidence synthesis, such as selective reporting, poor methodological quality in animal studies, and the challenges of managing complex preclinical data, thereby strengthening the bridge from bench to bedside [32] [33] [34].

Core Methodological Standards: Purpose, Components, and Application

Protocol Registration

Purpose and Rationale: Protocol registration is the a priori publication of a review's design, committing researchers to a predetermined plan. This practice is fundamental for transparency, as it reduces bias from post-hoc changes in methods based on knowledge of the results, deters duplication of effort, and allows peer feedback on proposed methods. Registration is increasingly a requirement for publication in peer-reviewed journals [35].

Key Registries and Data: For SRs of animal studies, PROSPERO's dedicated section (PROSPERO4animals) is a primary registry [33]. Empirical data from 2025 indicates that while registration is growing, only 51% of registered animal study SR protocols culminate in publication, highlighting a significant publication bias or attrition. The median time from protocol registration to published review is 16.2 months, which is 69% longer than authors typically anticipate (6.8 months) [33].

Table 1: Protocol Registration Metrics for Animal Study Systematic Reviews (2025 Data)

Metric	Value	Implication
Eligible Protocols Analyzed	1,365 protocols	Large, growing evidence base [33]
Publication Rate	51% (694/1,365)	Half of initiated reviews remain unpublished, indicating potential bias/waste [33]
Median Actual Time to Publish	16.2 months	Sets realistic expectations for project planning [33]
Median Anticipated Time to Publish	6.8 months	Highlights a widespread underestimation of required effort [33]

Essential Protocol Components: A robust protocol must include the review title, research question (e.g., PICO: Population, Intervention, Comparator, Outcome), a detailed search strategy with databases and draft queries, explicit inclusion/exclusion criteria, plans for data extraction and risk of bias assessment, and the intended approach to data synthesis [35].

PRISMA (Preferred Reporting Items for Systematic Reviews and Meta-Analyses)

Purpose and Evolution: PRISMA is an evidence-based reporting guideline, not a direct quality assessment tool. Its purpose is to ensure the complete, transparent, and replicable reporting of SRs and meta-analyses. The 2020 update refines the original standard to address newer forms of evidence synthesis [36] [37].

Core Components and Checklist: The guideline consists of a 27-item checklist and a flow diagram for reporting study selection. Key items cover the rationale, objectives, eligibility criteria, information sources, search strategy, study selection process, data collection process, risk of bias assessment, synthesis methods, and discussion of limitations and conclusions. The flow diagram visually documents the inflow of studies from identification through screening to inclusion [37] [38].

Application in Integrated Reviews: For reviews integrating animal and human evidence, PRISMA provides the overarching reporting structure. Reviewers should clearly delineate how evidence streams are handled separately and together. The PRISMA checklist ensures that the methods for both the preclinical and clinical arms of the review are reported with equal rigor [36].

SYRCLE (SYstematic Review Centre for Laboratory animal Experimentation)

Purpose and Tools: SYRCLE develops methodology tailored to SRs of animal intervention studies. Its flagship tool is the SYRCLE Risk of Bias (RoB) tool, a critical adaptation of the Cochrane RoB tool for preclinical specifics [32] [39].

Risk of Bias Tool (10 Domains): The tool assesses six types of bias through 10 signaling questions [32]:

• Sequence generation (selection bias).
• Baseline characteristics (selection bias): Assesses if groups were similar at baseline.
• Allocation concealment (selection bias).
• Random housing (performance bias): Specific to animal studies, as housing conditions can affect outcomes.
• Blinding of personnel/caregivers (performance bias).
• Random outcome assessment (detection bias): Accounts for circadian rhythms and other time-sensitive measures.
• Blinding of outcome assessor (detection bias).
• Incomplete outcome data (attrition bias).
• Selective outcome reporting (reporting bias).
• Other sources of bias.

Additional Resources: SYRCLE provides a step-by-step guide for comprehensive search strategies, including validated search filters for PubMed and Embase to efficiently identify animal studies. It also promotes the Gold Standard Publication Checklist (GSPC) to improve primary study reporting [39].

CAMARADES (Collaborative Approach to Meta-Analysis and Review of Animal Data from Experimental Studies) & SyRF

Purpose and Evolution: CAMARADES provides support, mentoring, and infrastructure for preclinical meta-research. It has evolved from a collaborative group to offering a practical online platform: the Systematic Review Facility (SyRF) [40].

The SyRF Platform: SyRF is a free, online, end-to-end platform designed to manage the entire SR workflow for preclinical studies. It supports protocol development, reference importing and deduplication, collaborative screening and data extraction (with user blinding), custom annotation, and data export for analysis. It is engineered to facilitate large, crowdsourced projects and the integration of automation tools [40].

CAMARADES Checklist: An earlier contribution was a quality checklist for animal studies, often used alongside SYRCLE's RoB tool. It includes items like peer-reviewed publication, statement of control of temperature, and use of animals with relevant comorbidities [34].

Emerging and Unifying Tools: CRIME-Q

Development and Purpose: The CRIME-Q tool (Critical Appraisal of Methodological Quality, Quality of Reporting and Risk of Bias in Animal Research) is a 2024 development that unifies assessment across three domains: Quality of Reporting (QoR), Methodological Quality (MQ), and Risk of Bias (RoB). It integrates items from SYRCLE's RoB, ARRIVE 2.0, and CAMARADES while adding unique items, particularly to assess technical ("bench-top") laboratory quality. It is designed to be universally applicable across interventional and non-interventional animal studies [34].

Validation: An internal validation study reported high inter-rater agreement. Cohen’s kappa indices were 0.86 for QoR items, 0.83 for MQ items, and 0.68 for RoB items, indicating substantial to almost perfect agreement [34].

Table 2: Comparison of Core Methodological Standards and Tools

Standard/Tool	Primary Purpose	Key Components/Items	Specific Application Context
Protocol Registration	Pre-commitment to plan; prevent bias	Research question, search strategy, inclusion criteria	Mandatory first step for all SRs, including animal & integrated reviews [33] [35]
PRISMA 2020	Reporting guideline	27-item checklist; flow diagram	Final reporting of any SR, ensuring transparency [36] [37]
SYRCLE RoB Tool	Risk of bias assessment	10 domains adapted for animal studies	Critical appraisal of internal validity of animal intervention studies [32]
CAMARADES/SyRF	Conduct support & infrastructure	Online platform (SyRF); quality checklist	Managing workflow for preclinical SRs; historical quality assessment [40]
CRIME-Q Tool	Unified critical appraisal	3 domains: QoR, MQ, RoB	Holistic quality assessment of any animal study (interventional/non-interventional) [34]

Integrated Application: Experimental Protocols for a Translational Systematic Review

Phase I: Protocol Development and Registration

• Define the Integrated Research Question: Formulate a translational question (e.g., "What is the efficacy and safety profile of drug X in animal models of disease Y and in human phase II/III trials?").
• Draft the Full Protocol: Using PRISMA-P as a guide, detail separate but parallel strategies for animal and human evidence streams. Specify databases (e.g., PubMed/MEDLINE, Embase, clinical trial registries), develop separate search strings using SYRCLE's animal filters where appropriate, and define inclusion criteria for both study types [39] [35].
• Register the Protocol: Submit the finalized protocol to PROSPERO (PROSPERO4animals) or another suitable registry like the Open Science Framework (OSF) before commencing the formal search. Record the unique registration number [33] [35].

Phase II: Search, Screening, and Data Management

• Execute Searches and Manage References: Run the registered searches across all databases. Import all references into a management platform. SyRF is strongly recommended for this phase, especially for the animal evidence stream, as it handles deduplication and allows for collaborative screening seamlessly [40].
• Screen Studies: Perform title/abstract and full-text screening in duplicate, independently, using the pre-defined inclusion/exclusion criteria. SyRF facilitates this by blinding reviewers to each other's decisions and tracking conflicts for resolution [40].
• Extract Data: Design and pilot data extraction forms. Extract study characteristics (e.g., species, model, intervention, human population, trial design) and quantitative outcome data in duplicate. SyRF supports customized annotation forms and extraction of data from figures with built-in tools [40].

Phase III: Critical Appraisal and Risk of Bias Assessment

• Assess Animal Studies: Use the SYRCLE RoB tool to judge the internal validity of each animal study across 10 domains. Alternatively, for a more comprehensive assessment covering reporting and technical quality, employ the CRIME-Q tool. Perform assessments in duplicate [32] [34].
• Assess Human Studies: Use an appropriate tool for clinical trials, such as the Cochrane RoB 2.0 tool for randomized trials.
• Document and Synthesize Appraisals: Create summary tables and graphs (e.g., traffic light plots) to present RoB judgments across all studies within each evidence stream.

Phase IV: Synthesis, Analysis, and Reporting

• Synthesize Evidence: Conduct narrative synthesis for each evidence stream, exploring relationships between study characteristics and findings. If appropriate, perform meta-analysis separately for animal and human data, acknowledging the fundamental differences in pooling.
• Integrate Findings: Create a structured summary table comparing the consistency, magnitude, and direction of effects between animal models and human trials. Discuss possible reasons for discordance (e.g., model validity, RoB, dosing, outcome timing).
• Write the Final Report: Adhere strictly to the PRISMA 2020 checklist and flow diagram. Report the process and results for animal and human evidence transparently. Discuss the implications of the integrated findings for translational science and future research [37].

Visualizing the Integrated Systematic Review Workflow

The following diagram outlines the integrated workflow, highlighting the points of application for each core standard.

Integrated Systematic Review Workflow for Translational Research

The Scientist's Toolkit: Essential Research Reagents and Platforms

Table 3: Key Research Reagent Solutions for Conducting Integrated Systematic Reviews

Item / Solution	Function / Purpose	Key Features / Notes
PROSPERO Registry	International prospective register for SR protocols.	Dedicated section for animal study SRs (PROSPERO4animals). Registration is free and provides a time-stamped, unique ID [33].
SyRF (Systematic Review Facility)	Online end-to-end platform for managing preclinical SRs.	Supports collaborative screening, data extraction, custom annotation, and data management. Facilitates blinding and conflict resolution. Free to use [40].
SYRCLE's Risk of Bias Tool	Critical appraisal tool for animal intervention studies.	10-domain tool adapted from Cochrane for animal-specific biases (e.g., random housing, blinding of caregivers) [32].
CRIME-Q Tool	Unifying critical appraisal tool for animal research.	Assesses Quality of Reporting, Methodological Quality, and Risk of Bias in one tool. Applicable to interventional and non-interventional studies [34].
PRISMA 2020 Checklist & Flow Diagram	Reporting guideline for systematic reviews.	27-item checklist and standardized flow diagram template to ensure complete and transparent reporting [37] [38].
SYRCLE Search Filters	Validated search strings for PubMed/Embase.	Filters designed to efficiently and sensitively retrieve animal studies, reducing irrelevant clinical trial results [39].
Reference Management Software	Software for storing, organizing, and deduplicating citations.	Tools like EndNote, Zotero, or Mendeley are essential. SyRF has built-in management for projects on its platform [40].

Systematic reviews have become a cornerstone of evidence-based medicine and public health decision-making. However, significant methodological challenges arise when attempting to integrate different streams of evidence, particularly epidemiological (human observational) studies and preclinical animal studies. Epidemiology provides direct evidence on human health risks but often lacks detailed exposure assessment and mechanistic insight [41]. Conversely, animal studies offer controlled experimental conditions and elucidation of biological pathways but suffer from limited generalizability to humans and frequent translational failures [9]. A structured workflow for integrating these complementary evidence types is therefore critical for robust hazard identification, risk assessment, and understanding disease mechanisms.

Current practices reveal substantial gaps. A survey of risk assessors found that while epidemiology holds great potential, common shortcomings include deficiencies in exposure assessment, lack of comprehensive uncertainty analyses, and failure to investigate thresholds of effect [41]. Similarly, systematic reviews of animal studies, though increasing in number, often exhibit methodological weaknesses, poor design, and reporting issues that hinder translation [9]. Furthermore, an analysis of systematic reviews of clinical prediction models found that a majority lacked standardized review questions and consistent data extraction methods [6]. These deficiencies underscore the need for a rigorous, transparent, and reproducible workflow to formulate questions, conduct parallel searches, and extract data for integrated evidence synthesis.

This article provides detailed application notes and protocols for a structured integration workflow, framed within a broader thesis on synthesizing epidemiological and animal evidence. It is designed for researchers, scientists, and drug development professionals conducting complex evidence syntheses for regulatory science, public health policy, or translational research.

Formulating Integrated Systematic Review Questions

The foundation of a successful integrated review is a precisely framed research question. This requires moving beyond a standard PICO (Population, Intervention, Comparison, Outcome) framework to one that explicitly incorporates elements for both evidence streams.

Core Protocol: The review protocol must pre-specify the rationale and objectives for integrating human and animal evidence. Following PRISMA-P (Preferred Reporting Items for Systematic Review and Meta-Analysis Protocols) guidelines is essential [42]. The protocol should detail the logic of integration: whether animal evidence will be used to assess biological plausibility for an epidemiological association, to inform dose-response, to identify susceptible life-stages, or to bridge data gaps for human health risk assessment [41]. Registration on platforms like PROSPERO or the Open Science Framework (OSF) before commencing the review enhances transparency and reduces bias [43].

Structured Question Framework: Develop a dual-strand question framework. For the epidemiological strand, use a modified PECO format (Population, Exposure, Comparator, Outcome). For the animal strand, use a PICO format tailored to experimental studies (Population/Animal Model, Intervention, Comparator, Outcome). A bridging element explicitly linking the two must be included.

Example: "What is the association between chronic exposure to [Chemical X] and [Human Outcome Y] in adult populations (epidemiological strand), and what is the effect of [Chemical X] on analogous [Pathophysiological Outcome Y*] in controlled mammalian in vivo studies (animal strand), in order to characterize the dose-response relationship and biological plausibility of the human health effect?"

Key Considerations:

• Outcome Harmonization: Define human health outcomes and analogous pathophysiological endpoints in animal studies. This may involve creating a tiered outcome hierarchy.
• Exposure/Intervention Alignment: Carefully align the human exposure scenario with the experimental intervention (e.g., route, timing, duration, chemical form).
• Purpose of Integration: Clearly state if integration is for hazard identification, risk assessment, or mechanistic understanding, as this will guide subsequent synthesis methods.

Protocol for Parallel Systematic Searches

Conducting comprehensive, parallel searches for human and animal literature is a critical step that requires meticulous planning to ensure both breadth and reproducibility.

Search Strategy Development

Develop separate, optimized search strategies for epidemiological and animal literature. Each strategy should be constructed using a combination of controlled vocabulary (e.g., MeSH terms, Emtree) and free-text keywords related to the exposure/intervention and outcomes [42].

Experimental Protocol for Search Strategy Testing:

• Identify Key Papers: Compile a benchmark set of 5-10 known, relevant articles for each evidence stream.
• Iterative Development: Draft a preliminary search string and run it in a primary database (e.g., PubMed for both streams).
• Sensitivity Testing: Calculate the sensitivity of the search by determining if it retrieves all benchmark articles. Revise the string to achieve near 100% sensitivity.
• Peer Review: Submit the final search strategies for peer review using tools like the PRESS (Peer Review of Electronic Search Strategies) guideline.
• Documentation: Record the final search strings for each database, including dates of execution and number of records retrieved.

Database Selection & Execution

Search multiple bibliographic databases in parallel. For animal studies, include PubMed/MEDLINE, Embase, and Web of Science. For epidemiological studies, include the above plus specialized databases like TOXLINE and GreenFile. The use of a database dedicated to systematic reviews of animal studies can also be invaluable for identifying existing syntheses [11]. Searches should be designed to capture both published and unpublished literature to mitigate publication bias [42].

Managing Parallel Evidence Streams

Use reference management software (e.g., EndNote, Zotero, Covidence) to manage retrieved citations. Create separate folders or libraries for the epidemiological and animal search results before the screening stage. This preserves the integrity of each parallel stream for independent evaluation and later integration.

Table 1: Parallel Search Workflow Phases

Phase	Epidemiological Evidence Stream	Animal Evidence Stream	Integration Action
Strategy Development	PECO-based strings; focus on human exposure terms.	PICO-based strings; focus on experimental intervention terms.	Align core exposure/intervention concept. Peer-review both strategies together.
Execution	Databases: PubMed, Embase, TOXLINE, etc.	Databases: PubMed, Embase, Web of Science, etc.	Run searches concurrently. Log dates/numbers separately.
Records Management	Dedicated library/folder for epidemiological records.	Dedicated library/folder for animal records.	Use consistent tagging (e.g., "EpiInitial", "AnimalInitial") in a single reference manager project.

Data Extraction and Harmonization Methodology

Data extraction is where the parallel evidence streams are prepared for integration. This requires standardized, pre-piloted forms and a focus on extracting comparable data points.

Designing Dual-Stream Extraction Forms

Create two linked data extraction forms—one for epidemiological studies and one for animal studies. Both should be based on established methodological checklists to ensure completeness and reduce bias.

• For Epidemiological Studies: Use or adapt items from the CHARMS (CHecklist for critical Appraisal and data extraction for systematic Reviews of prediction Modelling Studies) or other tools for observational studies [6]. Critical fields include study design, population characteristics, exposure assessment method, outcome definition, confounder adjustment, effect estimates (RR, OR, HR) with confidence intervals, and statistical analysis methods.
• For Animal Studies: Use or adapt items from the SYRCLE (SYstematic Review Centre for Laboratory animal Experimentation) risk of bias tool or similar. Critical fields include animal model species/strain/age, intervention details (dose, route, timing), comparator, primary outcome data (group size, mean, SD), study design (randomization, blinding), and funding source.

Bridging Fields: Include specific fields in both forms to enable linkage: - Chemical/Agent: Standardized identifier (e.g., CASRN). - Outcome Domain: Categorized pathophysiological effect (e.g., "hepatic steatosis", "neuroinflammation"). - Exposure/Intervention Metric: For dose-response integration, extract administered dose (animal) and, if available, internal dose metrics (like serum concentration) for both streams.

Experimental Protocol for Pilot Extraction and Calibration

• Form Piloting: Independently, two reviewers extract data from the same 2-3 studies from each evidence stream using the draft forms.
• Consistency Check: Compare extractions to identify discrepancies in interpretation, missing fields, or ambiguous field definitions.
• Form Refinement: Revise the forms and guidance notes to improve clarity and completeness.
• Reviewer Calibration: Hold a calibration meeting to resolve differences and ensure a shared understanding of all extraction criteria. Repeat piloting on new studies until high inter-rater reliability (e.g., Cohen's kappa > 0.8) is achieved.
• Independent Extraction: Proceed with independent extraction for all included studies by at least two reviewers. Disagreements are resolved by consensus or arbitration by a third reviewer.

Data Harmonization for Synthesis

This is the most critical step for integration. Transform extracted data into a comparable format.

• Dose Standardization: Convert all animal doses to a common metric (e.g., mg/kg body weight/day). For human data, convert exposure measures (e.g., occupational air levels, dietary intake) to estimated daily intake (mg/kg/day) where possible.
• Effect Size Standardization: For animal studies, calculate standardized mean differences (SMD) or response ratios for continuous outcomes. For epidemiological studies, use reported risk estimates (e.g., Odds Ratios).
• Risk of Bias/Study Quality: Appraise each study using appropriate tools (e.g., ROBINS-I for epidemiological studies, SYRCLE's RoB tool for animal studies). Record judgements per domain to inform sensitivity analyses during integration [44].

Table 2: Structured Framework for Data Extraction & Harmonization

Extraction Domain	Epidemiological Studies	Animal Studies	Harmonization Action for Integration
Study Identification	Author, year, design, country, funding.	Author, year, species/strain/sex, funding.	Categorize funding source (e.g., industry, public).
Exposure/Intervention	Exposure metric, assessment method, duration.	Compound, dose (mg/kg), route, frequency, duration.	Convert all doses to mg/kg/day. Note if biomarkers of internal dose are available.
Outcomes	Clinical endpoint, diagnostic criteria, effect estimate (OR, RR) with CI.	Measured endpoint, unit of measure, group mean & SD (or equivalent).	Map human and animal outcomes to a common health effect domain (e.g., "Liver Injury").
Confounders / Bias	Confounders adjusted for. ROBINS-I domains.	Experimental design (randomization, blinding). SYRCLE's RoB domains.	Apply GRADE or similar to rate confidence in each body of evidence separately before integration.
Data for Synthesis	Adjusted log effect estimate & SE.	N, mean, SD for each group.	Calculate SMD for animal data; prepare for cross-stream narrative or quantitative synthesis.

Integrated Analysis and Visualization Workflow

The integrated analysis follows a convergent segregation approach: evidence streams are analyzed separately initially, then findings are synthesized.

Workflow Protocol:

• Stratified Analysis: Conduct meta-analyses or narrative syntheses separately for the epidemiological and animal evidence. For animal data, explore heterogeneity by species, sex, or study design.
• Evidence Mapping: Create an evidence map comparing the two streams. One axis lists health outcomes, and separate columns show the direction, strength, and confidence of evidence from human and animal studies.
• Quantitative Integration (Where Feasible): In cases with sufficient, comparable dose-response data, consider a cross-species dose-response meta-analysis using benchmark dose (BMD) modeling or physiologically based pharmacokinetic (PBPK) modeling to extrapolate animal doses to human equivalent doses.
• Assess Consistency & Coherence: Formally assess the consistency of the direction of effect, dose-response gradients, and biological plausibility between the two evidence bodies. Inconsistencies should be investigated (e.g., due to species differences, exposure timing, or risk of bias).
• Grade Overall Confidence: Use a structured framework like GRADE or a customized approach to rate the overall confidence in the integrated conclusion, considering the strength, consistency, and coherence of both streams.

Table 3: Research Reagent Solutions for Integrated Reviews

Tool / Resource	Function in Integration Workflow	Key Features / Notes
Protocol Registries (PROSPERO, OSF) [42] [43]	Publicly registers review protocol to minimize bias, declare integration rationale.	PROSPERO is preferred for health-related reviews. OSF offers more flexibility for complex methodologies.
Database of Systematic Reviews of Animal Studies [11]	Identifies existing syntheses of animal evidence, preventing duplication and providing prior insights.	Freely available database of over 3,000 reviews; searchable by topic.
PRISMA-P & PRISMA Checklists [42]	Guides protocol development and final review reporting to ensure completeness and transparency.	PRISMA-P is for protocols; PRISMA 2020 is for the full review. Essential for publishing.
Covidence, Rayyan, EPPI-Reviewer	Web-based tools for managing parallel screening, selection, and data extraction phases.	Facilitates dual-stream management with custom extraction forms and collaboration features.
SYRCLE's Risk of Bias Tool	Standardized tool for assessing methodological quality of animal studies.	Critical for weighting animal evidence and exploring heterogeneity in synthesis.
CHARMS & PROBAST Tools [6]	Checklists for data extraction and risk of bias assessment for studies of prediction models; adaptable for observational studies.	Helps ensure comprehensive extraction of key epidemiological study details.
Graphical Tools (Graphviz, Lucidchart, Miro) [45]	Creates visual workflow diagrams (like those in this article) and evidence maps.	Enhances protocol clarity, team communication, and presentation of integrated results.
GRADE (Grading of Recommendations, Assessment, Development, and Evaluations)	Framework for rating the certainty (quality) of a body of evidence.	Can be adapted to grade confidence in integrated conclusions from two evidence streams.

The integration of epidemiological and preclinical animal evidence through systematic review and meta-analysis represents a powerful approach to translational science. This synthesis aims to strengthen the biological plausibility of associations identified in human populations and to inform the design of clinical trials based on robust preclinical data [9]. However, such cross-species evidence synthesis is intrinsically challenged by substantive and statistical heterogeneity. Heterogeneity refers to variability in study outcomes that exceeds what would be expected by chance alone [46]. In cross-species contexts, this arises from differences in species physiology, disease modeling, experimental designs, intervention protocols, and outcome measurements [9] [47].

Effectively managing this heterogeneity is not merely a statistical obstacle but a critical scientific opportunity. Exploring sources of variability can yield insights into the consistency of biological effects across models, the context-dependency of interventions, and the factors that may influence successful translation to humans [46] [48]. This document provides detailed application notes and protocols for conducting quantitative syntheses of cross-species data, with a focus on advanced strategies to characterize, quantify, and model heterogeneity.

Quantitative Frameworks and Heterogeneity Metrics

A meta-analysis of cross-species data typically pursues three statistical objectives: estimating an overall mean effect, quantifying the consistency (heterogeneity) among studies, and explaining the sources of that heterogeneity [49]. The following tables summarize core quantitative concepts and metrics essential for this process.

Table 1: Key Statistical Measures for Assessing Heterogeneity [46] [49]

Metric	Symbol	Interpretation	Calculation/Notes
Cochran’s Q	Q	Tests the null hypothesis that all studies share a common effect size. A significant p-value indicates the presence of heterogeneity.	Weighted sum of squared differences between individual study effects and the pooled effect. Follows a χ² distribution.
I² Statistic	I²	Describes the percentage of total variation across studies that is due to heterogeneity rather than chance.	I² = 100% × (Q - df)/Q. Values of 25%, 50%, and 75% are often interpreted as low, moderate, and high heterogeneity.
Between-Study Variance	τ² (tau²)	The absolute variance of true effect sizes across studies. Informs the width of prediction intervals.	Estimated via methods like DerSimonian-Laird, REML, or ML. Crucial for random-effects and multilevel models.
Prediction Interval	--	Forecasts the range within which the true effect of a new, similar study would fall, accounting for heterogeneity.	Pooled mean ± t-value × √(τ² + SE²). More intuitive and clinically relevant than confidence intervals for heterogeneous data [46].

Table 2: Common Effect Size Measures for Cross-Species Synthesis [49]

Effect Measure	Formula	Application Context	Considerations for Cross-Species Use
Standardized Mean Difference (SMD)	(Mean₁ - Mean₂) / SDpooled	Compares continuous outcomes (e.g., tumor size, biomarker level) between two groups. Hedges' g corrects for small sample bias.	Allows comparison across different measurement scales. Assumes similar variance structures across species, which may not hold.
Log Response Ratio (lnRR)	ln(Mean₁ / Mean₂)	For ratio-based outcomes (e.g., fold-change, enzyme activity). Interpreted as the percent change.	Intuitive for biological data. Requires positive means and careful handling of zero values.
Log Odds Ratio (lnOR)	ln((a/b) / (c/d))	For binary outcomes (e.g., survival, disease incidence).	Robust and widely used. Can be unstable with small sample sizes or zero cells.
Fisher’s z (Correlation)	0.5 × ln((1+r)/(1-r))	For synthesizing correlation coefficients (e.g., gene expression vs. phenotype).	Stabilizes the variance of correlation coefficients.

Table 3: Model Selection for Cross-Species Meta-Analysis [47] [49]

Model Type	Core Assumption	When to Use	Limitations for Cross-Species Data
Common/Fixed-Effect	All studies estimate one true effect size. Sampling error is the only source of variance.	When studies are functionally identical (e.g., same species, identical protocol). Rarely justified in cross-species synthesis.	Ignores between-study heterogeneity, leading to over-precise, potentially biased estimates.
Traditional Random-Effects	True effect sizes vary across studies, following a normal distribution with variance τ².	When heterogeneity is present and studies are considered a sample from a population of possible effects.	Treats all studies as independent. Violated when multiple effect sizes come from the same study (non-independence).
Multilevel (Hierarchical) Model	Accounts for hierarchical data structure (e.g., effect sizes nested within studies, studies nested within species).	The recommended approach for cross-species data, as it explicitly models statistical dependency and heterogeneity at multiple levels [47].	Requires more complex statistical implementation. Demands clear definition of the data hierarchy.

Core Experimental Protocols

Protocol 1: Multilevel Meta-Analysis for Non-Independent Effect Sizes

Background: Preclinical studies often report multiple relevant outcomes, time points, or experimental groups, generating multiple effect sizes per study. This creates statistical dependency that, if ignored, biases standard errors and inflates Type I error rates [47]. Multilevel meta-analysis (MLMA) models this dependency directly.

Materials: Dataset where each row is an effect size (ES), with associated sampling variance (v), and columns identifying the study and species of origin. Statistical software (e.g., R with metafor or brms packages).

Procedure:

• Define the Hierarchical Structure: Specify at least three levels: Level 1 (sampling variance, known), Level 2 (variance between effect sizes within the same study), Level 3 (variance between studies within the same species or between species).
• Fit the Three-Level Model:
  • In R (metafor), the structure is: rma.mv(yi = ES, V = v, random = ~ 1 | Species / Study, data = dataset)
  • This model estimates an overall pooled effect while partitioning variance (τ²) at the study (Level 2) and species (Level 3) levels.
• Quantify Heterogeneity: Calculate I² for each level. Level 3 I² indicates heterogeneity between species clusters; Level 2 I² indicates heterogeneity between studies within species.
• Interpret the Pooled Estimate: The overall mean is conditional on the modeled heterogeneity. Report it with its 95% confidence interval and, critically, a 95% prediction interval to show the expected range of effects for a new study [46].

Protocol 2: Cross-Species Evidence Integration Workflow

Background: This protocol outlines the end-to-end process for a systematic review and meta-analysis that explicitly integrates evidence from animal and human epidemiological studies.

Materials: Pre-registered protocol (PROSPERO), systematic review software (e.g., Covidence, Rayyan), data extraction forms, risk-of-bias tools (e.g., SYRCLE for animals, ROBINS-I for observational studies), statistical software.

Procedure:

• PICO Formulation: Define the Population, Intervention/Exposure, Comparison, and Outcome. For cross-species reviews, use broad PICO definitions with clear sub-grouping plans (e.g., Population: Homo sapiens and relevant animal models of disease X).
• Dual Searches: Conduct separate, tailored systematic searches in biomedical (e.g., PubMed, Embase) and species-specific (e.g., CAB Abstracts, Web of Science) databases. Merge results and deduplicate.
• Parallel Screening & Extraction: Screen and extract data separately for human and animal studies initially, using tailored forms. Create a unified data dictionary to harmonize key variables (e.g., dose to mg/kg/day, outcome timing to phases of disease).
• Structured Synthesis:
  • Species-Specific Analysis: Perform separate meta-analyses for human and animal data using appropriate models (random-effects for humans, multilevel for animals). Quantify and characterize heterogeneity within each evidence stream.
  • Comparative Qualitative Synthesis: Use a framework (e.g., Framework Synthesis [50]) to juxtapose findings. Create evidence tables comparing direction of effect, effect size magnitude, dose-response, and risk of bias across species.
  • Quantitative Integration (if justified): If effect measures are directly comparable and heterogeneity is understood, a cross-species meta-analysis with "species" as a moderator can be performed. This is a high-inference step requiring strong biological justification.
• Grading Cross-Species Evidence: Adapt the GRADE approach to assess the certainty of the translated evidence. Consider downgrading for interspecies indirectness, inconsistency between species, and imprecision in animal models; consider upgrading for large, consistent animal effects with evidence of a dose-response gradient.

Protocol 3: Meta-Regression and Subgroup Analysis to Explore Heterogeneity

Background: Meta-regression assesses whether continuous or categorical study-level covariates (moderators) explain between-study heterogeneity [49]. In cross-species analysis, potential moderators include species class, sex, intervention dose, study quality score, and year of publication.

Materials: Dataset with effect sizes and candidate moderator variables. Sufficient statistical power (≥ 10 studies per moderator is a common heuristic).

Procedure:

• Univariable Analysis: Fit a separate multilevel meta-regression model for each candidate moderator. For a categorical moderator (e.g., species class: rodent vs. non-human primate):
  • Model: rma.mv(ES ~ moderator, V = v, random = ~ 1 | Species/Study, data = dataset)
  • Interpret the coefficient for the moderator: its significance indicates whether effect size differs across levels.
• Assess Explained Variance: Compare the total between-study variance (τ²) of this model to the τ² from the intercept-only model (Protocol 1). The proportional reduction in τ² is an R²-like measure of variance explained by the moderator.
• Multivariable Analysis: If multiple significant moderators are identified, a multivariable model can be built to assess their independent contributions. Beware of overfitting.
• Subgroup Analysis as Visualization: For key categorical moderators (e.g., risk of bias: high/low), present separate pooled estimates for each subgroup in a forest plot. Test for subgroup differences using a mixed-effects model where subgroups are allowed to have different true effects.

The Scientist's Toolkit: Research Reagent Solutions

Table 4: Essential Toolkit for Cross-Species Evidence Synthesis

Category	Tool/Resource	Specific Function	Application Notes
Study Registration & Protocol	PROSPERO (International Prospective Register of Systematic Reviews)	Publicly registers systematic review protocols to reduce duplication bias and promote transparency [4].	Mandatory first step. Use the specific fields for "animal" studies.
Search & Management	CAB Abstracts, PubMed, Embase, Web of Science	Comprehensive literature searching across human and veterinary/animal science databases [51].	Tailor search strings with species-specific terms (e.g., MeSH "Disease Models, Animal").
	Systematic Review software (e.g., Covidence, Rayyan)	Manages title/abstract screening, full-text review, and conflict resolution with dual reviewers.	Essential for maintaining rigor and audit trails in high-volume searches.
Risk of Bias Assessment	SYRCLE's RoB Tool (for animal studies)	Evaluates internal validity of animal studies across domains like selection, performance, detection bias [4].	Use alongside human RoB tools (e.g., ROBINS-I for observational studies) for parallel assessment.
Statistical Analysis	R with metafor, brms, meta packages	Gold-standard environment for fitting multilevel, meta-regression, and advanced models [47] [49].	Steep learning curve but offers maximum flexibility. Online tutorials are available [47].
	JASP, RevMan	Provide point-and-click interfaces for standard meta-analysis.	Useful for simpler analyses but may lack advanced multilevel capabilities.
Data & Reporting	PRISMA (Preferred Reporting Items for Systematic Reviews and Meta-Analyses)	Reporting guideline to ensure complete and transparent manuscripts [4].	Use the PRISMA checklist and flowchart from the start of the project.
	FAIR Guiding Principles	Framework (Findable, Accessible, Interoperable, Reusable) for sharing meta-analytic data and code [30].	Deposit extracted data and analysis scripts in repositories like Figshare or Zenodo with a DOI.

The synthesis of diverse evidence streams, particularly epidemiological (human) and preclinical (animal) data, is a critical frontier in public health research and drug development. Systematic reviews and meta-analyses serve as the foundational methodology for this synthesis, providing a structured, transparent, and reproducible means to evaluate collective findings [52]. In public health, where decisions impact populations and resources, integrating these evidence types into decision-support models enhances the biologic plausibility of associations, improves risk assessment, and informs translational research priorities [9].

This case study details the application notes and protocols for constructing evidence-integrated decision support models. Framed within a broader thesis on synthesizing human and animal evidence, it provides a pragmatic roadmap for researchers and drug development professionals. The following sections outline standardized methodologies for evidence synthesis, present performance data from applied models, and visualize the integrative workflows essential for robust public health decision-making.

Application Notes: Data Synthesis for Model Development

Quantitative Synthesis of Systematic Review Characteristics

The landscape of systematic reviews (SRs), especially those evaluating clinical prediction models (CPMs), reveals rapid growth and significant methodological diversity. A scoping review of 1004 SRs of CPMs published between 2001-2023 provides key metrics for understanding this field [6].

Table 1: Characteristics of Systematic Reviews of Clinical Prediction Models (2001-2023) [6]

Characteristic	Category	Number (%) of SRs
Publication Volume	Published after 2020	669 (66.6%)
	Peak publication year (2020)	340 (33.7%)
Geographic Origin	Europe	443 (44.1%)
	Asia	268 (26.7%)
Model Type Focus	Prognostic models only	699 (69.6%)
	Diagnostic models only	169 (16.8%)
	Both prognostic & diagnostic	136 (13.6%)
Methodological Reporting	Used a structured review question framework (e.g., PICO)	117 (11.7%)
	Used a standardized data extraction checklist	202 (20.2%)
	Conducted a meta-analysis (vs. narrative only)	366 (36.5%)
	Assessed certainty of evidence (e.g., GRADE)	52 (5.2%)
Risk of Bias Assessment	Reported any quality/risk of bias assessment	768 (76.5%)
	Used PROBAST tool	280 (27.9%)
	Used QUADAS-2 tool	171 (17.0%)

Performance Metrics of Machine Learning in Public Health

Machine learning (ML) models are increasingly deployed as core components of data-driven public health decision support systems. A narrative review of 170 studies highlights their performance across key domains [53].

Table 2: Performance of Machine Learning Models in Public Health Applications [53]

Public Health Domain	Exemplary ML Techniques	Reported Performance Metrics	Primary Function
Disease Outbreak Forecasting	LSTM, GRU neural networks	Prediction accuracy: 88% - 95%	Early warning and surveillance
Genomic Data Analysis	Various supervised ML models	Improved risk assessment & pharmacogenomic modeling	Disease subtype discovery, personalized risk prediction
Mental Health Monitoring	NLP, wearable data analysis	Detection accuracy up to 91% for stress/depression	Real-time symptom tracking and intervention trigger
Hospital Resource Optimization	Deep learning forecasting models	Minimized error in emergency admission predictions	Efficient allocation of beds, staff, and equipment

Protocol for Integrated Evidence Review Registration

The prospective registration of a review protocol is a critical first step in ensuring transparency and reducing bias. The PROSPERO4animals registry provides a dedicated platform for reviews synthesizing animal evidence, which can be adapted for integrated human-animal reviews [54]. Key application notes include:

• Use Appropriate Frameworks: Formulate the review question using a structured framework. For integrated reviews, this may involve a hybrid approach:
  • PICO: For interventional questions (Population, Intervention, Comparison, Outcome).
  • PECO: For exposure questions (Population, Exposure, Comparison, Outcome).
  • Separate but linked questions for human and animal evidence streams [54] [55].
• Realistic Timeline: Estimate a minimum of 12 months for completion of a full systematic review with meta-analysis, accounting for the complexity of dual-stream data synthesis [54].
• Pre-data Extraction Registration: The protocol must be registered before data extraction begins to preserve the benefits of prospective registration and minimize reporting bias [54].

Experimental Protocols

Protocol 1: Dual-Stream Systematic Review with Meta-Analysis

This protocol details the steps for conducting a systematic review that integrates human (epidemiological) and animal (preclinical) evidence to inform a public health decision model.

I. Protocol Development & Registration

• Define Integrated Research Question: Frame overarching and sub-questions using PICO/PECO. Example: "What is the evidence that exposure to environmental pollutants impedes diet-induced weight loss and glycemic control in (a) humans and (b) animals?" [55].
• Register Protocol: Submit the detailed protocol to an appropriate registry (e.g., PROSPERO for health-related reviews, PROSPERO4animals for animal studies) [54].

II. Search Strategy & Study Selection

• Database Search: Execute comprehensive, standardized searches in at least two bibliographic databases per evidence stream (e.g., PubMed/MEDLINE, Embase for human evidence; PubMed, Web of Science for animal evidence) [52].
• Grey Literature: Search clinical trial registries, preprint servers, and dissertation databases to mitigate publication bias [56].
• Dual Screening: Two reviewers independently screen titles/abstracts and full texts against predefined inclusion/exclusion criteria using tools like Rayyan or Covidence [52]. Disagreements are resolved by consensus or a third reviewer.

III. Data Extraction & Quality Assessment

• Standardized Extraction: Use piloted, customized forms to extract data. For integrated reviews, forms must capture:
  • Human Studies: Study design, population, exposure/intervention, outcomes, effect estimates.
  • Animal Studies: Species, strain, model induction method, exposure regimen, outcome measures, sample size [9].
• Risk of Bias Assessment: Use domain-specific tools:
  • Human Studies: Cochrane RoB 2 for RCTs; Newcastle-Ottawa Scale for observational studies.
  • Animal Studies: SYRCLE's risk of bias tool [9].
  • Prediction Models: PROBAST tool [6].

IV. Data Synthesis & Integration

• Separate Quantitative Synthesis: Conduct meta-analyses for human and animal data streams independently where clinical and methodological homogeneity allows [52].
• Explore Heterogeneity: Use subgroup analysis (e.g., by species, study design, exposure level) and meta-regression to explore sources of heterogeneity [9].
• Comparative Integration: Create a structured summary table comparing the direction, magnitude, and consistency of effects, biological gradients (dose-response), and risk of bias across the two evidence streams. This narrative-biostatistical summary feeds directly into decision model inputs.

Protocol 2: Building a Data-Driven Decision Support Model

This protocol outlines the development of a decision support model (e.g., a clinical prediction model or resource optimization tool) informed by the synthesized evidence from Protocol 1.

I. Problem Framing & Data Infrastructure

• Define Decision Objective: Specify the model's goal (e.g., predict individual risk, optimize triage, forecast resource demand) [56].
• Assemble Data Ecosystem: Integrate diverse data sources, ensuring interoperability. Key strategies include using ontology-based data models (e.g., linking SNOMED CT, LOINC) and standards like HL7 FHIR for exchange [57].

II. Model Development & Training

• Feature Selection: Derive input variables (features) from the integrated evidence review, prioritizing factors with consistent support across human and animal studies.
• Algorithm Selection: Choose an algorithm suited to the data and task (e.g., logistic regression for interpretability, Random Forests or Gradient Boosting for complex relationships, neural networks for temporal data) [53] [56].
• Training & Validation: Split data into training/validation sets. Use cross-validation to tune hyperparameters and prevent overfitting. For models using real-world health data, ensure robust governance for privacy and security [57].

III. Performance Evaluation & Calibration

• Assess Discrimination & Calibration: Evaluate model performance using appropriate metrics (e.g., AUC-ROC, accuracy, F1-score). Calibration plots are essential for risk prediction models [6].
• Sensitivity Analysis: Test model robustness by varying key input parameters derived from the evidence synthesis, especially those where human and animal data disagree or have high uncertainty.

IV. Implementation Framework

• Explainability & Trust: Implement explainable AI (XAI) techniques (e.g., SHAP values) to make model decisions interpretable to public health practitioners [53].
• Integration into Workflow: Design the model as a component within a larger decision support system, considering user interface and integration with Electronic Health Records (EHRs) [56] [57].

Visualization of Workflows and Relationships

Evidence Integration for Public Health Decision Models

Decision Support Model Workflow

The Scientist's Toolkit: Research Reagent Solutions

Table 3: Essential Tools for Integrated Evidence Synthesis and Model Development

Tool / Resource	Category	Primary Function in Protocol	Key Application Note
Covidence / Rayyan	Study Screening	Manages import of search results, de-duplication, and dual-reviewer screening of titles/abstracts and full texts [52].	Essential for maintaining an audit trail and resolving conflicts during the study selection phase of Protocol 1.
PROSPERO / PROSPERO4animals	Protocol Registry	Provides prospective, time-stamped registration of systematic review protocols to reduce bias and avoid duplication [54].	Registration is mandatory before data extraction begins. PROSPERO4animals is specific for animal study reviews.
CHARMS Checklist	Data Extraction	Guides the extraction of critical data from primary studies of prediction models [6].	Ensures consistency when extracting model details (predictors, performance, validation) in reviews of CPMs.
PROBAST Tool	Risk of Bias Assessment	Assesses the risk of bias and applicability of diagnostic and prognostic prediction model studies [6].	The standard tool for evaluating primary studies in a prediction model SR (Protocol 1, Step III).
R with 'metafor' / 'meta' packages	Statistical Synthesis	Conducts meta-analysis, calculates pooled effect estimates, generates forest and funnel plots, and performs subgroup/meta-regression analyses [52].	The preferred open-source environment for the quantitative synthesis steps in Protocol 1.
LightGBM / LSTM Networks	ML Algorithm	Advanced machine learning algorithms for building high-accuracy prediction and forecasting models [53].	LightGBM is efficient for structured data; LSTMs are suited for time-series forecasting (e.g., outbreak prediction) in Protocol 2.
SHAP (SHapley Additive exPlanations)	Model Interpretability	Explains the output of any ML model by quantifying the contribution of each input feature to a specific prediction [53].	Critical for building trust and facilitating the implementation of "black box" models in clinical settings (Protocol 2, Step IV).
HL7 FHIR Standard	Data Interoperability	A modern standards framework for exchanging healthcare information electronically [57].	Enables the integration of diverse data sources (EHRs, wearables) into a cohesive ecosystem for model training and deployment.

Overcoming Obstacles: Tackling Heterogeneity, Bias, and Translation Challenges

Thesis Context: This document provides application notes and detailed methodological protocols for addressing three fundamental challenges in systematic reviews that seek to integrate animal (preclinical) and human (epidemiological, clinical) evidence: Model Relevance, Study Design Heterogeneity, and Publication Bias. Effective integration is critical for translational research, informing hypothesis generation for human studies, improving the design of clinical trials, and providing a more comprehensive biological understanding of disease mechanisms and risk factors [9].

Application Note: Assessing and Ensuring Model Relevance

Core Challenge: A primary limitation in translating animal evidence is the questionable relevance of animal models to human pathophysiology and exposure scenarios. The predictive validity for human outcomes is often low; for example, the average translation success rate from animal models of cancer to clinical trials is less than 8%, and of over 700 treatments effective in animal stroke models, only two are effective in humans [9]. In epidemiology, relevance is challenged by the use of inadequate exposure proxies (e.g., environmental models versus biomonitoring) that poorly represent the true biologically effective dose in humans [58].

Protocol 1.1: Framework for Assessing Translational Relevance of Animal Evidence

Objective: To systematically evaluate the biological, phenotypic, and interventional fidelity of animal models used in a body of preclinical literature.

Materials: SYRCLE's Animal Study Risk of Bias Tool; CAMARADES checklist; data extraction form tailored for relevance domains.

Procedure:

• Define the Human Condition: Precisely specify the human disease, exposure, or pathophysiology of interest (e.g., "post-menopausal osteoporosis," "chronic low-dose ambient PM2.5 exposure").
• Extract Model Characteristics: For each included animal study, catalog:
  • Species, Strain, Sex, and Age: Note if models use aged animals or specific genetic backgrounds relevant to the human condition.
  • Induction Method: Assess the face validity (e.g., ovariectomy for menopause, specific carcinogen for cancer).
  • Outcome Measures: Determine if endpoints are functional/clinical (e.g., fracture force, tumor metastasis) or merely mechanistic/molecular.
  • Intervention Timing & Dosing: Compare the intervention window (prophylactic vs. therapeutic) and pharmacokinetic/pharmacodynamic dosing to planned human application.
• Apply a Relevance Grading Schema: Categorize each study's model as having High, Moderate, or Low translational relevance based on pre-defined criteria (see Table 1).
• Stratify Analysis: Conduct meta-analyses or narrative synthesis separately for studies with high versus low relevance models. A significant treatment effect only in low-relevance models signals a high risk of translational failure.

Table 1: Criteria for Grading Translational Relevance of Animal Models

Relevance Domain	High Relevance	Moderate Relevance	Low Relevance
Face Validity	Model recapitulates key etiological factors and clinical symptoms of the human disease [9].	Model mimics some primary symptoms or pathology, but induction is artificial.	Model bears minimal phenotypic resemblance to the human condition.
Construct Validity	Underlying pathophysiology is mechanistically analogous to humans (supported by genetic/ molecular evidence).	Some shared pathways, but key mechanistic differences are known.	Mechanism of disease in the model is distinct from humans.
Predictive Validity	Model has a documented history of correctly predicting human response (efficacy or toxicity).	Unknown or mixed record of predictiveness.	Model has a history of generating false-positive or false-negative human predictions.
Interventional Parity	Treatment regimen (dose, timing, route) is clinically translatable.	Regimen requires significant scaling or adjustment for human use.	Regimen is purely experimental and not feasible in humans.

Protocol 1.2: Protocol for Evaluating Exposure Assessment in Observational Epidemiology

Objective: To critically appraise the accuracy and biological relevance of exposure measurement methods across epidemiological studies to be integrated.

Materials: Pre-defined criteria for exposure misclassification risk [58]; expertise in exposure science.

Procedure:

• Classify Exposure Metrics: Categorize the primary exposure metric used in each study (e.g., personal air monitor, stationary monitor with spatial interpolation, job-exposure matrix, self-reported questionnaire).
• Assess Misclassification Risk: For each study, judge the potential for non-differential (random) or differential (systematic) misclassification [58]:
  • High Confidence: Direct, quantitative biomonitoring (e.g., blood lead level) or validated personal monitoring during a relevant time window.
  • Medium Confidence: Well-calibrated environmental modeling or detailed occupational histories with expert assessment.
  • Low Confidence: Crude surrogate (e.g., distance to road, "ever/never" held a job title).
• Consider Direction of Bias: Evaluate how misclassification likely biases effect estimates (e.g., non-differential misclassification typically biases towards the null).
• Integrate with Animal Data: Use animal toxicokinetic studies to inform the biological plausibility of exposure levels and routes measured in human studies. Discrepancies may highlight unreliable exposure proxies in the epidemiological literature.

Visualization: Model Relevance Assessment Workflow

Diagram 1: A sequential workflow for assessing the relevance of individual studies prior to evidence synthesis.

Application Note: Managing Study Design Heterogeneity

Core Challenge: Both preclinical and epidemiological literatures are marked by profound methodological diversity. In animal research, heterogeneity arises from variations in species, strain, sex, experimental protocols, dosing, and outcome measurement [9]. In epidemiology, studies vary by design (cohort, case-control, cross-sectional), confounding control, and exposure/outcome definitions [58]. This heterogeneity complicates meta-analysis and can obscure true effects.

Protocol 2.1: Quantitative Protocol for Exploring Sources of Heterogeneity

Objective: To statistically identify and quantify the contribution of different study-level characteristics to the overall variability in effect sizes.

Materials: Statistical software (R, Stata); dataset of study effect sizes and covariates.

Procedure:

• Define Covariates of Interest: A priori, specify potential effect modifiers based on biological or methodological rationale (e.g., animal species, risk of bias score, study design in epidemiology).
• Perform Meta-Regression:
  • Use a random-effects model to account for residual heterogeneity.
  • Introduce one covariate at a time into the model: Effect Size ~ 1 + Covariate.
  • The coefficient for the covariate indicates how it modifies the effect size. A significant p-value (<0.1) suggests the covariate explains a portion of heterogeneity.
• Subgroup Analysis: For categorical covariates (e.g., species: mouse vs. rat), perform separate meta-analyses for each subgroup. Compare the summary effect sizes and their confidence intervals.
• Report Heterogeneity Metrics: For all models, report the I² statistic (percentage of total variability due to heterogeneity rather than chance) and the tau² (estimated variance of true effects).

Table 2: Common Sources of Heterogeneity and Data Extraction Items

Evidence Domain	Source of Heterogeneity	Data Extraction Item for Analysis
Animal Studies	Biological Model	Species (mouse, rat, primate), strain, sex, age/weight, disease induction method [9].
	Experimental Design	Timing of intervention relative to disease, dose/dosing regimen, route of administration, use of anesthesia [59].
	Outcome & Analysis	Primary outcome measure (behavioral, histological, molecular), duration of follow-up, method of statistical analysis [9].
Epidemiological Studies	Study Design & Population	Design (cohort, case-control), source population, sample size, follow-up length [58].
	Exposure Assessment	Exposure metric (biomarker, modeled, self-report), classification method (continuous, quartiles, binary) [58].
	Confounding & Bias Control	Confounders adjusted for, methods for handling missing data, risk of bias score [58].

Protocol 2.2: Protocol for Cohesive Evidence Integration Across Heterogeneous Studies

Objective: To move beyond simple pooling to a structured qualitative integration that explains heterogeneity and grades confidence in findings [58].

Materials: GRADE or GRADE-like frameworks; pre-specified criteria for weighting evidence.

Procedure:

• Do Not Force Quantitative Synthesis: If clinical, methodological, or statistical heterogeneity is too great (I² > 75%), forego meta-analysis and use structured narrative synthesis.
• Create "Summary of Findings" Tables: For each key outcome, tabulate the effect direction and magnitude from each study, alongside its relevance (Protocol 1.1) and risk of bias.
• Assess Consistency: Evaluate whether effects point in the same direction across studies of different designs and populations. Explore plausible reasons for inconsistency (e.g., effect modification by sex or exposure level).
• Grade the Overall Evidence: Using a framework like GRADE, rate the confidence in the body of evidence (high, moderate, low, very low) based on risk of bias, inconsistency, indirectness (relevance), imprecision, and publication bias. Explicitly note how heterogeneity impacts the rating.

Visualization: Evidence Integration Pathway

Diagram 2: A pathway for integrating heterogeneous evidence from animal and human studies.

Application Note: Detecting and Mitigating Publication Bias

Core Challenge: Publication bias, the preferential publication of statistically significant or "positive" results, distorts the evidence base. Surveys suggest only about 50% of animal experiments from non-profit institutes are published, with rates potentially below 10% in industry [60]. This leads to overestimates of effect sizes in meta-analyses and can trigger futile or premature clinical trials [9] [61].

Protocol 3.1: Protocol for Comprehensive Assessment of Publication Bias

Objective: To employ statistical and methodological tools to detect and evaluate the potential impact of missing studies.

Materials: Funnel plots; statistical tests (Egger's regression, trim-and-fill); registry search tools (ClinicalTrials.gov, SYRCLE's PROSPERO-like registries).

Procedure:

• Search Study Registries: Systematically search preclinical and clinical trial registries for completed but potentially unpublished studies matching your PECO/PICO question.
• Construct and Inspect Funnel Plots: Plot each study's effect size against its standard error. Asymmetry (a gap in the bottom-left quadrant indicating missing small, null studies) suggests publication bias. Note: heterogeneity can also cause asymmetry.
• Apply Statistical Tests:
  • Egger's Linear Regression Test: A formal test for funnel plot asymmetry (p < 0.1 indicates significant asymmetry).
  • Trim-and-Fill Method: Estimates the number of missing studies and imputes them to provide an "adjusted" effect size.
• Calculate a Fail-Safe N: Estimate how many null-result studies would be needed to overturn a statistically significant meta-analytic result.

Table 3: Publication Bias Assessment Tools and Interpretation

Tool/Method	Application	Interpretation & Caveats
Funnel Plot	Visual assessment of bias. Plot effect size (x) vs. precision (1/SE, y).	Asymmetry suggests bias but may be due to heterogeneity, chance, or true study size effects.
Egger's Regression Test	Statistical test for funnel plot asymmetry.	p-value < 0.10 suggests significant asymmetry. Low power when number of studies is small (<10).
Trim-and-Fill Method	Adjusts meta-analysis for missing studies.	Provides an estimate of the number of missing studies and a bias-adjusted effect size. Can be unstable.
Study Registry Search	Proactive search for unpublished data.	Finding completed but unreported studies is direct evidence of reporting bias.

Protocol 3.2: Protocol for Prospective Registration and Living Systematic Reviews

Objective: To prevent publication bias at its source and maintain an up-to-date evidence synthesis [10].

Materials: Public protocol registries (PROSPERO for clinical, Open Science Framework, SYRCLE).

Procedure:

• Mandatory Protocol Pre-registration: Before beginning the review, publish a detailed protocol specifying hypotheses, search strategy, inclusion criteria, and planned analyses. This locks in the methodology and reduces selective reporting within the review [10].
• Implement a "Living" Review Approach:
  • Establish regular, automated database searches (e.g., monthly).
  • Use a defined workflow to quickly screen new results, extract data, and update analyses.
  • Publish periodic updates to the review as significant new evidence emerges.
• Engage with Consortia: Collaborate with initiatives like CAMARADES and SYRCLE, which advocate for improved animal study design, reporting, and data sharing to create a less biased primary literature [10].

Visualization: Publication Bias & The Evidence Ecosystem

Diagram 3: How publication bias distorts the evidence base available for synthesis.

The Scientist's Toolkit: Key Reagent Solutions for Integrated Reviews

Table 4: Essential Resources for Conducting Integrated Systematic Reviews

Tool / Resource	Function / Purpose	Key Features / Notes
SYRCLE's Risk of Bias Tool	To critically appraise internal validity of animal studies.	Assesses sequence generation, blinding, outcome reporting, etc. Tailored for animal research.
CAMARADES Checklist	To assess methodological quality of preclinical studies.	Provides a framework for extracting data on study design, sample size, controls, etc.
GRADE Framework	To grade the certainty (quality) of a body of evidence.	Systematically evaluates risk of bias, inconsistency, indirectness, imprecision, publication bias.
PRISMA Guidelines	To ensure transparent and complete reporting of systematic reviews.	A 27-item checklist covering title, abstract, methods, results, discussion.
Burden of Proof Risk Function (BPRF) [62]	To quantitatively evaluate risk-outcome relationships, accounting for bias and heterogeneity.	Estimates the smallest level of risk consistent with data; complements GRADE.
Rayyan QCRI	A web-based tool for collaborative study screening and selection.	Manages blinding between reviewers, handles large volumes of references.
R packages (metafor, robvis)	To perform meta-analysis, meta-regression, and create risk-of-bias visualizations.	Provides comprehensive statistical environment for evidence synthesis.
Open Science Framework (OSF)	A platform for pre-registering review protocols and sharing data.	Mitigates publication bias by making methodology and intent public before review begins.

The systematic review represents the cornerstone of evidence-based decision-making, yet its application transcends the realm of clinical trials [9]. Within the broader thesis on integrating epidemiological and animal evidence, systematic review methodology serves as the essential, unifying framework. This integration is critical for fields like translational medicine, toxicology, and public health, where evidence must be drawn from multiple streams—human populations and controlled animal models—to form a coherent conclusion on disease etiology, intervention efficacy, or hazard identification [9].

The foundational challenge in such integration is the critical appraisal of each evidence stream's internal validity, which is threatened by different forms of bias. Animal intervention studies, while experimental, possess distinct methodological characteristics compared to randomized clinical trials (RCTs), such as induced disease models, small sample sizes, and environmental influences on outcomes [32]. Epidemiological studies, particularly non-randomized studies of exposures, face unique threats from confounding, measurement error, and selection bias that are inherently different from those in RCTs [63]. Therefore, employing design-specific tools is not merely an option but a necessity for accurate, cross-stream evidence evaluation.

This article provides detailed application notes and protocols for two pivotal risk of bias (RoB) tools: SYRCLE’s RoB tool for animal studies and the ROBINS-E tool for observational epidemiological studies of exposures. The goal is to equip researchers with the methodological precision needed to assess each evidence type rigorously, thereby enabling a valid and transparent synthesis of integrated evidence for scientific and policy decisions.

A variety of tools exist to assess the risk of bias, each tailored to specific study designs and their associated methodological challenges. The selection of an appropriate tool is the first critical step in a systematic review. The table below summarizes the key characteristics of major tools relevant to animal and human health research.

Table 1: Key Risk of Bias Tools for Animal and Epidemiological Studies

Tool Name	Primary Study Design	Core Purpose	Key Domains/Bias Types Addressed	Output/Rating
SYRCLE's RoB [32] [64] [65]	Animal intervention studies	Assess internal validity of animal experiments for systematic reviews.	Selection, performance, detection, attrition, reporting, and other biases (e.g., baseline characteristics, random housing).	Judgement (Low/High/Unclear) per 10 signalling items; no overall score.
ROBINS-E [66]	Non-randomized studies of exposures (observational epidemiology)	Assess risk of bias in observational studies investigating environmental, occupational, or other exposures.	Confounding, measurement of exposure, selection, post-exposure interventions, measurement of outcome, missing data, selective reporting.	Judgement (Low/Moderate/Serious/Critical) per domain; overall judgement; predicts direction of bias.
ROBINS-I	Non-randomized studies of interventions	Assess risk of bias in observational studies estimating effects of interventions.	Similar to ROBINS-E but focused on interventions.	Judgement per domain and overall.
Cochrane RoB 2	Randomized Controlled Trials	Assess risk of bias in randomized trials.	Bias from randomization, deviations, missing data, outcome measurement, result selection.	Judgement per domain and overall.
Navigation Guide/OHAT Tool [63] [67]	Human & Animal studies (parallel)	Evaluate internal validity across evidence streams using common terminology and domains.	Tailored domains for human and animal studies within a unified framework.	Risk-of-bias rating; used to assign studies to tiers for evidence synthesis.

The theoretical evolution of these tools highlights a shift towards greater integration. SYRCLE's tool was explicitly adapted from the Cochrane RoB tool to address animal-specific concerns [32]. More recently, frameworks like that proposed by [68] and tools like the National Toxicology Program's (NTP) Risk of Bias Tool [67] advocate for a unified approach to assessing bias—conceptualizing it as arising from common causes, common effects, or measurement errors—regardless of study design. This unified theory facilitates clearer communication and more coherent integration when appraising mixed evidence.

SYRCLE’s Risk of Bias Tool: Application Notes and Protocol

Tool Structure and Animal-Specific Adaptations

SYRCLE's RoB tool structures its assessment around 10 entries, each linked to a core type of bias through specific signalling questions [32] [65]. Half of the items are aligned with the Cochrane RoB tool, while the others are revised or new to address the unique context of animal experimentation.

Key adaptations include:

• Selection Bias (Baseline Characteristics): Requires assessment of similarity between groups at baseline, crucial due to typical small sample sizes [32].
• Performance Bias (Random Housing): A new item assesses if cages were randomized to avoid systematic environmental differences (e.g., temperature, light) that could influence outcomes [32].
• Performance Bias (Blinding): Emphasizes blinding of all personnel, including animal caregivers, who might alter behavior based on knowledge of treatment [32].
• Detection Bias (Random Outcome Assessment): Assesses whether animals were selected randomly for testing to avoid bias from circadian rhythms or investigator anticipation [32].

Step-by-Step Application Protocol

Phase 1: Preparation

• Define the Review Question: Precisely specify Population (animal model), Intervention, Comparator, and Outcome (PICO).
• Prioritize Baseline Characteristics: Before assessment, determine which animal characteristics (e.g., weight, age, disease severity score) are essential for comparability [32].
• Train the Review Team: Ensure all reviewers understand the tool's signalling questions and animal research methodologies.

Phase 2: Assessment for a Single Study

• Gather Full Text: Obtain the complete study manuscript and any supplementary protocols or data.
• Answer Signalling Questions: For each of the 10 items, answer the provided signalling questions (e.g., "Was the allocation sequence adequately generated and applied?"). Use "Yes," "No," or "Unclear" based on reported information.
• Make a Risk Judgement: For each item, synthesize the answers to the signalling questions to judge the risk of bias as "Low," "High," or "Unclear."
  • Example (Item 2: Baseline Characteristics): If the study reports comparable weight and age across groups at start, judge as "Low." If groups differ significantly on a prioritized characteristic with no adjustment, judge as "High." If characteristics are not reported, judge as "Unclear."

Phase 3: Synthesis and Reporting

• Tabulate Judgements: Create a table or figure summarizing the risk of bias judgements across all included studies.
• Incorporate into Analysis: Use the assessments to inform sensitivity or subgroup analyses (e.g., comparing pooled effects from studies with low vs. high risk of bias in key domains).
• Report Transparently: Clearly document the assessment process, all judgements, and how they informed the review's conclusions.

ROBINS-E and Epidemiological Tool Application: Notes and Protocol

The ROBINS-E Tool: Focus on Exposure Studies

The Risk Of Bias In Non-randomized Studies - of Exposure (ROBINS-E) tool, released in 2024, is a state-of-the-art tool designed specifically for observational epidemiology of exposures [66]. It moves beyond a simple checklist by requiring reviewers to specify the causal effect the study aims to estimate and to predict the direction of potential bias [66].

ROBINS-E assesses seven bias domains:

• Bias due to confounding.
• Bias arising from measurement of the exposure.
• Bias in selection of participants into the study (or into the analysis).
• Bias due to post-exposure interventions.
• Bias arising from measurement of the outcome.
• Bias due to missing data.
• Bias in selection of the reported result.

Step-by-Step Application Protocol for ROBINS-E

Phase 1: Preparatory Causal Thinking

• Define the Target Trial: Articulate the hypothetical randomized controlled trial (the "target trial") that the observational study is emulating. This includes its PECO components (Population, Exposure, Comparator, Outcome) and the intended causal effect.
• Specify the Causal Contrast: Clearly state the exact comparison the study result represents (e.g., "always exposed" vs. "never exposed").

Phase 2: Domain-Level Assessment

• Complete Signalling Questions: For each domain, work through the tailored signalling questions in the ROBINS-E template [66]. These questions probe the study's design, conduct, and analysis.
• Judge Domain Risk of Bias: Based on the answers, judge the risk of bias for the domain as "Low," "Moderate," "Serious," or "Critical."
• Predict Direction of Bias: For each domain judged as anything other than "Low," make a prediction: would the potential bias likely lead to underestimation, overestimation, or an unclear direction of the true effect?

Phase 3: Overall Assessment and Implementation

• Determine Overall Risk of Bias: The overall judgement is guided by the most severe domain-level judgements. A "Critical" judgement in any domain typically leads to an overall "Critical" rating.
• Use in Evidence Synthesis: Studies at "Critical" risk of bias are often excluded from primary meta-analyses. The direction of bias predictions can inform qualitative discussions on the robustness of findings and is a recommended improvement over simplistic scoring systems [63].
• Report: Present domain and overall judgements, along with directional predictions, in evidence tables.

Integrated Synthesis Protocol for Multi-Stream Evidence

Integrating evidence from SYRCLE-assessed animal studies and ROBINS-E-assessed human studies requires a structured, pre-planned protocol that goes beyond parallel reporting.

Phase 1: Problem Formulation & Parallel, Independent Appraisal

• Formulate a common research question (e.g., "Does chemical X cause adverse effect Y?").
• Conduct separate systematic searches for animal and human evidence.
• Apply the SYRCLE protocol (Section 3.2) and the ROBINS-E protocol (Section 4.2) independently to their respective evidence bases.

Phase 2: Translation and Alignment of Evidence

• Map Mechanistic Pathways: Create a diagram linking exposure to outcome, identifying key biological and pathological events. This map provides a framework to align findings across species.
• Align Outcome Measures: Determine how outcomes measured in animals (e.g., liver enzyme elevation, tumor histology) correspond to human health outcomes (e.g., clinical liver disease, cancer incidence).
• Assess Biological and Methodological Concordance/Discordance: Systematically compare the direction, magnitude, and consistency of effects across streams, while accounting for differences in risk of bias, exposure timing, and dose.

Phase 3: Integrated Weight-of-Evidence Assessment

• Triangulation: Use the principle of triangulation—seeking convergence from different methodological approaches and species—to strengthen causal inference [63].
• Generate Integrated Conclusions: Synthesize conclusions not by a simple vote count, but by considering the coherence of evidence across streams, the biological plausibility established by animal models, the human relevance from epidemiological data, and the internal validity of each contributing study as determined by the RoB tools.
• Identify Research Gaps: The integrated analysis should explicitly highlight gaps in either evidence stream (e.g., a consistent animal finding with insufficient high-quality human data).

The following diagram illustrates this integrated workflow for synthesizing evidence from animal and epidemiological studies:

Conducting rigorous, integrated systematic reviews requires specific resources and reagents. The table below details key solutions for the protocols described.

Table 2: Research Reagent Solutions for Integrated Risk of Bias Assessment

Item/Tool Name	Primary Function	Relevance to Protocol	Access/Example
SYRCLE's RoB Tool	Standardized worksheet for assessing 10 bias domains in animal studies.	Core tool for Phase 1-3 of the animal study assessment protocol.	Available in the primary publication [32].
ROBINS-E Template	Word or Excel template with signalling questions for 7 bias domains.	Core tool for Phase 1-3 of the epidemiological study assessment protocol.	Available for download from the official website [66].
Database of Animal Systematic Reviews [11]	A searchable database of over 3,100 systematic reviews of animal studies.	Aids in identifying existing reviews, avoiding duplication, and understanding methodological trends.	Freely available at Mendeley Data.
Protocol Registration Platform (e.g., PROSPERO, Open Science Framework)	Public registry for systematic review protocols.	Critical for minimizing reporting bias; allows pre-specification of methods for both animal and human streams.	PROSPERO accepts protocols for reviews of human and animal studies.
Causal Diagram/DAG Software (e.g., DAGitty)	Software for drawing and analyzing causal directed acyclic graphs (DAGs).	Essential for implementing the unified bias framework [68] and planning confounder adjustment in ROBINS-E.	DAGitty is a free, browser-based tool.
GRADE Framework	System for rating the overall certainty of a body of evidence.	Can be extended (with caution) to rate confidence in integrated evidence spanning animal and human studies.	Detailed guidance available from the GRADE working group.

Visualization of Core Concepts

A Unified Framework for Bias Across Study Designs

The following diagram illustrates the unified theoretical framework for bias [68], which is applicable to both experimental animal studies and observational human studies, facilitating integrated critical appraisal.

The persistent failure to translate therapeutic successes from animal models to human patients represents one of the most significant and costly challenges in biomedical research. This "translation gap" is starkly evidenced by the attrition rate of 90% to 95% for drugs that appear safe and effective in animal tests but subsequently fail in human clinical trials [69]. In fields like Alzheimer's disease (AD), despite decades of research and substantial investment, very few disease-modifying therapies have emerged, underscoring a fundamental disconnect between preclinical models and human pathology [70].

The roots of this crisis are multifaceted. First, most animal models, particularly transgenic models for diseases like AD, are engineered to represent familial disease forms that account for only about 5% of human cases, while clinical trials enroll patients with the sporadic form that constitutes the remaining 95% [70]. Second, there are insurmountable species differences in physiology, metabolism, genetics, and immune system function. For example, penicillin is toxic to guinea pigs, and paracetamol is poisonous to cats, illustrating that fundamental responses can be diametrically opposed between species [69]. Third, the artificial induction of diseases in otherwise healthy animals and the high-stress environment of laboratories create artefacts that do not reflect natural human disease progression [69].

This document provides application notes and detailed protocols designed to address these challenges. It is framed within a broader thesis on the systematic integration of epidemiological and animal evidence, proposing that a more rigorous, multi-modal, and human-focused approach to preclinical research is essential for bridging the translational divide.

Methodological Framework for Assessing Translatability

A critical first step in closing the translation gap is implementing robust frameworks to evaluate the translational relevance of preclinical models before they are used for therapeutic discovery. Traditional methods, like differential gene expression analysis, have limited utility because they rely on one-to-one gene homologs between species and ignore pathway-level biology [70]. Advanced computational approaches that analyze conserved biological pathways offer a more promising solution.

A Machine Learning Workflow for Translatability Assessment

A modified TransPath-C methodology provides a structured workflow to identify "translatable pathways"—shared dysregulation in phenotype-defining biological processes across animal models and human datasets [70]. This approach shifts the focus from individual genes to systems-level biology, offering a more holistic assessment of a model's relevance to human disease.

Table 1: Assessment of Translatability in Common Alzheimer's Disease Mouse Models Using a Pathway-Centric ML Workflow [70]

Animal Model	Translatable Pathways Identified?	Key Translational Findings	Implication for Human Relevance
APP/PS1	No	No pathways showed conserved dysregulation with human AD hippocampal data.	Limited utility for studying pathways translatable to sporadic human AD.
3×Tg	No	No pathways showed conserved dysregulation with human AD hippocampal data.	Limited utility for studying pathways translatable to sporadic human AD.
5×FAD	Yes	Shared dysregulation in SREBP control of lipid synthesis and Cytotoxic T-lymphocyte (CTL) activity pathways.	Higher relevance to human AD pathology; suggests roles for lipid metabolism and neuroinflammation.

The predictive validity of this workflow was demonstrated by its accurate forecast of the clinical failure of ibuprofen for AD treatment, based solely on preclinical microarray data from treated mice [70]. This shows the potential of such methodologies to de-risk drug development pipelines.

Integrating Human and Animal Evidence in Systematic Reviews

A parallel, complementary strategy is the formal integration of human and animal evidence streams in systematic reviews. A review on lead exposure and antisocial behavior demonstrated a protocol for synthesizing epidemiological and toxicological data, adapting approaches from the U.S. EPA [29]. The process involves:

• Conducting parallel systematic searches for human and animal studies.
• Summarizing evidence using a Population, Exposure, Comparator, Outcome (PECO) framework.
• Evaluating risk of bias and study sensitivity.
• Synthesizing evidence narratively by sub-outcome (e.g., aggression, social behavior).
• Integrating evidence streams to form a unified conclusion on causality [29].

This structured integration helps determine whether animal findings corroborate human epidemiological data, thereby assessing the animal model's validity for studying that specific human health outcome.

Diagram 1: ML workflow for translational assessment (63 characters)

Detailed Experimental Protocols

Protocol: Computational Assessment of Model Translatability

This protocol, adapted from a study evaluating Alzheimer's disease models, details steps to computationally assess the translational relevance of an animal model using pathway-centric machine learning [70].

Objective: To identify biological pathways with conserved dysregulation between a given animal disease model and human patient samples, thereby evaluating the model's translational relevance.

Materials & Software:

• Microarray or RNA-seq Data: From animal model tissue (disease vs. control) and corresponding human post-mortem or biopsy tissue (disease vs. control). Must be from analogous anatomical regions.
• Data Sources: Gene Expression Omnibus (GEO), ArrayExpress.
• Quality Control Tool: GEMMA database for data quality scoring [70].
• Computational Environment: R (packages: fgsea for GSEA, sparsepca) and Python (e.g., scikit-learn for SVM, PowerTransformer).

Procedure:

• Data Acquisition and QC:
  • Source datasets from public repositories. Ensure species, disease condition, and tissue region match.
  • Filter datasets using a quality score (e.g., GEMMA score ≥ 0.4) [70].
• Pathway Enrichment Scoring:
  • Normalize raw gene expression data (e.g., using Robust Multichip Averaging for microarrays).
  • For each sample, calculate a pre-ranked gene list based on fold-change expression compared to controls.
  • Perform pre-ranked Gene Set Enrichment Analysis (GSEA) using the fgsea package in R against curated pathway gene sets (e.g., BIOCARTA, KEGG).
  • Extract Normalized Enrichment Scores (NES) for each pathway in each sample, creating a pathway (p) x sample (n) matrix for the animal and human datasets separately.
• Data Transformation and sPCA:
  • Apply a power transformation (e.g., Yeo-Johnson) to the NES matrices to normalize variance.
  • Perform Sparse Principal Component Analysis (sPCA) on the animal model's NES matrix. sPCA reduces dimensionality and noise by identifying a reduced set of pathways that explain the maximum variance (presumably linked to the disease phenotype).
  • Optimize the penalty parameter to ensure sparsity and interpretability.
• Machine Learning Classification & Projection:
  • Use the significant principal components (PCs) from the animal sPCA model as features to train a classifier (e.g., Support Vector Machine) to distinguish between animal disease and control states.
  • Project the human NES data onto the same animal-derived PCs. Use the trained classifier to predict the "phenotype" (disease/control) of the human samples.
  • Evaluate classifier performance. Pathways loading heavily on the most predictive PCs are considered "translatable pathways."

Interpretation: A model with multiple high-weight translatable pathways is considered more relevant to human disease. The classifier's accuracy on human data indicates the predictive translational power of the animal model's pathway signature.

Protocol: Functional Validation of Biomarkers in Human-Relevant Models

To move beyond correlation, biomarkers and mechanisms must be functionally validated in systems that more closely mimic human physiology [71].

Objective: To test the functional role and therapeutic relevance of a candidate biomarker or target identified in animal studies, using advanced human-relevant in vitro models.

Materials:

• Patient-Derived Organoids or 3D Co-cultures: Generated from primary human cells or induced pluripotent stem cells (iPSCs) relevant to the disease (e.g., tumor organoids, brain organoids) [71] [69].
• Microphysiological Systems (MPS / Organ-on-a-Chip): For more complex, dynamic physiological modeling (e.g., Blood-Brain Barrier-on-a-Chip) [69].
• Assay Reagents: Cell viability/cytotoxicity assays, cytokine ELISAs, immunostaining antibodies, qPCR probes for pathway analysis.
• Modulation Tools: CRISPR-Cas9 for gene knockout, siRNA for knockdown, recombinant proteins or inhibitory compounds.

Procedure:

• Model Establishment & Characterization:
  • Culture patient-derived organoids or establish co-culture systems (e.g., tumor cells with immune and stromal cells) [71].
  • Characterize the model's key pathological features (e.g., protein aggregation, cytokine secretion, gene expression signature) to confirm it recapitulates aspects of the human disease.
• Biomarker/Target Modulation:
  • In the validated model, modulate the expression or activity of the candidate biomarker/target. This can be done via genetic manipulation (CRISPR, siRNA) or pharmacological inhibition/activation.
• Functional Outcome Assessment:
  • Phenotypic Readout: Measure changes in the core disease phenotype (e.g., tumor organoid growth/size, amyloid-beta secretion in a neural model, inflammatory cytokine release).
  • Pathway Analysis: Use qPCR, western blot, or single-cell RNA-seq to verify expected downstream pathway activation or repression.
  • Therapeutic Context: If a therapeutic is involved, test its efficacy in the model and correlate response with the biomarker's baseline level or dynamic change.
• Longitudinal Analysis:
  • For dynamic processes like treatment resistance, perform repeated sampling over time to track biomarker changes and model evolution [71].

Interpretation: A candidate that, when modulated, directly and consistently alters the disease-relevant phenotype in a human-derived model provides strong functional evidence supporting its translational relevance and value as a therapeutic target or biomarker.

The Scientist's Toolkit: Research Reagent Solutions

Table 2: Essential Reagents and Models for Translationally-Focused Research

Item / Solution	Function & Application	Key Consideration for Translation
Patient-Derived Xenografts (PDX)	Immunodeficient mice implanted with fragments of a patient's tumor. Used for in vivo drug efficacy and biomarker studies [71].	Retains the original tumor's genetic and histological heterogeneity better than cell lines. Crucial for validating biomarkers in a complex in vivo context.
Induced Pluripotent Stem Cell (iPSC)-Derived Organoids	3D structures grown from human iPSCs that mimic organ architecture and function (e.g., brain, liver, gut) [69].	Provides a human-specific, potentially patient-specific platform for disease modeling, mechanism study, and personalized drug screening.
Organ-on-a-Chip (OoC) Systems	Microfluidic devices lined with living human cells that simulate organ-level physiology and fluid flow [69].	Allows study of dynamic processes (e.g., metastasis, immune cell trafficking) and multi-organ interactions in a controlled human-relevant microenvironment.
Multi-Omics Profiling Suites	Integrated genomic, transcriptomic, proteomic, and metabolomic analysis platforms [71].	Enables identification of context-specific, clinically actionable biomarkers and therapeutic targets by capturing the complex molecular landscape of human disease.
Cross-Species Pathway Analysis Software	Computational tools (e.g., for implementing the TransPath-C workflow) that analyze conserved pathway dysregulation rather than single gene homologs [70].	Moves the focus from poorly conserved individual gene expression to more evolutionarily conserved systems-level biology, improving translatability predictions.

Future Directions: Programmable Virtual Humans and Integrated Systems

The ultimate future of translational research lies in moving from isolated models to integrated, human-focused systems. The emerging concept of "programmable virtual humans" represents a paradigm shift [72]. These are comprehensive computational models that integrate multi-scale data—from molecular interactions to whole-organ physiology—using AI and systems biology. Researchers could simulate drug effects and disease progression in a virtual patient population, identifying likely failures and optimal candidates before any in vivo work begins [72].

This future depends on the synergistic integration of the methodologies described here:

• Validated, Human-Relevant Building Blocks: Data from functionally validated organoids, MPS, and PDX models feed into the computational framework.
• AI-Powered Insights: Machine learning analyzes these integrated datasets to identify robust, translatable disease signatures and predict outcomes.
• Systematic Evidence Integration: Formal review frameworks continuously incorporate new epidemiological and high-quality preclinical evidence to validate and refine the virtual models [29].

Diagram 2: Integrated system for translational prediction (59 characters)

Adopting the rigorous assessment protocols, human-focused models, and integrative frameworks outlined in these application notes is essential for transforming preclinical research into a more predictive and successful engine for human therapeutic discovery.

Systematic reviews are the cornerstone of evidence-based medicine, yet their traditional execution is fraught with inefficiencies that delay the translation of research into practice. This is particularly critical in the context of integrating epidemiological and animal evidence, a synthesis essential for understanding disease mechanisms, assessing drug safety, and bridging the gap between preclinical discovery and clinical application [9]. Animal studies provide foundational biological insights and preliminary efficacy data, but their translation to human outcomes is often poor, with success rates in areas like stroke and cancer being less than 8% [9]. Conversely, epidemiological studies, including burgeoning digital data streams, offer real-world population-level insights but introduce novel biases related to data sourcing and measurement [73].

This article details three pivotal optimization strategies—pre-registration, automated screening, and improved reporting—framed within a thesis on integrative evidence synthesis. We present application notes and experimental protocols designed to enhance the rigor, efficiency, and equity of systematic reviews that seek to harmonize evidence across the translational spectrum.

Pre-registration Protocols for Integrative Reviews

Pre-registration of a systematic review protocol mitigates reporting bias, clarifies the research question, and prevents unnecessary duplication of effort [51]. For reviews integrating animal and human data, a robust protocol must explicitly address the distinct challenges of each evidence stream.

Application Note: PROSPERO for Preclinical-Clinical Reviews

The International Prospective Register of Systematic Reviews (PROSPERO) accepts protocols for reviews of animal studies, providing a public record of the planned methodology [51]. Registration is a critical first step that forces researchers to define a priori how they will handle translational questions, such as defining criteria for analogous populations (e.g., a specific disease model in rodents and the corresponding human patient population) and interventions across species.

Protocol: PROSPERO Registration for an Integrative Review

Objective: To publicly register a protocol for a systematic review investigating the efficacy of a novel anti-inflammatory compound across animal models of rheumatoid arthritis and human epidemiological/clinical trial data. Steps:

• Define the Integrative PICOS Framework: Elaborate the Population, Intervention, Comparison, Outcome, and Study Design for both animal and human components. Specify how outcomes will be mapped (e.g., "reduction in joint swelling score" in animals to "change in Disease Activity Score-28" in humans).
• Specify Databases: Plan searches in both biomedical (e.g., PubMed/MEDLINE, Embase) and preclinical databases (e.g., PubMed, EMBASE, Web of Science, alongside specialized resources like CAB Abstracts for veterinary literature) [51].
• Detail Synthesis Plan: State if animal and human data will be synthesized separately or if a formal quantitative integration (e.g., a cross-species meta-analysis) will be attempted. Justify the choice.
• Plan Bias/Quality Assessment: Select appropriate tools for each study type (e.g., SYRCLE's risk of bias tool for animal studies, Cochrane RoB 2 for RCTs, and specific tools for observational epidemiological studies).
• Submit to PROSPERO: Complete the mandatory and recommended fields on the PROSPERO website, ensuring the unique integrative aspects are clearly described.

Automated Screening for High-Volume Evidence Streams

Manual literature screening is a major bottleneck. AI-powered screening tools can drastically accelerate this process while maintaining, and sometimes enhancing, accuracy [74].

Application Note: Performance of LLM-Based Screening Tools

Recent advancements employ Large Language Models (LLMs) with prompt engineering for screening. The LitAutoScreener tool, which uses a chain-of-thought reasoning approach within the PICOS framework, demonstrated high performance in screening drug intervention studies [74]. As shown in Table 1, leading LLMs achieved near-perfect recall, ensuring minimal relevant literature is missed.

Table 1: Performance Metrics of LLM-Based Screening Tools (Validation Cohort Data) [74]

Model (Task)	Accuracy (%)	Recall (%)	Exclusion Concordance (%)	Avg. Processing Time
GPT-4o (Title-Abstract)	99.38	100.00	98.85	1-5 seconds/article
Kimi (Title-Abstract)	98.94	99.13	94.79	1-5 seconds/article
DeepSeek (Title-Abstract)	98.85	98.26	96.47	1-5 seconds/article
GPT-4o (Full-Text)	100.00	100.00	N/A	~60 seconds/article

Protocol: Implementing an AI-Assisted Screening Workflow

Objective: To efficiently screen a large corpus of literature (e.g., 10,000+ citations) for a review on the cardiovascular safety of a class of drugs, using AI to prioritize relevant records. Tools: DistillerSR (with AI Classifiers), Rayyan AI, or a custom LLM implementation like LitAutoScreener [75] [76]. Steps:

• Pilot Training: Manually screen a random sample of 500-1000 articles. Use these labeled references to train or calibrate the AI tool's relevance predictions.
• Workflow Configuration: Set up a priority screening workflow. The AI continuously re-ranks the unscreened citations, putting those it predicts as most relevant at the top of the reviewer's queue [76].
• Dual Review with AI Check: Two independent reviewers screen the AI-prioritized list. The AI also acts as a "third reviewer," flagging citations it predicts as relevant but that were excluded by human reviewers for a quality check [76].
• Continuous Learning: As screening progresses and the human team makes more decisions, the AI model can be periodically retrained to improve its predictions for the remaining corpus.
• Validation: After screening, calculate the work saved over sampling (WSS) metric. For example, if 95% of included studies were found after screening only 50% of the total citations, the WSS@95 is 50%, indicating a 50% reduction in screening effort.

Diagram Title: AI-Assisted Literature Screening and Quality Control Workflow

Improved Reporting for Equity and Translational Insight

Enhanced reporting goes beyond checklist adherence. It requires methodological transparency and a commitment to equitable data practices that ensure findings are valid for diverse populations.

Application Note: Phenomenological Data Filtering for Equity

Common data-filtering rules in epidemiology, such as excluding values outside 3-5 standard deviations, are based on norms from dominant populations and can systematically erase physiological truths of marginalized communities [77]. A novel phenomenological approach prioritizes within-individual comparisons, retaining more data from underrepresented groups without compromising analytic integrity [77]. For example, applying this method to Alaska Native EHR data retained a truer representation of the population's cardiometabolic profile compared to standard methods [77].

Protocol: Implementing Phenomenological Data Filtering

Objective: To clean a longitudinal electronic health record (EHR) dataset for a cardiometabolic study while preserving data from a historically marginalized population. Steps:

• Exclude Biologically Impossible Values: Remove values that are undeniably erroneous for any human (e.g., systolic blood pressure of 3000 mmHg).
• Within-Person Standard Deviation Filtering: For each individual in the dataset with multiple measurements over time, calculate their personal mean and standard deviation for each variable. Exclude a value only if it falls outside a pre-defined range (e.g., ±3 SD) from that individual's own mean. This preserves individuals whose baseline physiology is at the cohort's margins but is stable for them.
• Individual-Level Imputation: For missing data, use imputation methods (e.g., last observation carried forward, linear interpolation) at the individual level rather than imputing based on population averages. Comparison of Outcomes: As shown in Table 2, this method typically retains more participants and a wider range of physiological values than the common cohort-based approach [77].

Table 2: Comparison of Common vs. Phenomenological Data-Filtering Approaches [77]

Filtering Approach	Core Principle	Advantage	Disadvantage	Impact on Marginalized Groups
Common (Cohort)	Excludes data points outside population-level ranges (e.g., 3-5 SD from cohort mean).	Simple to automate; effective at removing gross errors.	Erases valid data from individuals whose physiology differs from the population norm.	High risk of data loss; reinforces health norms of dominant populations.
Phenomenological (Individual)	Excludes data points outside an individual's own historical range.	Retains population diversity; more equitable; better for longitudinal analysis.	Computationally more intensive; requires multiple measurements per individual.	Preserves physiological truth; leads to more representative and generalizable findings.

Diagram Title: Comparison of Cohort vs. Phenomenological Data-Filtering Protocols

Protocol: Reporting Integrated Reviews with PRISMA

Objective: To comprehensively report a systematic review integrating animal and epidemiological evidence. Guidelines: Adhere to the PRISMA (Preferred Reporting Items for Systematic Reviews and Meta-Analyses) statement and its extensions. Key Integrative Reporting Items:

• Abstract: Clearly state the review integrates multiple evidence streams.
• Methods:
  • Search: List all databases, including preclinical and veterinary sources. Document search strategies for both animal and human terms.
  • Synthesis: Describe methods for comparing or correlating findings across species (e.g., qualitative summary tables, quantitative cross-species dose-response modeling).
• Results:
  • Flow Diagram: Use a modified PRISMA flow diagram that visually separates and then integrates the evidence streams from animal and human studies.
  • Summary of Evidence: Present animal and human findings side-by-side. Discuss concordance, discordance, and translational gaps.
• Discussion: Interpret findings in the context of the Evidence Integration Matrix (Table 3), which helps frame the translational value and research implications.

Table 3: Evidence Integration Matrix for Interpreting Cross-Species Findings

Animal Evidence	Human Epidemiological Evidence	Interpretation & Implication
Strong & Consistent	Strong & Consistent	High confidence in association. Supports mechanism and public health action.
Strong & Consistent	Weak, Null, or Absent	Highlights a translational gap. Investigate model validity, exposure timing, or species-specific biology.
Weak or Inconsistent	Strong & Consistent	Suggests animal models may not capture key human determinants. Focus on human-based mechanistic studies.
Weak or Inconsistent	Weak or Inconsistent	Inconclusive. Highlights need for more primary research with improved study design in both fields.

Table 4: Key Research Reagent Solutions for Integrative Systematic Reviews

Tool / Resource	Type	Primary Function in Integrative Reviews	Key Consideration
DistillerSR [76]	AI-Powered Review Software	Manages the entire review lifecycle. AI prioritizes screening, checks exclusions, automates PRISMA diagrams.	Enterprise-level solution; ideal for large, compliant reviews in pharma/device sectors.
PROSPERO [51]	Protocol Registry	Public pre-registration platform for systematic review protocols, including animal studies.	Mandatory for many high-impact journals; prevents duplication and bias.
Rayyan [75]	Web-Based Screening Tool	Facilitates blinded collaborative screening with AI features to prioritize references.	Freemium model; good for academic and smaller-scale collaborative projects.
SYRCLE's Risk of Bias Tool [9]	Quality Assessment Tool	Standardized tool to assess risk of bias in animal intervention studies.	Essential for critically appraising the internal validity of preclinical evidence.
CAMARADES / SYREAF [51]	Collaborative Initiatives & Resources	Provide support, methodology, and infrastructure for systematic reviews of animal studies.	Key for networking and accessing preclinical review methodology expertise.
LitAutoScreener (or similar LLM) [74]	Custom AI Screening Model	High-accuracy, rapid screening based on PICOS criteria via prompt-engineered LLMs.	Requires technical expertise for implementation; offers high performance per validation studies.
Phenomenological Filtering Protocol [77]	Data Cleaning Methodology	An equitable approach to filtering outliers in epidemiological/clinical datasets.	Crucial for research involving marginalized populations to avoid perpetuating bias.

Optimizing systematic reviews through mandatory pre-registration, validated AI screening tools, and equity-focused reporting protocols is no longer speculative but a necessary evolution. For the critical task of integrating epidemiological and animal evidence—a synthesis at the heart of translational science—these strategies collectively address core challenges of volume, bias, and transparency. By adopting the detailed application notes and protocols presented here, researchers can produce more rigorous, efficient, and actionable evidence syntheses that accelerate the responsible translation of biomedical research from bench to population health.

Systematic reviews (SRs) and meta-analyses represent the pinnacle of evidence synthesis, crucial for guiding clinical practice, policy, and future research. Within the context of a broader thesis on integrating epidemiological and preclinical evidence, pediatric and specific disease area reviews present unique methodological challenges and opportunities. The pediatric population is not a homogeneous group but encompasses a dynamic continuum of physiological development from neonate to adolescent. This necessitates specialized approaches in evidence synthesis that account for age-related changes in disease manifestation, drug metabolism, and treatment response [4]. Furthermore, specific disease areas, such as otitis media (OM) in children, require integration of diverse evidence streams—from global burden epidemiology to animal model studies of pathogenesis—to build a complete picture necessary for effective drug development and public health intervention [78] [4]. This article details the application notes and protocols for conducting rigorous systematic reviews in these specialized contexts, providing a framework for researchers and drug development professionals to synthesize high-quality, actionable evidence.

Epidemiological Considerations & Quantitative Disease Burden

A robust understanding of disease epidemiology forms the essential foundation for any pediatric-focused review. This involves precisely quantifying the burden across different age strata, geographic regions, and sociodemographic groups, which in turn informs the prioritization of research questions and the interpretation of preclinical and clinical findings.

Case Study: The Global Burden of Otitis Media in Children Otitis media serves as a paradigm for a pediatric-specific condition with a significant global health footprint. Analysis of the Global Burden of Disease (GBD) 2021 data reveals the scale of the issue [78].

Table 1: Global Epidemiological Burden of Otitis Media in Children (0-14 years), 2021 [78]

Metric	Estimate	95% Uncertainty Interval
Global Incident Cases	297,243,470	205,198,444 – 431,726,180
Age-Standardized Incidence Rate (per 100,000)	14,775	10,199 – 21,459
Disability-Adjusted Life Years (DALYs)	1,035,749	Not Reported
Age-Standardized DALY Rate (per 100,000)	51.48	Not Reported

The burden is not evenly distributed. The incidence rate is highest among children aged 2-4 years, accounting for approximately one-third of all cases [78]. Furthermore, a clear inverse association exists between sociodemographic development and disease burden. Regions with a low Sociodemographic Index (SDI), such as Eastern Sub-Saharan Africa and South Asia, bear the highest age-standardized prevalence and DALY rates, while high-SDI regions like Central Europe and East Asia experience the lowest [78]. Key attributable risk factors identified include secondhand smoke and particulate matter pollution [78]. For a reviewer, this epidemiological profile underscores the necessity of stratifying analysis by age and considering environmental and socioeconomic confounders when synthesizing evidence on interventions or pathophysiology.

Integrating Preclinical Evidence: From Animal Models to Pediatric Relevance

The integration of preclinical evidence from animal and in vitro studies is a critical bridge to understanding disease mechanisms and therapeutic potential, but requires careful translation to the pediatric context. Well-conducted systematic reviews of preclinical research can prevent research waste, improve animal model validity, and inform the design of clinical trials [79] [4].

Special Protocols for Preclinical Review: The methodology for preclinical SRs must be as rigorous as its clinical counterpart. Key steps include [79] [80] [4]:

• Protocol Registration: Registering the review protocol on a dedicated platform like PROSPERO4animals is mandatory to enhance transparency, reduce bias, and avoid duplication [79].
• Comprehensive Search: Searches must extend beyond standard bibliographic databases (e.g., PubMed, Embase) to include specialized preclinical registers and sources to minimize publication bias [81].
• Pediatric-Specific Data Extraction: This is the most critical adaptation. Data extraction forms must capture:
  • Animal Age & Developmental Stage: The exact age, postnatal day, or weight of animals must be recorded and mapped to corresponding human pediatric stages (e.g., neonatal, infant, adolescent) [4].
  • Model Justification: The rationale for the chosen species and model in relation to the pediatric human condition.
  • Outcome Alignment: Ensuring measured outcomes (physiological, histological, behavioral) have direct relevance to pediatric disease manifestations [4].
• Risk of Bias & Quality Assessment: Using tools like the SYRCLE's risk of bias tool for animal studies to evaluate study design, blinding, randomization, and outcome reporting [4].
• Evidence Grading: Applying adapted GRADE frameworks to assess the certainty (e.g., confidence) in the synthesized preclinical evidence [4].

The primary goal is to determine whether the available preclinical data is sufficiently robust and relevant to justify translation into pediatric clinical trials or if it instead highlights fundamental gaps requiring further basic research [4].

Table 2: Key Considerations for Integrating Preclinical Evidence into Pediatric Reviews

Consideration	Description	Tool/Resource
Developmental Translation	Explicitly linking the age/developmental stage of the animal model to a human pediatric age group.	Species-specific developmental timelines [4].
Model Validity Assessment	Evaluating how well the animal model recapitulates key pathophysiological features of the pediatric disease.	CAMARADES framework; SYRCLE's tool [79] [4].
Outcome Relevance	Ensuring primary outcomes in animal studies are meaningful surrogates for clinically relevant outcomes in children.	Expert consultation; Core outcome set development.
Dose & Pharmacokinetics	Critical appraisal of dosing regimens, considering maturational changes in metabolism and clearance.	Comparative pharmacokinetic literature.

Application Notes & Detailed Protocols for Evidence Synthesis

Conducting a high-quality systematic review in pediatrics requires strict adherence to established protocols with specific modifications. The following workflow and protocols detail this process.

Protocol: Multi-Stage Evidence Synthesis Workflow

The following diagram outlines the integrated workflow for synthesizing epidemiological and preclinical evidence within a pediatric systematic review.

Protocol: Detailed Data Collection & Extraction

Data extraction is a critical phase requiring precision and pediatric-specific adaptations. It should be performed in duplicate by independent reviewers [80] [81].

• For Epidemiological & Clinical Studies: Extract data on population age subgroups, diagnostic criteria, prevalence/incidence rates, measures of association (RR, OR), and confounder adjustment. The unit of interest is the study, not the report; multiple publications of the same study must be linked [81].
• For Preclinical Studies: Use a customized extraction form that includes [4] [81]:
  • Animal Model Details: Species, strain, sex, exact age/weight, method of induction of disease or injury.
  • Intervention Details: Dose, timing, route, and formulation relative to developmental stage.
  • Outcome Data: Quantitative results for all reported outcomes, with careful note of the measurement timepoint and method.
  • Study Design: Randomization, blinding, sample size calculation, compliance with animal welfare ethics.

All data should be collected and archived in a structured, shareable format (e.g., structured spreadsheet or systematic review software) to allow for future updates and data sharing [81].

Conducting specialized systematic reviews requires a curated set of methodological resources and platforms. The following table details key tools for researchers.

Table 3: Research Reagent Solutions for Pediatric & Preclinical Systematic Reviews

Tool/Resource	Primary Function	Application Note
PROSPERO (International)	Registry for prospective systematic review protocols in health and social care.	Mandatory for clinical/review questions to prevent duplication and bias [80].
PROSPERO4animals	Dedicated registry for protocols of systematic reviews of animal studies.	Promotes rigor, reduces unnecessary animal use, and enables feedback [79].
PRISMA 2020 Statement & Checklists	Evidence-based minimum set of items for reporting systematic reviews and meta-analyses.	Guides transparent reporting; use PRISMA-P for protocols [80].
SYRCLE's Risk of Bias Tool	Tool for assessing methodological quality and risk of bias in animal intervention studies.	Critical for evaluating internal validity of preclinical evidence [4].
GRADE (Grading of Recommendations Assessment, Development and Evaluation)	Framework for rating the certainty of evidence and strength of recommendations.	Can be adapted to grade confidence in synthesized preclinical evidence [4].
Covidence, Rayyan	Web-based platforms for managing screening and data extraction in duplicate.	Streamlines the review process and enhances collaboration among team members [80].
CAMARADES (Collaborative Approach to Meta-Analysis and Review of Animal Data from Experimental Studies)	Provides methodological support, guidance, and tools for preclinical meta-analysis.	Key resource for best practices in designing and conducting preclinical SRs [79].

Visualization: The Pediatric Systematic Review Process

The final diagram synthesizes the entire pediatric systematic review process, integrating the parallel streams of clinical/epidemiological and preclinical evidence into a unified synthesis, as guided by PRISMA standards [80].

Measuring Success: Validating Integrated Reviews and Comparing Cross-Species Outcomes

This document establishes application notes and protocols for three core validation criteria—sensitivity, timeliness, and data quality—for systems integrating epidemiological and animal health evidence. This work is situated within a broader thesis on advancing systematic review methodologies for One Health challenges, which require synthesizing data across human, animal, and environmental domains [14]. The integration of disparate surveillance and research systems is not merely a technical endeavor but a fundamental prerequisite for robust evidence generation in zoonotic disease research, antimicrobial resistance, and environmental health [82].

The drive for integration stems from the need for joint data collection, analysis, and preparedness, particularly for emerging infectious diseases where human and animal interfaces are critical [14]. However, combining systems introduces complexity and potential points of failure. Without standardized validation benchmarks, the performance and reliability of the integrated output remain uncertain. Therefore, defining and measuring these criteria is essential to ensure that integrated systems fulfill their promise of providing actionable, evidence-based insights for researchers and drug development professionals. This framework addresses the gap between technical integration and scientifically credible output, ensuring that combined data streams are not only connected but also fit for purpose in high-stakes research and policy contexts [83].

Defining and Quantifying the Core Validation Criteria

The performance of an integrated evidence system must be evaluated against standardized, quantifiable metrics. The following three criteria form a foundational triad for validation.

• Sensitivity refers to the system's ability to correctly identify true-positive events or data points of interest—such as disease outbreaks, emerging pathogen strains, or adverse drug effects—minimizing false negatives [14]. In integrated One Health systems, high sensitivity is critical for early warning and detection of zoonotic spillover events. Quantitatively, it is measured as the proportion of true events detected by the system. A systematic review of integrated health surveillance systems reported achieved sensitivity values ranging from 63.9% to 100%, with a median of 79.6% [14].

• Timeliness measures the speed between the occurrence of an event and the availability of processed, actionable information from the system to key stakeholders [14]. It directly impacts the effectiveness of response strategies, from clinical interventions to public health measures. Delays in data flow, processing, or reporting degrade the system's utility. Evaluations show that integration can improve timeliness significantly, with recorded improvements ranging from 10% to 91% (median 67.3%) [14]. For dynamic modeling, timeliness also pertains to the rapid deployment of analytical models, such as those for estimating transmission parameters (e.g., R0) during an outbreak [84].

• Data Quality is a composite criterion encompassing accuracy, completeness, consistency, and interoperability. High-quality data are representative, reliably measured, and structured in a way that allows for valid integration and analysis [83]. Inconsistencies in data parameters—such as varying definitions for clinical symptoms across human and veterinary reports—are a major barrier [82]. Data quality improvements following integration have been reported in the range of 73% to 95.4% (median 87%) [14]. A key aspect is semantic consistency, which ensures that data from different sources share common definitions and formats, enabling meaningful aggregation [14].

Table 1: Quantitative Benchmarks for Validation Criteria from Integrated Surveillance Systems [14]

Validation Criterion	Definition	Key Quantitative Benchmark (Range)	Median Performance Reported
Sensitivity	Proportion of true events correctly detected	63.9% – 100%	79.6%
Timeliness	Improvement in speed of data-to-action cycle post-integration	10% – 91% faster	67.3% faster
Data Quality	Improvement in accuracy, completeness, and interoperability post-integration	73% – 95.4% improvement	87% improvement

Application Notes and Methodological Protocols

Protocol for Assessing Sensitivity in an Integrated System

Objective: To empirically measure the sensitivity of an integrated human-animal disease reporting system for detecting suspected zoonotic outbreak clusters.

Background: Sensitivity assessment requires a known set of positive events (gold standard) against which system alerts are compared [14]. In real-world surveillance, this is often done retrospectively using confirmed outbreak data.

Experimental Protocol:

• Define Gold Standard Cohort: Compile a verified list of laboratory-confirmed zoonotic disease outbreaks (e.g., avian influenza H5N1, West Nile virus) within a defined geographical region and time period (e.g., one year). Sources include national public health agency reports, animal health department bulletins, and peer-reviewed outbreak reports [84].
• System Alert Generation: Run the integrated system's analytics (e.g., aberration detection algorithms, natural language processing of clinical reports) over the same spatiotemporal domain.
• Data Matching and Calculation: For each verified outbreak, determine if the system generated an alert within a specified pre-onset window (e.g., 0-14 days before official confirmation). Calculate sensitivity as: (Number of outbreaks detected by the system) / (Total number of verified outbreaks) * 100%.
• Stratified Analysis: Report sensitivity stratified by disease, data source (human vs. animal), and reporting jurisdiction to identify performance gaps [83].

Protocol for Evaluating and Enhancing Timeliness

Objective: To audit the data flow timeline and identify bottlenecks within an integrated evidence pipeline, and to model the impact of timeliness on predictive accuracy.

Background: Timeliness is a function of data collection latency, processing time, and reporting frequency [14]. It is critical for models used in outbreak response, where delays directly reduce forecast utility [84].

Experimental Protocol:

• Process Mapping and Time-Stamping: Document each step from primary data entry (e.g., farm report, clinic EHR) to the availability of an analyzed indicator on a dashboard. Implement automated time-stamps at each stage (collection, submission, integration, analysis, publication).
• Bottleneck Analysis: Calculate the average duration and variance for each stage over a 6-month period. Identify stages with the longest delay and highest variability.
• Modeling Timeliness Impact: Using historical outbreak data, simulate the effect of data delays on the performance of a short-term forecasting model (e.g., an ARIMA or compartmental model) [84]. Incrementally lag the input data and measure the degradation in forecasting error (e.g., Mean Absolute Percentage Error). This quantifies the cost of delay in actionable terms.
• Intervention Trial: Implement a technical or procedural intervention (e.g., automated data ingestion, streamlined validation rules) to address the primary bottleneck. Re-measure the end-to-end timeliness for a subsequent 3-month period to quantify improvement.

Framework for Auditing and Standardizing Data Quality

Objective: To conduct a structured audit of data quality across human and animal health datasets prior to integration, and to implement standardization protocols.

Background: Integrated analysis is compromised by incompatible data structures, coding variances, and missing values [82]. A pre-integration audit based on established parameters is essential [83].

Experimental Protocol:

• Parameter Inventory: Create a comprehensive inventory of all data parameters (e.g., species, age, clinical signs, diagnostic test results, location) from each source system, using tools like the One Health Participatory Surveillance Data Parameters Compendium as a reference [82].
• Gap and Overlap Analysis: Map parameters across systems to identify: a) Direct matches (e.g., "date of birth"), b) Semantic overlaps requiring mapping (e.g., "fever" vs. "pyrexia" vs. "temperature >38.5°C"), and c) Critical gaps where a key parameter is absent in one stream.
• Quality Metric Calculation: For each key parameter, calculate:
  • Completeness: (% of records with non-null values).
  • Plausibility: (% of records with values within biologically/clinically plausible ranges).
  • Cross-form consistency: For parameters present in multiple sources, measure the agreement rate (e.g., Cohen's kappa) for a sample of matched records.
• Implementation of Semantic Consistency Rules: Develop and deploy a data harmonization protocol. This may include:
  • A controlled vocabulary (ontologies like SNOMED-CT, VO) for core concepts.
  • Transformation rules to convert local codes to standard codes.
  • Business rules for handling missing data (e.g., imputation flags, exclusion criteria).

Table 2: Workflow for Validating an Integrated Evidence System

Phase	Protocol Activity	Primary Output	Validation Criterion Addressed
1. Design & Mapping	Inventory data parameters and sources; map integration architecture [82].	Data flow diagram; parameter gap analysis.	Data Quality
2. Baseline Measurement	Retrospective calculation of sensitivity and timeliness using historical gold-standard data [14].	Baseline performance metrics (sensitivity %, median delay).	Sensitivity, Timeliness
3. Pre-Integration Audit	Assess completeness, plausibility, and consistency of source datasets [83].	Data quality audit report with metric scores.	Data Quality
4. Harmonization & Integration	Apply semantic consistency rules and integrate data streams [14].	Harmonized, query-ready integrated database.	Data Quality
5. Post-Integration Validation	Re-calculate sensitivity and timeliness; run test forecasts with integrated data [84].	Post-integration performance metrics; model accuracy report.	Sensitivity, Timeliness, Data Quality

(Title: Validation Workflow for Integrated Evidence Systems)

Advanced Integration: Incorporating AI and Protecting Privacy

The integration of evidence systems is evolving beyond simple data pooling. Two advanced paradigms are critical for next-generation validation frameworks.

• AI-Integrated Mechanistic Modeling: Combining the data-mining power of Artificial Intelligence (AI) with the causal structure of mechanistic epidemiological models (e.g., SIR models) enhances forecasting and validation [85]. AI can be used to infer missing parameters, calibrate models with real-time data, or directly enhance forecasts within a physics-informed framework. Validation Note: When AI components are used, traditional criteria must still be applied to the final output. Furthermore, new criteria such as algorithmic fairness and model explainability become necessary to ensure the integrated model's recommendations are unbiased and interpretable for decision-makers [85].

• Federated Learning for Privacy-Preserving Integration: Federated Learning (FL) enables the training of analytical models across decentralized data sources (e.g., different hospitals or veterinary networks) without exchanging raw data [86]. This aligns with the One Health need to integrate sensitive data across jurisdictions while adhering to strict privacy regulations. Validation Note: In an FL-based system, timeliness must account for communication rounds between the central server and local nodes. Data quality audits must assess local data distributions to prevent bias in the global model from non-IID (Independent and Identically Distributed) data. The robustness of the integration against adversarial nodes or poor-quality local updates becomes a new critical metric [86].

(Title: Data Flow in a Modern Integrated Evidence System)

Table 3: Essential Toolkit for Developing and Validating Integrated Evidence Systems

Tool / Resource Name	Category	Primary Function in Validation	Reference / Source
PRISMA-P Checklist	Methodological Guideline	Provides a rigorous protocol framework for conducting systematic reviews of system performance, ensuring transparent and reproducible evaluation [14].	[14]
One Health Data Parameters Compendium	Reference Standard	Serves as a cross-sectoral dictionary for auditing data fields, identifying semantic gaps, and promoting standardization across human, animal, and environmental datasets [82].	[82]
CDC/WHO Surveillance Evaluation Framework	Evaluation Framework	Outlines core attributes (including sensitivity, timeliness, data quality) and provides structured questions for systematic system assessment [83].	[83]
Physics-Informed Neural Network (PINN) Architecture	AI/Modeling Tool	Enables the integration of mechanistic model equations (e.g., differential equations for disease spread) into neural network training, enhancing forecast validity and interpretability [85].	[85]
Federated Learning (FL) Platform (e.g., Flower, NVIDIA FLARE)	Technical Infrastructure	Provides the decentralized software framework to train models across data silos without raw data exchange, addressing privacy constraints in integration [86].	[86]
Semantic Harmonization Engine (e.g., OHDSI-OMOP)	Data Processing Tool	Applies standardized vocabularies and ontologies to transform heterogeneous source data into a common format (semantic consistency), a prerequisite for valid analysis [14].	[14]
Spatiotemporal Analysis Software (e.g., SaTScan)	Analytical Tool	Detects unusual clustering of events in space and time, used to test the sensitivity of the integrated system for early outbreak signal detection [84].	[84]

Systematic reviews that integrate evidence from both human (epidemiological) and animal (preclinical) studies are critical for advancing translational science and addressing complex One Health questions [87] [14]. The integration of these distinct evidence streams provides a more comprehensive understanding of disease etiology, intervention efficacy, and public health risks, supporting decisions from drug development to environmental policy [87] [4]. However, the methodological quality and potential for bias within the systematic reviews themselves vary considerably, which can threaten the validity of their conclusions if not properly appraised [88] [89].

Within the context of a broader thesis on integrating epidemiological and animal evidence, the selection and application of appropriate quality assessment tools is not merely a procedural step but a foundational scientific activity. Standard tools like AMSTAR-2 (A MeaSurement Tool to Assess systematic Reviews) and ROBIS (Risk Of Bias In Systematic reviews) were developed to address these concerns, yet they differ in their primary focus—methodological quality versus risk of bias [88] [90]. Furthermore, the unique challenges of cross-disciplinary, integrated reviews may necessitate the development or adaptation of custom tools [14] [91]. This article provides detailed application notes and experimental protocols for employing these frameworks within integrated systematic review research, ensuring that synthesized evidence is robust, reliable, and fit for informing critical decisions in research and drug development.

Framework Comparison and Operational Characteristics

AMSTAR-2 and ROBIS are the two most prominent tools for appraising systematic reviews, each with a distinct conceptual focus and structure. Their operational characteristics are summarized in Table 1.

Table 1: Core Characteristics of AMSTAR-2 and ROBIS

Feature	AMSTAR-2	ROBIS
Primary Aim	Assess methodological quality and confidence in review results [88].	Assess risk of bias introduced by the review process [88] [90].
Number of Items	16 items [88] [89].	24 signaling questions across core phases [89].
Key Domains/Phases	Covers PICO development, search, selection, data extraction, bias assessment, synthesis, heterogeneity, reporting, and conflicts [88].	Phase 1: Relevance (optional). Phase 2: Concerns in 4 domains (eligibility; study identification/selection; data collection/appraisal; synthesis). Phase 3: Overall risk of bias judgment [90].
Response Options	Yes / Partial Yes / No [88].	Yes / Probably Yes / Probably No / No / No Information [88].
Overall Judgment	Critically Low / Low / Moderate / High confidence, based on critical flaws in key items [88].	Low / High / Unclear concern for bias in each domain and overall [90].
Typical Assessment Time	Median: 51 minutes (3.2 min/item) [89].	Median: 64 minutes (2.7 min/item) [89].
Best Application Context	Efficient evaluation of methodological rigour; overviews of reviews [88] [89].	In-depth evaluation of potential for biased conclusions; guideline development [89].

Recent large-scale comparative data illuminate the performance and outcomes of these tools. In a study of 200 systematic reviews, 73% were rated as low or critically low quality by AMSTAR-2, while 81% were judged to have a high risk of bias by ROBIS [89]. This indicates a widespread prevalence of methodological shortcomings and potential bias in published systematic reviews. The median inter-rater agreement for both tools in application studies is substantial, at approximately 0.61 [88] [89].

Application Notes for Integrated Epidemiological and Animal Evidence Reviews

Applying AMSTAR-2 and ROBIS to reviews that integrate human and animal evidence presents specific challenges and necessitates careful interpretation.

• Assessing Comprehensive Searches (AMSTAR-2 Item 3, ROBIS Domain 2): A key strength of an integrated review is its cross-disciplinary scope. Assessors must verify that search strategies adequately cover both biomedical (e.g., PubMed, Embase) and preclinical/zoological databases (e.g., Web of Science, BIOSIS) [87]. The justification for the chosen databases is critical.
• Appraising Risk of Bias in Primary Studies (AMSTAR-2 Items 9, 13): Integrated reviews include diverse study types (e.g., cohort studies, randomized trials, animal experiments). The review should use appropriate, validated risk-of-bias tools for each study design (e.g., ROB-2 for trials, SYRCLE's risk-of-bias tool for animal studies). The assessment's influence on the synthesis must be clear [4].
• Evaluating Synthesis and Heterogeneity (AMSTAR-2 Items 11, 15; ROBIS Domain 4): A major challenge is the quantitative integration of disparate evidence streams. Assessors should note whether the review performed separate syntheses for human and animal data or used advanced methods for integration (e.g., cross-design synthesis). The investigation of heterogeneity must consider sources unique to each evidence type (e.g., clinical populations vs. animal models) [87].
• Judging Overall Risk of Bias (ROBIS Phase 3): When making an overall judgment, consider if limitations in one evidence stream (e.g., high risk of bias in all animal studies) were appropriately considered when drawing unified conclusions about the overall body of evidence [87] [90].

Protocols for Tool Application and Integrated Review Conduct

Protocol for Comparative Assessment Using AMSTAR-2 and ROBIS

This protocol is designed to generate reliable, head-to-head comparisons of systematic review quality and risk of bias, as undertaken in recent studies [88] [89].

• Team Training & Calibration: Prior to assessment, all reviewers must complete standardized training on both tools using available guidance [90]. Independently assess 3-5 pilot reviews not in the sample, discuss discrepancies, and refine shared understanding of signaling questions.
• Independent Dual Assessment: Each systematic review in the sample is assessed independently by two reviewers using both AMSTAR-2 and ROBIS. The order of tool application should be randomized to avoid sequence bias.
• Data Recording: Use a pre-piloted electronic form to record: a) all item-level responses, b) domain/judgment summaries, and c) the time taken for each assessment.
• Consensus Meeting: Reviewers meet to resolve discrepancies for each review. A third arbitrator resolves persistent disagreements.
• Data Analysis:
  • Calculate inter-rater reliability (e.g., Gwet's AC1/AC2) for items and overall judgments before consensus [88].
  • Analyze the distribution of quality (AMSTAR-2) and risk-of-bias (ROBIS) ratings.
  • Calculate median assessment times and compare per-item efficiency [89].
  • Identify reviews with discordant ratings (e.g., high quality but high risk of bias) for qualitative analysis.

Protocol for Conducting an Integrated Human-Animal Evidence Systematic Review

This protocol outlines a rigorous methodology for integrating epidemiological and preclinical evidence, incorporating quality assessment at its core [87] [4].

• Protocol Registration: Register the review protocol in PROSPERO, detailing the integrated PECO/PICO framework.
• Search Strategy: Develop searches with a librarian to cover both clinical/public health and animal/toxicology literature across multiple databases [87]. Search strategies must be reproducible.
• Study Selection & Data Extraction: Use a two-stage (title/abstract, full-text) screening process with dual independent reviewers. Extract data into structured templates capturing: study design, population/model, exposure/intervention, outcomes, and key results.
• Risk of Bias/Quality Assessment in Primary Studies: Apply design-specific tools to primary studies (e.g., ROBINS-I for observational human studies, SYRCLE tool for animal studies). Do not use AMSTAR-2 or ROBIS here; these are for the systematic review itself.
• Quality Assessment of Included Systematic Reviews: If the integrated review includes other systematic reviews (an overview), appraise them using AMSTAR-2 and/or ROBIS following the protocol in Section 4.1.
• Evidence Synthesis: Synthesize human and animal evidence separately at first, narratively and meta-analytically if feasible. Subsequently, develop an integrated synthesis using a framework like HAWC (Health Assessment Workspace Collaborative) to visualize strength and coherence across evidence streams [87]. Explicitly rate the overall certainty or strength of integrated evidence.
• Reporting: Adhere to PRISMA guidelines, with extensions as needed for complex reviews. Diagram the integrated synthesis workflow.

Diagram 1: Workflow for an Integrated Human-Animal Evidence Systematic Review. The protocol encompasses steps from registration to reporting, highlighting parallel paths for appraising primary studies and existing systematic reviews before integrated synthesis [87].

Decision Framework for Tool Selection and Custom Tool Development

Selection Between AMSTAR-2 and ROBIS

The choice between AMSTAR-2 and ROBIS depends on the review's purpose, resources, and required output. The following decision pathway (Diagram 2) provides a guided selection process.

Diagram 2: Decision Pathway for Selecting a Quality Assessment Tool. The flowchart guides users to the most appropriate tool (AMSTAR-2, ROBIS, both, or custom) based on the specific objectives and context of their appraisal task [88] [89].

Developing Custom Tools for Integrated Reviews

When standard tools are insufficient, custom frameworks can be developed. A 2020 review of integrated human-animal surveillance systems identified four core integration mechanisms—interoperability, convergent integration, semantic consistency, and interconnectivity—which can inspire analogous mechanisms for evidence synthesis [14] [91]. For instance, a custom tool for integrated reviews might include modules assessing:

• Semantic Consistency: Are outcome measures and exposure variables harmonized across human and animal studies?
• Data Interoperability: Is the data extraction framework structured to enable cross-species comparison?
• Convergent Integration: Does the synthesis methodology formally evaluate concordance/discordance and biological plausibility across evidence streams?

Table 2: Quantitative Outcomes of Integrated Surveillance Systems (Analogy for Evidence Synthesis)

Integration Mechanism	Number of Publications [14]	Key Strengthened Attribute	Reported Performance Improvement (Range) [14]
Interoperability	35	Timeliness	10% - 91% (median 67.3%)
Convergent Integration	27	Sensitivity	63.9% - 100% (median 79.6%)
Semantic Consistency	21	Data Quality	73% - 95.4% (median 87%)
Interconnectivity	19	Acceptability	Qualitative improvement reported

The Scientist's Toolkit: Essential Reagents for Integrated Review Research

Table 3: Key Research Reagent Solutions for Integrated Systematic Reviews

Tool / Resource	Function	Relevance to Integrated Reviews
HAWC (Health Assessment Workspace Collaborative)	An open-source platform for managing and visualizing data for human health assessments [87].	Facilitates structured data extraction, visualization of evidence streams, and transparent integration of human and animal evidence [87].
PROSPERO Register	International database for prospectively registering systematic review protocols [4].	Critical for preventing duplication, reducing bias, and demonstrating protocol adherence, especially for novel integrative methods.
SYRCLE's Risk of Bias Tool	Tool for assessing risk of bias in animal intervention studies [4].	The standard for quality appraisal of primary animal studies included in the review, enabling fair comparison with human study quality.
FAIR Data Principles	Guidelines to make data Findable, Accessible, Interoperable, and Reusable [30].	A framework for planning data extraction and sharing from integrated reviews, promoting reuse and meta-science. Essential for reviews handling diverse data types [30].
PECO/PICO Framework	Structured format for defining review questions (Population, Exposure/Intervention, Comparator, Outcome).	Must be carefully adapted to encompass both human (PICO) and animal (PECO) study parameters within a single, coherent research question [87].
GRADE (or adapted) Framework	System for rating the certainty of evidence and strength of recommendations.	Requires adaptation to rate the certainty of integrated evidence, considering coherence between human and animal findings as a key domain [4].

The translational gap between preclinical animal studies and human health outcomes remains a significant challenge in biomedical and veterinary research. While animal models are indispensable for understanding disease pathophysiology and testing interventions under controlled conditions, their predictive value for human epidemiological endpoints is often limited [9]. Systematic reviews reveal that only 37% of highly-cited animal study findings are successfully replicated in human randomized controlled trials, with successful translation rates in fields like stroke and cancer being less than 8% [9]. This discrepancy underscores an urgent need for rigorous methodologies to align outcomes from animal models with relevant human epidemiological data, thereby enhancing the validity and utility of preclinical evidence.

This article provides detailed application notes and protocols framed within a broader thesis on integrating animal and epidemiological evidence in systematic reviews. It is designed for researchers, scientists, and drug development professionals seeking to strengthen the translational bridge. We present standardized frameworks for comparative analysis, explicit experimental protocols for key methodologies, and visualization of complex pathways and workflows. The goal is to foster a more systematic, transparent, and effective approach to leveraging animal data in predicting and understanding human health outcomes in both biomedical and One Health contexts.

Application Notes: Frameworks for Alignment

This section outlines conceptual and practical frameworks for aligning animal model outcomes with human epidemiological data, focusing on measurable endpoints and integrated burden assessment.

Defining and Harmonizing Endpoints

A critical first step in alignment is the explicit definition and harmonization of measurable endpoints across animal and human studies. Animal studies typically focus on physiological or molecular biomarkers (e.g., cytokine levels, tumor volume), while human epidemiology prioritizes clinical and population-level outcomes (e.g., incidence, mortality, quality-adjusted life years). Successful translation requires mapping preclinical biomarkers to clinically relevant endpoints.

• Case Study – PASC (Long COVID): Research on Post-Acute Sequelae of COVID-19 illustrates the endpoint alignment challenge. Human PASC is defined by persistent symptoms (e.g., fatigue, cognitive dysfunction) over months [92]. Animal models must therefore be evaluated beyond the acute infection phase (e.g., >14 days post-infection) for analogous endpoints, such as long-term pulmonary fibrosis, neuroinflammation, or behavioral changes assessed via imaging or functional tests [92]. The severity of the acute phase in the animal model (influenced by species, viral variant, and inoculation route) must correspond to the human cohort being modeled (e.g., hospitalized vs. mild cases) [92].
• Considerations for Humane Endpoints: In animal studies, ethical guidelines mandate the use of humane endpoints to prevent undue suffering. These endpoints, such as >20% body weight loss or moribund state, must be critically evaluated for their correlation with meaningful human disease states rather than serving as mere proxies for death [93].

The Multi-Sectoral Burden Framework for One Health Integration

For diseases with agricultural, zoonotic, or environmental dimensions, alignment requires a framework that captures the multi-sectoral burden. Traditional economic evaluations in animal health often focus narrowly on production losses, neglecting externalities on public health and the environment [94]. The Social Cost-Benefit Analysis (SCBA) framework, aligned with One Health principles, provides a structure for integrating these disparate endpoints [94].

This framework quantifies burden and intervention impacts across three domains:

• Animal Health: Using metrics like the Animal Health Loss Envelope (AHLE), which calculates the economic loss due to disease compared to an ideal healthy population [94].
• Human Health: Quantifying disability-adjusted life years (DALYs) or cost-of-illness from zoonotic diseases.
• Environmental Health: Assessing impacts on biodiversity, greenhouse gas emissions, and ecosystem services [94].

Epidemiological models for livestock diseases, such as network-based spread models for African Swine Fever, can generate outputs (e.g., number of farms infected, time to control) that serve as inputs for macroeconomic and sectoral burden models [95] [96]. A major identified gap is the typical lack of feedback loops from these socioeconomic consequences back to the epidemiological model parameters (e.g., changed farmer behavior affecting transmission rates) [95].

Table 1: Key Quantitative Data on Animal Study Translation and Synthesis

Metric	Data	Source/Context
Annual NIH Spending on Animal Research	$12.0 - $14.5 billion	Stable over the past decade [9]
Translation of Highly-Cited Animal Studies to Human Trials	37% (95% CI, 26% to 48%) replicated	Based on analysis of prestigious journal papers [9]
Successful Translation in Stroke Models	~0.3% (2 of 700+ treatments)	Only aspirin and alteplase confirmed effective [9]
Successful Translation in Cancer Models	< 8% average rate	From animal models to clinical cancer trials [9]
Concordance of Human Adverse Drug Reactions	37% to >70% predicted by animals	Depends on species, drug, and target organ [9]
Animal Systematic Reviews in Neuroscience (2022)	305 published	Demonstrating rapid growth from 5 in 2007 [10]

Table 2: Alignment of Animal Model Features with Human PASC Epidemiology

Human Epidemiological Factor	Consideration for Animal Model Alignment	Example Model/Approach
Infection Severity Spectrum	Model choice should match cohort severity.	K18-hACE2 mice (severe) vs. hACE2 KI mice (mild-moderate) [92]
Viral Variant	Inoculum variant may influence long-term outcomes.	Studies using Wuhan, Delta, or Omicron variants [92]
Sex and Age Differences	Models should incorporate demographic variables.	Using aged or female animals to match higher risk groups [92]
Prolonged Symptom Duration	Follow-up must extend beyond acute phase (>14 days).	Imaging and behavioral tests at 4-12 weeks post-infection [92]
Multi-Organ Involvement	Endpoints should assess multiple systems.	Combined lung histology, brain MRI, and cardiac function [92]

Experimental Protocols

Protocol for Integrating Animal and Epidemiological Data in Systematic Reviews

Objective: To conduct a systematic review that explicitly synthesizes evidence from animal models and human epidemiological studies to assess the translational validity of a specific biomarker or pathophysiological mechanism.

• Protocol Registration & Question Formulation:

  • Register the review protocol on a platform like PROSPERO (for health-related reviews) or the Open Science Framework.
  • Define a PICO (Population, Intervention, Comparison, Outcome) or PECO (Population, Exposure, Comparison, Outcome) question that is applicable across species. Example: In mammals (P), does chronic low-level exposure to contaminant X (E/I), compared to no exposure (C), increase the risk of hepatic fibrosis (O)?

• Systematic Search Strategy:

  • Database Search: Search biomedical (PubMed, Embase), agricultural (CAB Abstracts), and environmental databases.
  • Species-Specific Filters: Use validated animal study filters (e.g., the SYRCLE animal filter) alongside terms for human observational studies (cohort, case-control) [51] [10].
  • Grey Literature: Search pre-print servers and relevant organizational reports.

• Screening, Data Extraction, and Quality Assessment:

  • Dual Independent Review: Conduct title/abstract and full-text screening by two reviewers independently.
  • Standardized Extraction: Extract data into forms capturing species, model details, exposure/intervention parameters, endpoint measures, and key results.
  • Risk of Bias Assessment: Use tailored tools. For animal studies, apply the SYRCLE's risk of bias tool. For epidemiological studies, use tools like ROBINS-I for non-randomized studies.

• Alignment and Synthesis:

  • Tabulate Results: Create side-by-side tables of outcomes from animal and human studies, noting the direction, magnitude, and consistency of effects.
  • Assess Alignment: Critically evaluate whether the molecular, physiological, or behavioral endpoints in animals are valid proxies for the clinical or population-level endpoints in humans. Document gaps and discrepancies.
  • Narrative & Quantitative Synthesis: Provide a narrative summary of the evidence landscape. If sufficient, comparable data exist, perform a meta-analysis stratified by species or conduct a meta-regression to explore sources of heterogeneity (e.g., dose, species, study quality).

Protocol for Network-Based Epidemic Modeling Integrating Animal Movement Data

Objective: To model the spread of a livestock disease (e.g., African Swine Fever) by estimating a synthetic animal movement network and coupling it with an epidemiological model to identify high-risk premises [96].

• Data Collation:

  • Premises Data: Gather data on farm locations, operation types (e.g., nursery, finisher), and herd sizes from agricultural censuses or regulatory databases [96].
  • Movement Constraints: Define rules governing plausible movements based on operation types (e.g., pigs move from nurseries to finishers, not vice versa).
  • Distance Data: Obtain distances between premises or their geographic coordinates.

• Synthetic Network Generation (Maximum Entropy Approach):

  • Formulate Constraints: Use available aggregate data (e.g., total county-level sales, average herd size) as constraints for the network.
  • Generate Network: Apply a maximum entropy model to estimate the most probable movement network that satisfies all constraints (operation type, size, distance) [96]. This creates a directed, weighted graph where nodes are farms and edges represent the number of animals moved.

• Network Analysis and Epidemic Simulation:

  • Calculate Centrality Metrics: Analyze the generated network to identify high-risk nodes using metrics like out-degree (number of farms supplied) and out-strength (total number of animals moved off-farm) [96].
  • Parameterize Compartmental Model: Define disease-specific parameters (latency, infectious period, transmission rates) within a Susceptible-Exposed-Infectious-Removed (SEIR) framework.
  • Run Stochastic Simulations: Initiate outbreaks at random nodes and at high-centrality nodes. Compare outcomes like epidemic size, duration, and geographic spread.
  • Output for Burden Assessment: Translate model outputs (e.g., number of infected farms over time) into economic inputs for sectoral or multi-sectoral burden assessments [95] [94].

Pathway and Workflow Visualizations

Diagram 1. Workflow for systematic review integration of animal and human evidence. [9] [51] [10]

Diagram 2. Pathway for multi-sectoral burden assessment of animal disease. [95] [96] [94]

Diagram 3. Process for network-based epidemic modeling with synthetic data. [96]

The Scientist's Toolkit: Research Reagent Solutions

Table 3: Essential Research Reagents, Models, and Tools for Alignment Research

Item	Function in Alignment Research	Key Considerations
Genetically Modified Mouse Models (e.g., K18-hACE2)	Models severe human disease for pathogens with species-specific receptor barriers (e.g., SARS-CoV-2). Enables study of acute and post-acute phases [92].	Choose model matching human disease severity of interest. Requires BSL-3 containment for pathogens like SARS-CoV-2.
Non-Human Primate (NHP) Models	Provides the closest phylogenetic and physiological analogy to humans for complex diseases (e.g., malnutrition, PASC). Critical for vaccine and therapeutic PK/PD studies [92] [97].	High cost, complex ethics, and limited availability. Essential for final preclinical validation.
Specific Pathogen-Free (SPF) Swine	Standardized large animal model for infectious disease (e.g., ASF, influenza), nutritional, and translational physiology research. Anatomy/physiology closely mirrors humans [97].	Housing and handling require specialized facilities. Useful for agricultural and biomedical endpoints.
In Vivo Imaging Systems (MRI, Micro-CT, PET)	Enables longitudinal, non-invasive assessment of structural and functional endpoints (e.g., lung fibrosis, brain atrophy, tumor metabolism) in animal models, aligning with clinical diagnostic tools [92].	High capital and operational cost. Requires expertise in image acquisition and analysis. Bridges preclinical and clinical phenotypes.
Maximum Entropy Network Modeling Software (e.g., R maxent package)	Generates probabilistic synthetic animal movement networks from incomplete data. Informs epidemic models in data-scarce settings [96].	Relies on quality of input constraints and assumptions. Output is a statistical estimate requiring validation where possible.
Systematic Review Management Software (e.g., Rayyan, Covidence)	Facilitates collaborative, blinded screening of large volumes of literature for integrative systematic reviews covering multiple species and study designs [51] [10].	Cloud-based platforms streamline workflow but require subscription. Essential for managing dual-species review teams.
Risk of Bias Tools (SYRCLE's RoB, ROBINS-I)	Standardized critical appraisal checklists to assess methodological quality and potential bias in animal studies and human observational studies, respectively. Allows for quality-weighted comparison [9] [10].	Application requires training for consistency. Results inform sensitivity analyses in synthesis.

The integration of epidemiological and animal evidence represents a paradigm shift in systematic review research and predictive clinical modeling. This approach, central to the One Health framework, acknowledges the interconnectedness of human, animal, and environmental health systems [98]. The core thesis posits that the synthesis of diverse data streams—spanning human epidemiology, veterinary science, wildlife disease ecology, and molecular omics—fundamentally enhances the accuracy, timeliness, and applicability of predictions in clinical research and drug development.

Fragmented data systems, particularly in low- and middle-income countries (LMICs), have historically hindered effective pandemic response and risk assessment [98]. Concurrently, challenges such as antimicrobial resistance (AMR) and emerging zoonoses demand predictive models that transcend traditional disciplinary boundaries [99] [100]. The integration of machine learning with classical epidemiology, the application of geostatistics to animal disease data, and the establishment of robust data standards are critical innovations driving this field forward [99] [101] [102]. This article evaluates the impact of such integration through quantitative evidence, detailed experimental protocols, and visualizations of the synthetic workflows that underpin modern predictive research.

Quantitative Evidence: The Impact of Integrated Data Systems

The predictive value of integrated research is substantiated by comparative data on outbreak management, economic burden, and model performance. The following tables summarize key quantitative findings.

Table 1: Impact of Data Integration on Outbreak Preparedness and Management

Metric	Fragmented System (Example)	Integrated System (Goal/Example)	Data Source
Local Data Utilization	Minimal, delayed use; data reported centrally with little local action [98].	Real-time, actionable data for local decision-making and risk communication [98].	Analysis of PHC systems in LMICs [98].
Outbreak Reporting	Significant underreporting (e.g., canine rabies cases) [102].	Enhanced detection and reporting via integrated surveillance networks.	Geostatistical study in Morocco [102].
AMR Burden (Global)	1.27 million direct deaths annually attributed to bacterial AMR [99].	Predictive models aim to reduce burden through targeted interventions [99].	WHO/Review data [99].
Projected AMR Cost	Could cost global economy up to USD 100 trillion by 2050 [99].	Economic savings through preventative, data-driven strategies [99].	Review of AMR economics [99].
Stakeholder Satisfaction	Low satisfaction with current animal disease data; processes seen as lacking transparency [103].	High potential for improved evidence-based policy and resource allocation [103].	Global survey of GBADs users [103].

Table 2: Case Study – Global Avian Influenza (AIV) with Zoonotic Potential (Oct 2025)

Virus Type	Reported Outbreaks/Events (Since last update)	Countries/Territories Affected	Key Species Affected	Implication for Integrated Prediction
HPAI (H5Nx, etc.)	954	38	Poultry, wild birds (eagles, swans, gulls), mammals (bear, cattle, seals) [100].	Highlights multi-species transmission chains requiring integrated animal-human surveillance.
H5N1	286 (subset of total)	Multiple (e.g., USA, Europe, Asia) [100].	Chicken, turkey, wild birds, marine mammals [100].	Demonstrates need for real-time data sharing across poultry, wildlife, and public health sectors.
Human Cases	9 new events reported [100].	Not specified in summary.	N/A	Critical outcome metric; underscores the necessity of predictive spillover models.

Detailed Experimental Protocols for Integrated Predictive Research

Protocol 1: Geostatistical Prediction of Animal Disease Hotspots

This protocol utilizes Ordinary Kriging to interpolate and predict disease incidence across space from point data, addressing issues of underreporting [102].

• Data Compilation: Assemble a georeferenced dataset of reported animal disease cases (e.g., canine rabies) over an extended period (e.g., 2000-2018) [102].
• Descriptive Spatial Analysis: Map reported cases to identify obvious gaps and areas of apparent clustering that may reflect reporting bias rather than true incidence.
• Variogram Modeling: Calculate the experimental semivariogram to model the spatial dependence structure of the data. This function quantifies how data similarity decreases with distance.
• Kriging Interpolation: Apply the Ordinary Kriging regression method using the fitted variogram model. This generates a continuous predicted surface of disease risk across the entire study area, providing estimates for unsampled locations.
• Cross-Validation: Validate the model by iteratively removing known data points, predicting their values using the remaining data, and comparing predictions to the true values. This step evaluates prediction accuracy (e.g., root-mean-square error) [102].
• Cluster Evaluation & Field Validation: Overlay predicted high-risk clusters with recent, high-quality georeferenced data (e.g., from the last 3 years) and environmental variables (e.g., roads, railways). Correlate predicted hotspots with true recent cases and infrastructure to assess biological and epidemiological plausibility [102].

Protocol 2: Implementing a Minimum Data Standard for Wildlife Disease Studies

This protocol ensures collected data are FAIR (Findable, Accessible, Interoperable, Reusable) from inception, enabling future integration [101].

• Assess Fit-for-Purpose: Confirm the study involves examining wild animal samples for parasites/pathogens. Each future record must be attributable to a host, diagnostic method, result, parasite ID (if positive), and date/location [101].
• Tailor the Data Standard: Select applicable fields from the standard's 40 core data fields (e.g., host species, animal ID, test name, result, GPS coordinates). For non-required fields, choose relevant ontologies (e.g., NCBI Taxonomy for species) and determine if any study-specific fields are needed [101].
• Format the Data: Structure the dataset in a "tidy" format where each row represents a single diagnostic test outcome. Use provided .csv or .xlsx templates to organize data into Sample, Host, and Parasite tables as needed [101].
• Validate the Data: Use the provided JSON Schema or dedicated R package (wddsWizard) to check data against the standard's rules, ensuring completeness and correct formatting [101].
• Share the Data: Deposit the validated dataset and associated metadata in both a generalist repository (e.g., Zenodo) for persistence and a specialist platform (e.g., the PHAROS database) for community access and integration [101].

Protocol 3: Network-Based Multi-Omics Integration for Drug Target Identification

This protocol leverages biological networks to integrate heterogeneous omics data for discovering novel drug targets [104].

• Network Construction: Compile or select relevant biological networks (e.g., Protein-Protein Interaction (PPI), gene co-expression, or gene regulatory networks) specific to the disease context from public databases (e.g., STRING, BioGRID).
• Multi-Omics Data Mapping: Prepare and normalize genomics (e.g., mutation), transcriptomics (e.g., RNA-seq), and/or proteomics data from patient or model system samples. Map these molecular features (e.g., differentially expressed genes) onto the corresponding nodes in the biological network.
• Integration via Network Propagation/Diffusion: Apply algorithms (e.g., random walk with restart) to propagate the "signal" from the initial mapped omics data across the network. This smoothes the data and identifies network neighborhoods enriched for disease signals, highlighting key functional modules [104].
• Prioritization of Candidate Targets: Rank genes/proteins within the enriched modules based on network properties (e.g., centrality measures like betweenness), the strength of the omics signal, and known disease association. This generates a prioritized list of potential drug targets.
• Biological Validation & Tool Development: Select top-ranked candidates for experimental validation (e.g., in vitro knock-down assays). Concurrently, the integrated model can be developed into a decision support tool (DST) for exploring target hypotheses and predicting drug responses [104] [103].

Visualization of Integrated Research Workflows

Diagram 1: Integrated Evidence Synthesis Workflow

A workflow for synthesizing diverse data sources into predictive insights.

Diagram 2: Predictive Modeling Pipeline for Zoonotic Threats

A pipeline transforming integrated data into actionable forecasts.

Table 3: Research Reagent Solutions for Integrated Predictive Studies

Tool/Resource Category	Specific Examples	Function in Integrated Research
Data Standards & Templates	Wildlife Disease Data Standard (WDDS) templates (.csv, .xlsx) [101]; DataCite Metadata Schema [101].	Provides a consistent structure for collecting and reporting wildlife pathogen data, ensuring interoperability and reusability for meta-analyses.
Data Validation & Management Tools	wddsWizard R package [101]; JSON Schema for WDDS [101].	Automates validation of datasets against reporting standards, reducing errors and improving data quality prior to sharing or integration.
Controlled Vocabularies & Ontologies	NCBI Taxonomy, Environment Ontology (ENVO), Disease Ontology (DO) [101].	Enables semantic interoperability by standardizing terms for species, environments, and diseases across studies from different domains.
Network Analysis & Multi-Omics Platforms	Network propagation algorithms (e.g., random walk); Graph Neural Networks (GNNs); STRING, BioGRID databases [104].	Facilitates the integration of genomic, transcriptomic, and other omics data onto biological networks to identify key functional modules and drug targets.
Geostatistical & Spatial Analysis Software	Ordinary Kriging algorithms; GIS software (e.g., QGIS, ArcGIS); R packages (gstat, sp) [102].	Predicts disease distribution in unsampled areas, identifies spatial clusters and risk hotspots, and links outbreaks to environmental drivers.
Epidemic Intelligence & Decision Support Tools	Go.Data; District Health Information System 2 (DHIS2) [98]; Model-driven DSTs [103].	Supports real-time data collection, contact tracing, outbreak analytics, and provides interfaces for stakeholders to interact with predictive models for decision-making.

Benchmarking and Future Directions for Validation Research

The integration of epidemiological (human) and preclinical (animal) evidence within systematic reviews represents a critical frontier in biomedical research. This integration is a cornerstone of the One Health approach, which emphasizes collaborative, multi-sectoral strategies to address health threats at the human-animal-environment interface [14]. In the context of systematic reviews, this approach seeks to synthesize disparate data streams to provide a more holistic and robust evidence base for understanding disease mechanisms, assessing therapeutic efficacy, and informing public health interventions and drug development pathways.

However, the translational pathway from bench to bedside is fraught with challenges. Well-documented issues include the poor reproducibility of animal studies, failures in translating promising animal results to successful human clinical trials, and heterogeneous reporting standards across study types [9]. A 2021 cross-sectional study of 442 preclinical systematic reviews (published 2015-2018) found that reporting of key methodological details was inconsistent, with less than half reporting a risk of bias assessment for internal validity, and none reporting methods for evaluating the construct validity of animal models [31]. These deficiencies undermine the reliability of the synthesized evidence and its utility for decision-making.

This application note establishes that rigorous validation research is not merely beneficial but essential for advancing this integrative field. Validation here refers to the systematic processes of benchmarking current methodological practices, assessing the quality and credibility of synthesized evidence, and developing standardized protocols to ensure transparency, reproducibility, and utility. By benchmarking current practices and charting clear future directions, this framework aims to elevate the scientific rigor of integrated reviews, thereby accelerating the translation of robust research findings into clinical applications and effective health policies.

Benchmarking Current Landscapes: Practices and Performance Gaps

A quantitative benchmark of current practices reveals significant gaps between aspirational goals of seamless evidence integration and on-the-ground realities in both systematic review methodology and the broader validation industry.

Table 1: Benchmarking Integration Mechanisms in Health Surveillance Systems (Systematic Review Data)

Integration Mechanism	Definition	% of Publications (n=102)	Primary Attributes Addressed	Reported Performance Improvement
Interoperability	Ability of systems to exchange & use information.	34.3% (35)	Sensitivity, Timeliness	Sensitivity median: 79.6% [14]
Convergent Integration	Merging technology with processes & knowledge.	26.5% (27)	Data Quality, Acceptability	Data Quality median: 87% [14]
Semantic Consistency	Use of standard data definitions & formats.	20.6% (21)	Sensitivity, Timeliness	Timeliness median: 67.3% [14]
Interconnectivity	Basic data/file transfer between systems.	18.6% (19)	Sensitivity	Not specifically quantified [14]

A 2020 systematic review of 102 publications on integrating human and animal health surveillance provides a foundational benchmark. It categorized integration into four primary mechanisms, with interoperability and convergent integration being the most common [14]. These integrated systems showed measurable improvements in key performance attributes: sensitivity (median 79.6%), data quality (median 87% improvement rate), and timeliness (median 67.3% improvement) [14]. This demonstrates the tangible value of structured integration but also highlights that such practices are not yet universal.

Table 2: Benchmarking Validation Practices and Preclinical Review Methodology (2025 & Recent Study Data)

Benchmarking Category	Metric	Finding	Source / Context
Industry Validation Resources	Dedicated Staffing	4 in 10 companies run validation with <3 dedicated staff.	2025 State of Validation Report [105]
	Outsourcing	70% outsource part of their validation workload.	2025 State of Validation Report [105]
	Digital Adoption	Only 16% have fully adopted Computer Software Assurance (CSA).	2025 State of Validation Report [105]
Preclinical Review Methodology	Duplicate Processes	Selection & data extraction done in duplicate in 67.9% & 46.7% of reviews.	Methodological Review (2018-2020) [106]
	Risk of Bias (RoB) Assessment	Conducted in 83.5% of reviews; SYRCLE RoB tool used in 50.8%.	Methodological Review (2018-2020) [106]
	Protocol Registration	Only 25% of reviews were prospectively registered.	Methodological Review (2018-2020) [106]
	Animal Model Reporting	Animal species/strain detailed in only 59% of reviews.	Methodological Review (2018-2020) [106]

The 2025 State of Validation Report, surveying over 300 professionals, underscores a resource-constrained environment. A lean operational model is prevalent, with high reliance on outsourcing and slow adoption of modern digital assurance paradigms like Computer Software Assurance (CSA) [105]. This context is critical for understanding the practical constraints faced by research teams.

Concurrently, a 2022 methodological review of 212 preclinical systematic reviews with meta-analyses (2018-2020) reveals persistent methodological shortcomings. While there is improvement (e.g., widespread RoB assessment), critical practices like duplicate data extraction and protocol registration are inconsistently applied. Furthermore, a meta-epidemiological analysis within that review of 763 animal studies found that key risk of bias items like allocation concealment and blinding were mostly rated "unclear," and sample size calculation was virtually never reported [106]. These gaps directly threaten the validity of the integrated evidence being produced.

Validation Frameworks and Integration Protocols

To address the benchmarked gaps, structured validation frameworks and explicit protocols are required. These protocols must guide the integration of evidence from study inception through to analysis, with continuous quality checks.

3.1 Core Validation Framework for Integrated Reviews The following workflow establishes a cyclical process of planning, execution, and quality assurance for reviews integrating animal and human evidence.

Diagram Title: Validation Workflow for Integrated Evidence Reviews

3.2 Protocol 1: Evidence Integration via Semantic Consistency and Interoperability Objective: To integrate epidemiological and animal studies by harmonizing data elements (semantic consistency) and enabling cross-domain analysis (interoperability), moving beyond simple co-location of evidence (interconnectivity) [14].

Materials: Access to epidemiological (e.g., PubMed, EMBASE) and preclinical (e.g., PubMed, Web of Science) databases; Reference management software (e.g., EndNote, Covidence); Data extraction tool (e.g., custom spreadsheet, Systematic Review Facility (SRF)); Controlled vocabularies (MeSH, OMIM, SPIRIT-AHC).

Procedure:

• Define Core Common Data Elements (CDEs): Assemble a team with domain expertise in both clinical epidemiology and preclinical research. For the research question (e.g., "Role of cytokine X in septic shock"), define CDEs such as: Population descriptor (human demographics/animal species-strain), Intervention/Exposure (dose, route, timing), Comparator, Primary Outcome (with harmonized definition and measurement unit), Study Design.
• Map Study-Specific Data to CDEs: During data extraction, map all variables from individual studies (human and animal) to the pre-defined CDEs. Document all transformations and assumptions (e.g., converting units, standardizing scoring scales). This creates a semantically consistent data layer.
• Implement an Interoperable Data Schema: Structure the extracted data using a standardized schema (e.g., OHDSI OMOP CDM adaptation for preclinical data, or ISA-TAB). This allows the use of common analysis tools across the integrated dataset.
• Perform Cross-Domain Analysis: Execute analyses that leverage the integrated dataset. This may include:
  • Sequential Analysis: Using animal model meta-regression results (e.g., effect size variation by dose) to inform the interpretation of human observational data.
  • Joint Display of Evidence: Creating structured summaries (e.g., matrices, heat maps) that juxtapose evidence strength, direction, and risk of bias from both domains for specific endpoints.
  • Quantitative Integration (where appropriate): For directly comparable interventions and outcomes, statistical synthesis across species using multilevel or hierarchical models that account for species as a grouping factor, acknowledging this is a high-order integration requiring robust methodology.

3.3 Protocol 2: Meta-Epidemiological Analysis for Systematic Review Validation Objective: To empirically evaluate whether methodological flaws (risk of bias) or specific study characteristics in the primary animal studies included in a systematic review are associated with larger or more favorable effect sizes, which would indicate systematic bias in the evidence base [106].

Materials: A completed systematic review with meta-analysis of preclinical studies; Statistical software (R, Stata, Python); Packages for meta-analysis (e.g., metafor in R) and meta-epidemiological modeling.

Procedure:

• Dataset Preparation: From the systematic review, extract a dataset where each row is an individual experimental arm (or study, depending on the model). Essential columns include: a unique study ID, the calculated effect size (e.g., Standardized Mean Difference, SMD) and its variance, and binary or categorical variables for key methodological features (e.g., randomization: yes/no/unclear; blinding: yes/no/unclear; sample size calculation: reported/not reported).
• Fit a Meta-Epidemiological Model: Use a linear mixed-effects model (or a robust variance estimation model suitable for meta-analytic data with multiple arms per study) [106]. The model structure: Effect Size ~ Methodological Feature + (1|Study_ID). The intercept represents the pooled effect size when the feature is "absent" (e.g., no blinding), and the coefficient for the feature represents the average change in effect size when the feature is "present" (e.g., blinding implemented).
• Interpretation & Validation Inference: Analyze the coefficient and its confidence interval for each methodological feature.
  • A coefficient significantly greater than zero suggests that studies with that methodological strength (e.g., randomization) report larger effect sizes, which may be counter-intuitive but warrants investigation.
  • A coefficient significantly less than zero suggests that studies without that methodological rigor report larger, potentially inflated, effect sizes—this is evidence of bias.
  • A non-significant coefficient (as found in the 2022 review for items like randomization and blinding) indicates no statistically detectable association in that dataset, but does not prove absence of bias [106].
• Report: This analysis should be a standard validation step in the discussion section of a preclinical meta-analysis, informing the confidence in the pooled effect estimate and highlighting critical methodological weaknesses in the primary literature.

Table 3: The Scientist's Toolkit for Integrated Validation Research

Tool / Reagent	Category	Primary Function	Key Application in Validation
SYRCLE's Risk of Bias Tool	Critical Appraisal	Assesses internal validity of animal studies (e.g., seq. gen., blinding).	Benchmarking quality of primary evidence; identifying bias sources [31] [106].
PRISMA-P Checklist	Reporting Guideline	Protocol items for systematic reviews & meta-analyses.	Ensuring transparent, reproducible review protocol design & registration [106].
OHDSI OMOP Common Data Model	Data Standard	Standardizes vocabularies & structures for observational health data.	Enabling semantic consistency & interoperability for integrating human epi. data [14].
CAMARADES / SYRCLE Meta-Analysis Guidance	Methodology Guide	Provides methods for synthesis & heterogeneity investigation in animal data.	Validating analytical approaches & exploring translational gaps [9] [106].
Database of Systematic Reviews of Animal Studies	Resource Database	Freely accessible repository of >3,100 preclinical reviews.	Benchmarking topics, avoiding duplication, methodological research [11].

Future Directions: AI, Digital Tools, and Collaborative Infrastructures

The future of validation research lies in leveraging technology to automate quality checks, enhance integration, and foster global collaboration.

4.1 Artificial Intelligence for Automated Validation Checks: AI and machine learning can transform labor-intensive validation steps. Natural Language Processing (NLP) models can be trained to automatically extract PICO elements, identify protocol deviations in published papers against registry entries, and even perform preliminary risk-of-bias assessments by detecting reporting patterns. AI can also help identify semantic inconsistencies by mapping free-text outcome descriptions in animal studies to standardized human clinical trial outcomes. This automation will free researcher time for higher-order integrative analysis and complex bias investigation.

4.2 Advanced Digital Validation and CSA: The life sciences industry's slow adoption of Computer Software Assurance (CSA) highlights a gap that research can lead in bridging [105]. Future validation platforms for systematic reviews should embody CSA principles: a risk-based approach focusing on critical data integrity and analysis steps. This includes version-controlled, electronic protocol registries; automated audit trails for every data point from extraction to final forest plot; and integrated, validated statistical packages that prevent analytical errors. Blockchain-like technology could be explored for providing immutable provenance tracking for the integrated evidence synthesis pipeline.

4.3 Global Collaborative Infrastructures: To overcome resource constraints and fragmentation, the field requires shared digital infrastructures. This includes:

• Curated, Linkable Repositories: Extending existing databases [11] to link preclinical systematic reviews not only to their constituent animal studies but also to subsequent human clinical trials and epidemiological studies, creating an evidence trajectory map.
• Living, Integrated Reviews: Moving beyond static documents to dynamic, versioned reviews hosted on platforms that allow continuous integration of new evidence from both domains, with automated updating of meta-analyses and bias assessments.
• Open Validation Tools: Development and maintenance of open-source software tools for performing the protocols described herein (e.g., automated meta-epidemiological analysis), ensuring all researchers can apply the highest validation standards regardless of resources.

In conclusion, benchmarking reveals a field with proven value but inconsistent methodological rigor. By adopting structured validation frameworks, implementing specific integration and analysis protocols, and embracing a future of AI-enhanced, digitally-native, and collaborative research infrastructures, the integration of epidemiological and animal evidence can mature into a more reliable, transparent, and powerful engine for scientific discovery and human health improvement.

Conclusion

The strategic integration of epidemiological and animal evidence within systematic reviews represents a powerful evolution in evidence-based research, directly serving the needs of translational scientists and drug developers. By building a strong foundational rationale, applying rigorous and standardized methodologies, proactively troubleshooting integration challenges, and establishing robust validation frameworks, researchers can create more predictive and clinically relevant evidence syntheses. This holistic approach not only strengthens the scientific justification for moving from bench to bedside but also aligns with the 'One Health' initiative by fostering a unified understanding of disease across species. Future progress depends on wider adoption of protocol pre-registration, the development of shared data standards and ontologies, and continued investment in tools that automate and enhance the quality of integrated reviews. Ultimately, mastering this integration is key to reducing translational failure, optimizing resource use, and accelerating the development of effective interventions for human and animal health [citation:1][citation:5].

References

• 1. Levelling the Translational Gap for Animal to Human ... [https://www.mdpi.com/2076-2615/10/7/1199]
• 2. The continued importance of animals in biomedical research [https://www.nature.com/articles/s41684-024-01458-4]
• 3. A practical guide to preclinical systematic review and meta- ... [https://pmc.ncbi.nlm.nih.gov/articles/PMC7431149/]
• 4. Value of preclinical systematic reviews and meta-analyses ... [https://www.nature.com/articles/s41390-024-03197-1]
• 5. Epidemiology and reporting characteristics of preclinical ... [https://pubmed.ncbi.nlm.nih.gov/33951050/]
• 6. Epidemiology and reporting characteristics of systematic ... [https://www.sciencedirect.com/science/article/pii/S0895435625000964]
• 7. Translational Preclinical Pharmacologic Disease Models for ... [https://pmc.ncbi.nlm.nih.gov/articles/PMC6394514/]
• 8. Preclinical research strategies for drug development [https://amsbiopharma.com/preclinical-research-drug-development/]
• 9. Importance of Systematic Reviews and Meta-analyses ... [https://pmc.ncbi.nlm.nih.gov/articles/PMC7479780/]
• 10. Quality, topics, and demographic trends of animal systematic ... [https://translational-medicine.biomedcentral.com/articles/10.1186/s12967-024-05992-0]
• 11. Developing a database of systematic reviews of animal ... [https://www.sciencedirect.com/science/article/pii/S0273230021000805]
• 12. How long does it take to complete and publish a systematic ... [https://pmc.ncbi.nlm.nih.gov/articles/PMC12487012/]
• 13. An analysis of trends in the use of animal and non-animal ... [https://www.frontiersin.org/journals/lab-on-a-chip-technologies/articles/10.3389/frlct.2024.1426895/full]
• 14. A systematic review on integration mechanisms in human ... [https://pmc.ncbi.nlm.nih.gov/articles/PMC7993536/]
• 15. Real-World Evidence [https://www.fda.gov/science-research/science-and-research-special-topics/real-world-evidence]
• 16. Real-World Evidence: A Primer - PMC - PubMed Central - NIH [https://pmc.ncbi.nlm.nih.gov/articles/PMC9815890/]
• 17. What is Preclinical Research and Why is it so Important? [https://www.als.net/news/what-is-preclinical-research/]
• 18. Introduction to real-world evidence studies - PMC [https://pmc.ncbi.nlm.nih.gov/articles/PMC8323556/]
• 19. Real world evidence [https://en.wikipedia.org/wiki/Real_world_evidence]
• 20. Preclinical development [https://en.wikipedia.org/wiki/Preclinical_development]
• 21. The power of real-world data to deliver more for patients [https://www.jnj.com/office-of-the-chief-medical-officer/the-power-of-real-world-data-to-deliver-more-for-patients]
• 22. Real World Data [https://www.cdisc.org/standards/real-world-data]
• 23. One Health: A Holistic Approach to Tackling Global ... [https://pmc.ncbi.nlm.nih.gov/articles/PMC11042131/]
• 24. Steps towards operationalizing One Health approaches [https://www.sciencedirect.com/science/article/pii/S2352771424000661]
• 25. PRISMA 2020 flow diagram [https://www.prisma-statement.org/prisma-2020-flow-diagram]
• 26. Step 6: PRISMA Flow Diagram & Screen - Systematic Reviews [https://libguides.mq.edu.au/systematic_reviews/prisma_screen]
• 27. Investigational New Drug (IND) Application [https://www.fda.gov/drugs/types-applications/investigational-new-drug-ind-application]
• 28. Increasing the utility of epidemiologic studies as key ... [https://pmc.ncbi.nlm.nih.gov/articles/PMC11775416/]
• 29. A Systematic Review of Human and Animal Evidence [https://www.sciencedirect.com/science/article/pii/S0160412025005379]
• 30. Systematic review of the status of veterinary epidemiological ... [https://bmcvetres.biomedcentral.com/articles/10.1186/s12917-021-02971-1]
• 31. Epidemiology and reporting characteristics of preclinical ... [https://journals.plos.org/plosbiology/article?id=10.1371/journal.pbio.3001177]
• 32. SYRCLE's risk of bias tool for animal studies [https://bmcmedresmethodol.biomedcentral.com/articles/10.1186/1471-2288-14-43]
• 33. How long does it take to complete and publish a systematic ... [https://bmcmedresmethodol.biomedcentral.com/articles/10.1186/s12874-025-02672-5]
• 34. CRIME-Q—a unifying tool for critical appraisal of ... [https://pmc.ncbi.nlm.nih.gov/articles/PMC11656974/]
• 35. Evidence Synthesis (Systematic Reviews) - Guides at Penn ... [https://guides.library.upenn.edu/c.php?g=475980&p=10909213]
• 36. PRISMA statement [https://www.prisma-statement.org/]
• 37. An updated guideline for reporting systematic reviews [https://www.equator-network.org/reporting-guidelines/prisma/]
• 38. PRISMA 2020 checklist [https://www.prisma-statement.org/prisma-2020-checklist]
• 39. Systematic Review Centre for Laboratory Animal ... [https://norecopa.no/3r-guide/systematic-review-centre-for-laboratory-animal-experimentation-syrcle]
• 40. Development and uptake of an online systematic review platform [https://pmc.ncbi.nlm.nih.gov/articles/PMC8647599/]
• 41. Improving the integration of epidemiological data into ... [https://pmc.ncbi.nlm.nih.gov/articles/PMC11492098/]
• 42. LibGuides: Systematic Reviews: Step 2: Develop a Protocol [https://guides.lib.unc.edu/systematic-reviews/protocol]
• 43. 3. Write and Register a Protocol - Systematic Reviews - Guides [https://guides.mclibrary.duke.edu/sysreview/protocol]
• 44. The reporting quality of meta-epidemiological studies needs ... [https://systematicreviewsjournal.biomedcentral.com/articles/10.1186/s13643-024-02661-7]
• 45. Ultimate Guide to Visual Workflow Design | May 26, 2025 [https://www.lightningventures.com.au/blogs/ultimate-guide-to-visual-workflow-design]
• 46. Heterogeneity in meta-analyses: an unavoidable challenge ... [https://pmc.ncbi.nlm.nih.gov/articles/PMC12326561/]
• 47. Advanced methods and implementations for the meta- ... [https://www.sciencedirect.com/science/article/pii/S014976342200505X]
• 48. Meta-analysis, complexity, and heterogeneity: a qualitative ... [https://systematicreviewsjournal.biomedcentral.com/articles/10.1186/s13643-016-0366-6]
• 49. Quantitative evidence synthesis: a practical guide on meta ... [https://link.springer.com/article/10.1186/s13750-023-00301-6]
• 50. Systematic Reviews and Meta-Analyses: Synthesis & Discussion [https://guides.lib.vt.edu/SRMA/synthesis]
• 51. Systematic reviews of animal studies – Report of an ... [https://veterinaryevidence.org/index.php/ve/article/download/653/888?inline=1]
• 52. A comprehensive guide to conduct a systematic review and ... [https://pmc.ncbi.nlm.nih.gov/articles/PMC12366998/]
• 53. Advancement in public health through machine learning [https://journalofbigdata.springeropen.com/articles/10.1186/s40537-025-01201-x]
• 54. Navigating PROSPERO4 animals : 10 top tips for efficient... [https://bmcmedresmethodol.biomedcentral.com/articles/10.1186/s12874-024-02146-0]
• 55. PROSPERO: A systematic of human and review ... animal evidence [https://rke.abertay.ac.uk/en/publications/prospero-a-systematic-review-of-human-and-animal-evidence-that-en]
• 56. Data-driven decision making in patient management [https://bmcmedinformdecismak.biomedcentral.com/articles/10.1186/s12911-025-03072-x]
• 57. Challenges and strategies in building a foundational digital ... [https://www.frontiersin.org/journals/health-services/articles/10.3389/frhs.2025.1600689/full]
• 58. Challenges and recommendations on the conduct of ... [https://pmc.ncbi.nlm.nih.gov/articles/PMC7666644/]
• 59. Systematic Reviews of Animal Models: Methodology versus ... [https://pmc.ncbi.nlm.nih.gov/articles/PMC3558708/]
• 60. Publication Bias in Laboratory Animal Research: A Survey on ... [https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0043404]
• 61. Why Are So Many Epidemiology Associations Inflated or ... [https://www.sciencedirect.com/science/article/abs/pii/S1047279708003591]
• 62. The Burden of Proof studies: assessing the evidence of risk [https://www.nature.com/articles/s41591-022-01973-2]
• 63. Risk of Bias Assessments and Evidence Syntheses for ... [https://pmc.ncbi.nlm.nih.gov/articles/PMC7489341/]
• 64. SYRCLE RoB tool [https://www.latitudes-network.org/tool/syrcle-rob-tool/]
• 65. SYRCLE's risk of bias tool for animal studies [https://pubmed.ncbi.nlm.nih.gov/24667063/]
• 66. Risk of bias tools - ROBINS-E tool [https://www.riskofbias.info/welcome/robins-e-tool]
• 67. Risk of Bias Tool - National Toxicology Program - NIH [https://ntp.niehs.nih.gov/research/assessments/noncancer/riskbias]
• 68. Assessing risk of bias: a proposal for a unified framework for ... [https://bmcmedresmethodol.biomedcentral.com/articles/10.1186/s12874-020-01115-7]
• 69. THE FUTURE IS ANIMAL-FREE - ACCELERATING ... [https://www.eceae.org/arguments/the-future-is-animal-free-accelerating-humane-and-human-relevant-science]
• 70. Translatability of Animal Models for Alzheimer's Disease ... [https://pmc.ncbi.nlm.nih.gov/articles/PMC12603623/]
• 71. Bridging the Gap: Translating Preclinical Biomarkers to ... [https://blog.crownbio.com/bridging-the-gap-translating-preclinical-biomarkers-to-clinical-success]
• 72. Programmable Virtual Humans Offer a New Path for Drug ... [https://datascience.virginia.edu/news/bridging-translational-gap-programmable-virtual-humans-offer-new-path-drug-discovery]
• 73. Epidemiological methods in transition: Minimizing biases in ... [https://pmc.ncbi.nlm.nih.gov/articles/PMC11730375/]
• 74. Development and Validation of an Automated Literature ... [https://pmc.ncbi.nlm.nih.gov/articles/PMC12404845/]
• 75. AI tools in evidence synthesis - Searching for Systematic ... [https://libguides.kcl.ac.uk/systematicreview/ai]
• 76. Systematic Review Software | Literature Review Software [https://www.distillersr.com/products/distillersr-systematic-review-software]
• 77. Protocol for improving equity in quantitative big data cleaning [https://pmc.ncbi.nlm.nih.gov/articles/PMC12225664/]
• 78. Background [https://www.frontiersin.org/journals/pediatrics/articles/10.3389/fped.2025.1513629/xml/nlm]
• 79. Experts publish the latest guide for systematic reviews of ... [https://www.radboudumc.nl/en/research/news/news-items-by-our-research-institute/2024/experts-publish-the-latest-guide-for-systematic-reviews-of-preclinical-research]
• 80. Writing a Systematic Review and Meta-analysis: A Step-by ... [https://pmc.ncbi.nlm.nih.gov/articles/PMC12402582/]
• 81. Chapter 5: Collecting data [https://www.cochrane.org/authors/handbooks-and-manuals/handbook/current/chapter-05]
• 82. Data Parameters From Participatory Surveillance Systems in ... [https://publichealth.jmir.org/2025/1/e55356]
• 83. A Framework for Evaluating the Use of Surveillance ... [https://pmc.ncbi.nlm.nih.gov/articles/PMC12307093/]
• 84. A systematic review of epidemiological modelling in ... [https://www.frontiersin.org/journals/veterinary-science/articles/10.3389/fvets.2024.1459293/full]
• 85. Integrating artificial intelligence with mechanistic ... [https://www.nature.com/articles/s41467-024-55461-x]
• 86. Federated Learning in Public Health: A Systematic Review ... [https://www.mdpi.com/2227-9032/13/21/2760]
• 87. A systematic review of human and animal evidence [https://pubmed.ncbi.nlm.nih.gov/41175853/]
• 88. A comparison of two assessment tools used in overviews ... [https://pmc.ncbi.nlm.nih.gov/articles/PMC8543959/]
• 89. A comparative study of ROBIS and AMSTAR-2 tools [https://www.cambridge.org/core/journals/research-synthesis-methods/article/exploring-the-methodological-quality-and-risk-of-bias-in-200-systematic-reviews-a-comparative-study-of-robis-and-amstar2-tools/EF5DB99AC8C6BC968B58B5D924455D8C]
• 90. ROBIS tool - Population Health Sciences [https://www.bristol.ac.uk/population-health-sciences/projects/robis/robis-tool/]
• 91. A systematic review on integration mechanisms in human ... [https://pubmed.ncbi.nlm.nih.gov/33829132/]
• 92. Post Pandemic Problem, is there an animal model suitable ... [https://www.nature.com/articles/s44303-025-00101-2]
• 93. Establishing Humane Endpoints - UCI Office of Research [https://research.uci.edu/animal-care-and-use/policies-and-guidance/establishing-humane-endpoints/]
• 94. A framework for quantifying the multisectoral burden of ... [https://www.frontiersin.org/journals/veterinary-science/articles/10.3389/fvets.2025.1476505/full]
• 95. A Scoping Review and Taxonomy of Epidemiological ... [https://www.sciencedirect.com/science/article/abs/pii/S016758772500279X]
• 96. Animal movement estimation and network-based epidemic ... [https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0326234]
• 97. Animal models for understanding the mechanisms of ... [https://pmc.ncbi.nlm.nih.gov/articles/PMC12507597/]
• 98. Enhancing human and animal health data integration ... [https://pmc.ncbi.nlm.nih.gov/articles/PMC11961054/]
• 99. The Synergy of Machine Learning and Epidemiology in ... [https://pmc.ncbi.nlm.nih.gov/articles/PMC11505168/]
• 100. Global AIV with Zoonotic Potential [https://www.fao.org/animal-health/situation-updates/global-aiv-with-zoonotic-potential/en]
• 101. A minimum data standard for wildlife disease research and ... [https://www.nature.com/articles/s41597-025-05332-x]
• 102. Using geostatistics to better understand the epidemiology ... [https://www.sciencedirect.com/science/article/pii/S2405844021001249]
• 103. Current and potential use of animal disease data by ... [https://www.sciencedirect.com/science/article/pii/S0167587724000758]
• 104. Network-based multi-omics integrative analysis methods in drug... [https://biodatamining.biomedcentral.com/articles/10.1186/s13040-025-00442-z]
• 105. 2025 State of Validation Report [https://stateofvalidation.com/2025-state-of-validation-report?utm_campaign=11947020-ispe-platinum-2025&utm_source=ispe-sponsorship-page&utm_medium=State%20of%20Validation&utm_content=SOVLink]
• 106. A methodological review with meta-epidemiological ... [https://www.nature.com/articles/s41598-022-24447-4]